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Hana Elisabeth Baker 
 
MECHANISMS UNDERLYING CARDIOVASCULAR BENEFITS OF SODIUM 
GLUCOSE CO-TRANSPORTER-2 INHIBITORS:  MYOCARDIAL SUBSTRATE OR 
SODIUM/HYDROGEN EXCHANGER? 
 
Recent clinical outcome studies demonstrate that Sodium glucose cotransporter 2 
inhibitors (SGLT2i) significantly reduce major adverse cardiovascular events and heart 
failure outcomes in subjects with type 2 diabetes mellitus.  At present, several hypotheses 
have been proposed to explain the observed cardiovascular benefit of SGLT2i, however, 
the mechanisms responsible remain to be elucidated.  This investigation tested the 
hypothesis that SGLT2i improves cardiac function and efficiency during acute, regional 
ischemia/reperfusion injury via preferential shifts in myocardial substrate selection and/or 
inhibition of cardiac sodium/hydrogen exchanger-1 (NHE-1). 
Our initial investigation evaluated the effects of 24 hour pretreatment of the SGLT2i 
canagliflozin on cardiac contractile function, substrate utilization, and efficiency before and 
during regional myocardial ischemia/reperfusion injury in healthy swine. At the onset of 
ischemia, canagliflozin increased left ventricular end diastolic and systolic volumes which 
returned to baseline with reperfusion. This increased end diastolic volume was directly 
associated with increased stroke volume and stroke work relative to controls during 
ischemia. Canagliflozin also increased cardiac work efficiency during ischemia relative to 
control swine. No differences in myocardial substrate uptake of glucose, lactate, fatty acids 
or ketones were detected between groups. In separate experiments using a longer 60 min 
coronary occlusion, canagliflozin significantly diminished myocardial infarct size.   
Subsequent studies investigated the effect of an acute administration (15-30 min 
pre-treatment) of canagliflozin and the NHE-1i cariporide on cardiac contractile function 
vii 
efficiency in response to myocardial ischemia/reperfusion injury.  Similar to our initial 
studies, canagliflozin increased diastolic filling, stroke work and improved cardiac work 
efficiency relative to untreated control hearts during the ischemic period. In contrast, 
cariporide did not alter ventricular filling volume, cardiac output or work efficiency at any 
time point.  Additional examination of AP-1 cells transfected with wild-type NHE-1 showed 
dose-dependent inhibition of NHE-1 activity by cariporide, while canagliflozin had minimal 
effect on overall activity.  This investigation demonstrates that SGLT2i improves cardiac 
function and efficiency during acute, regional ischemia in healthy swine. However, the 
present data fail to support the hypothesis that these SGLT2i-mediated improvements 
involve either preferential alterations in myocardial substrate utilization or the inhibition of 
NHE-1 activity.  
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Chapter 1:  Introduction 
 
Population at risk for cardiovascular disease 
Cardiovascular disease is a group of diseases that affect the heart and/or blood 
vessels, including coronary heart disease, hypertensive cardiovascular disease, 
peripheral vascular disease, rheumatic heart disease, congenital heart 
disease.  Constituting a considerable health care burden across the world, cardiovascular 
disease accounts for over 17 million deaths annually, and is a global concern killing more 
people than all cancers combined (Figure 1.1) [24, 127].  Cardiovascular disease is also 
the leading cause of death in the United States, with approximately 630,000 Americans 
dying from some form of heart disease each year (Figure 1.2)  [122].  The American Heart 
Association estimates that almost half of the US population (>130 million people) will have 
some form of heart disease by 2035, with the estimated total medical costs (direct and 
indirect) for caring for these individuals reaching over $1 trillion in that same time 
frame.  Significant contributors to the rising cardiovascular disease burden, as well as 
major cardiovascular risk factors, include increased prevalence of kidney disease and the 
continued epidemic of obesity, and the rising prevalence of type 2 diabetes. 
Cardiovascular disease represents a complex group of diseases, and unsurprisingly, is 
associated with numerous risk factors (e.g. smoking, high cholesterol, hypertension, 
obesity and diabetes).  Although advances in the treatment of cardiovascular disease have 
been made, a better understanding of the complex interplay between cardiovascular risk 
factors is needed for further progress in this area. 
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Figure 1.1 Number of deaths in 2016 by cause. 
Specific cause of death globally regardless of risk factors (environmental, diet and 
other lifestyle factors. [24] 
Figure 1.2 Breakdown of cardiovascular disease related deaths in the 
United States (2015).  [24] 
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Cardiovascular disease in obesity and diabetes 
Obesity, as defined by body mass index (BMI) ≥ 30 kg/m2, makes up one of the 
most important cardiovascular disease risk factors as the prevalence of obesity has 
increased over the last several decades affecting approximately 2.1 billion adults globally 
(Figure 1.4) [87, 145].  Recent studies have estimated that 70% of adults in the United 
States are overweight or obese and that this is similar between men and women 
regardless of race/ethnicity (Figure 1.3) [44, 148].  Obesity, a chronic metabolic disease 
has a significant impact on the cardiovascular system.   Obese men and women when 
compared to normal weight, gender and age matched individuals were more likely to have 
a stroke, heart attack, heart failure or cardiovascular death [87].  Obesity leads to several 
structural and functional changes in the cardiovascular system, including reduced cardiac 
output, increased systemic resistance, increased left ventricular mass and wall thickness 
and left ventricular systolic dysfunction [26]. 
■ Overweight (BMI of 25 to 29.9) 
■ Obesity (BMI of 30+) 
■ Extreme obesity (BMI of 40+)  
■ Men  
■ Women 
Figure 1.3 Incidence of obesity. 
Estimate of overweight or obese adults in the United States. [44] 
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Obesity itself is associated with several cardiovascular risk factors including, insulin 
resistance and type 2 diabetes [6, 24, 38, 82, 148].  Approximately 90-95% of all 
diagnosed diabetic cases in adults are obesity related type 2 diabetes [135].  The 
prevalence of diabetes has also increased over the last several decades (Figure 1.4) and 
it is predicted that the number of diabetic individuals will increase by approximately 54% 
to over 54 million Americans by 2030.  Suffering from type 1 or type 2 diabetes increases 
an individual’s risk of a cardiovascular related death by up to 50%.  Major causes of 
mortality in diabetic individuals includes, coronary heart disease, cerebrovascular disease 
and peripheral artery disease [137]. 
 
Obesity and diabetes are independent risk factors for cardiovascular disease and 
the combination of the two increases the rate and severity of cardiovascular disease [119, 
124, 148].  Additionally, dysmetabolic individuals (i.e. obese individuals with insulin 
Figure 1.4 Age-adjusted prevalence of obesity and diabetes among adults in the 
United States. [122] 
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resistance or type 2 diabetes) are associated with cardiovascular pathophysiological 
changes including changes in myocardial substrate metabolism, impaired oxygen 
supply/demand balance, concentric cardiac hypertrophy and diastolic contractile 
dysfunction [148].  These pathophysiological changes are distinct to this dysmetabolic 
population and the mechanisms driving these changes remain poorly understood.  
Moreover, many therapies used in type 2 diabetes management have failed to reduce 
adverse cardiovascular outcomes.  Some therapies are even associated with an increased 
risk for incident heart failure in diabetic individuals [14, 51, 151]. Together this highlights 
the need to better understand the mechanisms driving the dysmetabolic cardiac changes 
and the need for new therapeutic options for treating cardiovascular disease in 
dysmetabolic individuals. 
 
Anti-hyperglycemic therapies and cardiovascular risk 
Numerous therapies are available to control glucose levels in diabetic individuals.  
However, despite having tightly controlled glucose levels, diabetic individuals still have an 
increased risk of heart disease and stroke.  Metformin, sulfonylureas, meglitinides, 
thiazolindinediones, and dipeptidyl-peptidase-4 inhibitors, 
 despite their long term glucose control, all fail to reduce adverse cardiovascular 
outcomes [85].  The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial 
even suggested cardiovascular harm related to aggressive glucose lowering with anti-
hyperglycemic agents [51, 57].  Additionally, in 2007 a meta-analysis published by Nissen 
and Wolski reported a 43% increase in myocardial infarction and a 64% increase in death 
from cardiovascular causes with rosiglitazone, an anti-diabetic drug in the 
thiazolidinedione class [73, 76].  Data from the RECORD (Rosiglitazone evaluated for 
cardiovascular outcomes in oral agent combination therapy for type 2 diabetes) trial 
demonstrated an increased risk for heart failure with rosiglitazone, no effect on 
6 
cardiovascular mortality and was inconclusive regarding myocardial infarction [75].  
However, the alarming findings from the initial 2007 meta-analysis by Nissen and Wolski 
led the Food and Drug 
Administration (FDA) to issue a 
guidance in 2008 requiring 
cardiovascular disease risk 
assessment for all new glucose 
lowering drugs.  In short, the new 
FDA guidance for industry 
requires pharmaceutical 
companies to demonstrate that 
the upper bound of the two-sided 
95 percent confidence interval for 
the estimated hazard risk ratio for 
cardiovascular events including 
cardiovascular mortality, 
myocardial infarction, and stroke 
to be less than 1.3 (hazard ratio = treatment hazard rate/placebo hazard rate therefore, a 
parameter or outcome with a hazard ratio < 1 improves with treatment, >1 worsens with 
treatment) (Figure 1.5)  [4, 76].   
Figure 1.5 FDA guideline for glucose lowering 
drugs.  
Examples of hazard ratios (HR) and the upper limit 
of the 95 % confidence interval (CI) and regulatory 
consequences of each outcome. S superiority, NI 
non-inferiority, I inferiority, UP underpowered. [4] 
7 
Since the FDA guidance was issued, two classes of glucose lowering drugs, 
dipeptyidyl-peptidase-4 inhibitors (DPP-4i), and glucagon-like peptide-1 receptor agonist 
(GLP-1 RA) have completed cardiovascular outcome trials.   Three trials have reported 
outcome data for DPP-4i, SAVOR-TIMI for Saxagliptin, EXAMINE for alogliptin and 
TECOS for sitagliptin.  All three trials met the primary outcome of less than 1.3 hazard 
ratio (HR) but, none were associated with any cardiovascular benefit [60, 139, 157].  
Additionally, saxagliptin was associated with an increased risk for incident heart failure 
(HR 1.27) and the FDA recommended a warning label for aloglipitin use in patients with a 
history of heart and kidney disease [139, 157].  See figure 1.6. 
 
 
There are currently 4 completed trials for GLP-1 RA.  ELIXA, the first reported trial, 
demonstrated noninferiority of lixisenatide using a 4-point major adverse cardiovascular 
events (MACE) (composite of nonfatal stroke, nonfatal myocardial infarction, 
cardiovascular death and hospitalization for unstable angina), but did not find any 
cardiovascular benefit [121].  The LEADER trial which evaluated liraglutide treatment, 
0.0 0.5 1.0 1.5 2.0
Heart Failure 
Hostpitalizations 
Mortality
Cardiovascular 
Deaths
Myocardial 
Infarction
MACE
DPP-4i
Hazard Ratio
SAVOR-TIMI
EXAMINE
TECOS
Figure 1.6 Cardiovascular outcomes for SAVOR-TIMI, EXAMINE AND TECOS 
TRIALS. [60, 139, 155] 
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demonstrated a significant reduction in 3-point MACE (composite of nonfatal stroke, 
nonfatal myocardial infarction, and cardiovascular death) [106]. The benefit observed in 
the LEADER trial was mainly driven by the significant reductions in cardiovascular deaths.  
These findings led to a new indication for liraglutide, to reduce the risk of MACE in type 2 
diabetic adults with cardiovascular disease [76].   SUSTAIN-6 confirmed noninferiority of 
long-acting semaglutide on 3-point MACE.  Significant reductions in nonfatal stroke and 
trends towards decreased non-fatal myocardial infarctions were reported with semaglutide 
treatment [106].  The fourth reported trial, EXSCEL evaluated extended release exenatide.  
It confirmed noninferiority with no significant improvements in cardiovascular outcomes 
[74].  See figure 1.7. 
 
 
Since the 2008 FDA guidelines were issued several cardiovascular outcome trials 
have been completed and results published.  These trials demonstrate a range of results, 
i.e. several agents were not associated with an increased cardiovascular risk (beyond an 
unacceptable level, HR > 1.3), some were associated with an increased risk for heart 
0.0 0.5 1.0 1.5 2.0
Heart Failure
 Hostpitalizations 
Mortality
Cardiovascular 
Deaths
Myocardial 
Infarction
MACE
GLP-1 RA
Hazard Ratio
ELIXA
LEADER
SUSTAIN-6
EXSCEL
Figure 1.7 Cardiovascular outcomes for ELIXA, LEADER, SUSTAIN-6 AND 
EXSCEL. [74, 76, 106] 
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failure (saxagliptin and alogliptin) and some agents (i.e. GLP-1 inhibitors, specifically 
liraglutide and semaglutide) demonstrated cardiovascular benefits.  Together these data 
and the increased cardiovascular risk in dysmetabolic patients highlight the need for 
evaluating the appropriate glucose lowering treatment for type 2 diabetic patients at risk 
for cardiovascular disease as well as the need for new anti-hyperglycemic agents with 
added cardiovascular benefits. 
 
Sodium glucose Transporter 2  
 In 1960, Bob Crane proposed the sodium/glucose cotransport hypothesis, that 
glucose was transported across the plasma membrane of the digestive surface (brush 
border of the intestines) by a 
sodium/glucose carrier 
complex (Figure 1.8).  Crane 
believed this active transport of 
glucose was the result of the 
sodium gradient maintained by 
a second sodium pump 
(possibly the Na+/K pump) 
[159].   Prior to this there were 
no explanations for active 
membrane transport of glucose or other molecules in the body.  Aside from some minor 
points, this model remains valid today [159].  
In the early 1980’s researchers found that glucose transport in the proximal tubule 
of the kidneys was more rapid than in the distal tubule, this ultimately led to the discovery 
of sodium glucose cotransporters (SGLT) [159].  In 1987 Wright et al. successfully cloned 
Figure 1.8 SGLT model drawn by Bob Crane. 
[159] 
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the intestinal sodium/glucose transporter SGLT1 in small intestines and in 1992 Wells et 
al. successfully identified and cloned SGLT2 in the kidney [156, 159].  
Sodium glucose transporters are encoded by genes in the SLC5A family.  The 
SGLT family consists of 6 members (SGLT1-6), SGLT1 and 2 are sodium dependent 
glucose cotransporters, SGLT3 a glucose 
sensor, SGLT4 and 6 are sodium dependent 
multivitamin transporters and SGLT5 a 
thyroid iodide transporter [134].  For this 
proposal, the focus will be on SGLT2 and 
briefly on SGLT1.   SGLT2 is highly 
expressed in the kidney and in contrast to 
SGLT1 has a low affinity for glucose but, a 
high capacity for its transport with a 1:1 sodium 
to glucose coupling ratio (Figure 1.9) [134].  
SGLT2 is in the S1 and S2 segments of the 
proximal tubules in the kidney and under 
normal conditions is responsible for 90% of 
glucose reabsorption. SGLT1 is in the S2 and 
S3 segments of the proximal tubule and is 
responsible for 10% of glucose reabsorption 
[31] (Figure 1.10).   In hyperglycemia SGLT2 activity is upregulated ultimately contributing 
to hyperglycemia [107].  SGLT2 inhibitors (SGLT2i) block reabsorption of filtered glucose 
in the kidney resulting in glucose excretion in the urine leading to reduced plasma glucose 
levels. Because of their role in glucose reabsorption, SGLT, particularly SGLT2 are an 
ideal therapeutic target for insulin independent glucose lowering.  In 2013 canagliflozin 
Figure 1.9 SGLT mechanism in the 
proximal tubule. [70] 
Figure 1.10 SGLT in the kidney and 
effect on glucose homeostasis. [31] 
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was the first FDA approved SGLT2i for treatment of type 2 diabetes.  This was later 
followed by the approval of dapagliflozin and empagliflozin [152].  
 
SGLT2i and cardiovascular events  
 FDA required studies of effects of SGLT2i on cardiovascular disease have yielded 
promising results.  Three trials have been completed.  The first was the EMPAREG 
OUTCOME trial evaluating empagliflozin treatment in T2DM patients with high 
cardiovascular risk.  Empagliflozin significantly reduced 3-point MACE which was driven 
by a significant reduction in cardiovascular deaths [164].  Treatment with empagliflozin 
also resulted in significant reductions in all-cause mortality and heart failure 
hospitalizations [164].  The CANVAS trial was the second trial to be completed in patients 
with high cardiovascular risk.  CANVAS, which evaluated the treatment effects of 
canagliflozin on 3-point MACE, also demonstrated significant reductions [114].  CANVAS 
reported reductions in mortality and heart failure hospitalizations although the differences 
were not significant [114].  DECLARE-TIMI 58, the most recently completed trial, 
confirmed noninferiority of dapagliflozin with no reductions in MACE in patients at risk for 
atherosclerotic cardiovascular disease [158].  Although dapagliflozin failed to reduce 
MACE, reductions in cardiovascular deaths and heart failure hospitalizations were 
reported [158].  See figure 1.11. 
The most impressive results from these trials were the effects on heart failure 
hospitalizations and overall cardiovascular deaths.  SGLT2i were the first glucose lowering 
drug class to be associated with significant reductions heart failure hospitalizations.  
Furthermore, the reduction in heart failure outcomes was observed within weeks of 
beginning treatment and was maintained for several years [164].  Additionally, all three 
SGLT2i have been found to significantly reduce cardiovascular mortality in type 2 diabetic 
patients.  Data reported from the three SGLT2i trials were unexpected and together 
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indicate the improvements in cardiovascular outcomes with SGLT2i may be a class effect 
that warrants further investigation.  See figure 1.12. 
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Figure 1.11 Cardiovascular outcomes for EMPAREG, CANVAS AND DECLARE. 
[114, 158, 164] 
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Figure 1.12 Heart failure outcomes for EMPAREG, CANVAS, DECLARE and CVD-
REAL. [114, 158, 164] 
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SGLT2 expression 
The cardiovascular benefits of SGLT2i are surprising and do not appear to be 
mediated by direct effects of these agents on the SGLT2 transporter in cardiovascular 
tissues, as SGLT2 protein expression is not detected in the heart or vasculature [32, 65, 
68].  Zhou et al. performed early studies to identify SGLT1 and SGLT2 gene expression 
in 23 human tissues using real time polymerase chain reaction (RT-PCR).  They reported 
high levels of SGLT1 expression in the small intestines and expression to varying degrees 
in the left ventricle, kidney, colon, testis, trachea, prostate, lung and liver.  Zhou et al. also 
reported that SGLT2 mRNA was ubiquitously expressed in several human tissues with the 
highest level of expression in the kidney.  This expression pattern of SGLT2 could be 
problematic as using an agonist or antagonist to a target found in a wide variety of tissues 
could cause unanticipated, unwanted effects. Following the studies of Zhou et al., Chen 
et al. set out to extensively evaluate the mRNA expression profile of SGLT2 and several 
of its related family members (SGLT1, SAAT1 (also known as SGLT3), SMIT (sodium 
myoinositol cotransporter 1), SGLT4, SGLT5 and SGLT6).  These studies used 
quantitative RT-PCR to evaluate 72 normal human tissues from three separate donors.  
Additionally, they used five different primer/probe sets spanning the entire SGLT2 mRNA.   
Chen et al. found similar expression of SGLT1 as Zhou et al. however, the pattern of 
SGLT2 expression differed.  Chen et al. concluded that the expression pattern of SGLT2 
was highly restricted to the kidney in humans (Figure 1.13) and was not ubiquitously 
expressed as stated by Zhou et al.  Further, additional groups have confirmed Chen el 
al’s, findings that SGLT2 mRNA expression was only observed in the kidneys in humans 
and was not expressed in the heart [43, 153].  Due to the lack of SGLT2 expression in the 
heart, precisely how SGLT2i improves cardiovascular outcomes remains an enigma.  
14 
 
Proposed mechanisms of cardiovascular protection 
Numerous mechanisms have been proposed for the observed SGLT2i 
cardiovascular benefits, including diminished artery stiffness, effects on sodium/fluid loss 
and weight loss, influences on renin-angiotensin system and anti-hypertensive effects, 
anti-inflammatory capacity and AMPK activation [33-35, 69, 92, 109, 150] (Figure 1.14).   
Additionally, several pre-clinical studies attempting to elucidate the proposed SGLT2i 
mediated cardioprotective mechanisms have been published (Table 1).  These published 
pre-clinical studies demonstrate a variety of potential SGLT2i mediated effects (i.e. 
improved cardiac function, reduced atherosclerosis, modulation of neurohormones, 
reduced inflammation and fibrosis) [64, 94, 140, 162] in various pre-clinical models (i.e. 
Diabetic Akita mice, STZ-induced diabetic rats, ZDF diabetic and ZL nondiabetic rats, 
nondiabetic pigs) [63, 80, 97, 130].  While there is an abundance of data attempting to 
explain the SGLT2i mediated cardiovascular effects, some inconsistencies exist within the 
Figure 1.13 Quantitative PCR tissue expression profiling of thE SGLT2 gene in 
various human tissues. [32] 
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published pre-clinical studies.  For example, Chan et al., observed no improvements in 
blood glucose, systolic blood pressure (SBP), glomerular filtration rate (GFR) or urinary 
albumin creatinine ratio in the diabetic Akita mouse model when treated with canagliflozin 
[80].  Demarco et al. observed improvements in glycemia and proteinuria in obese/diabetic 
db/db mice with empagliflozin treatment [61] and Abu Seif et al. demonstrated blood 
pressure reductions in albino rats treated with canagliflozin [2].  Santos-Gallego et al. 
evaluated the effects of empagliflozin in nondiabetic pigs and demonstrated improved left 
ventricular function due to improved myocardial energetics [130] however, Lim et al. 
reported reduced myocardial infarct size in both diabetic and nondiabetic rats with 
canagliflozin treatment independent of glycemic status [97].   
Several hypotheses have been proposed to explain the SGLT2i cardiovascular 
benefits and the literature appears to be settling on two, the “thrifty fuel hypothesis” and 
the “sodium hypothesis”.  Recent published literature suggests effects on myocardial 
substrate metabolism, secondary to changes in systemic substrate availability, could 
explain the cardiovascular benefits of SGLT2i [1, 39, 46-48, 83, 123, 143]. This is referred 
to as the “thrifty fuel hypothesis”.  Other evidence suggests that the SGLT2i mediated 
cardioprotective effects could be due to direct inhibition of the sodium hydrogen 
exchanger-1 (NHE-1).  This is called the “sodium hypothesis” [19, 23, 25, 149]. 
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Figure 1.14:  Potential mechanisms underlying cardiovascular benefits of SGLT2i. 
[35] 
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Table 1 SGLT2i pre-clinical studies                                                                                 
Mechanism Outcomes Animal model 
and SGLT2 
inhibitor 
Findings Reference 
Cardiac 
Function 
• Dysglycemia, 
proteinuria, 
aortic stiffness, 
and diastolic 
dysfunction 
• Obese/diabetic 
female db/db 
mice. 
• Oral 
empagliflozin 
(10 mg/kg/day) 
for 5 weeks 
• Improvements in 
septal wall motion, 
flow propagation 
velocity, left ventricular 
filling pressure, 
isovolumic relaxation 
time and myocardial 
performance 
Habibi et 
al., 2015 
[61] 
• Cardiovascular 
injury and 
cognitive decline  
• db/db mice 
• Standard diet 
or standard diet 
containing 
0.03% 
empagliflozin for 
10 weeks 
• Ameliorated 
cardiovascular injury, 
remodeling, 
vascular dysfunction, 
and cognitive decline 
Lin et al., 
2014 [98] 
• Myocardial 
fibrosis through 
regulation of 
macrophage 
phenotypes and 
SGLT1 
augmentation 
• Role of signal 
transducer and 
activator of 
transcription 3 
(STAT3) in 
cardiac fibrosis 
• in vivo and ex 
vivo 
experiments 
• Non-diabetic 
male Wistar rats 
• Dapagliflozin 
(0.1 mg/kg/day 
by oral gavage), 
phlorizin (0.4 
g/kg/day 
injected s.q.), 
combination of 
dapagliflozin + 
S3I-201 (10 
mg/kg per day, a 
STAT3 inhibitor, 
injected i.p.), or 
phlorizin + S3I-
201 
• Attenuated 
myofibroblast 
infiltration and cardiac 
fibrosis via increased 
STAT3 activity and 
STAT3 nuclear 
translocation 
Lee et al., 
2017 [95] 
• OGlcNAcylated 
protein levels  
• Lipodystrophic 
Bscl2-/- (SKO) 
and wild-type 
(control) mice 
• Dapagliflozin 
(1 mg/kg in 
drinking water 
for 8 weeks) 
• Reduced O-
GlcNAcylated FOXO1 
levels and prevented 
development of 
hypertrophic 
cardiomyopathy 
Joubert et 
al., 2017 
[81]  
• NLRP3 and 
inflammasome 
activation  
• BTBR ob/ob 
and wild-type 
(control) mice 
• Dapagliflozin 
(1 mg/kg/day 
mixed with food) 
for 8 weeks 
• Attenuated the 
development of 
fibrosis and 
remodeling and 
deterioration of left 
ventricular function via 
NLRP3, TNFa, and 
caspase-1 
Ye et al., 
2017 [162] 
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• Cardiac 
function 
• C57Bl/6 mice 
• Transverse 
aortic 
constriction 
• Empagliflozin 
(10mg/kg) daily 
by oral gavage 
for 2 weeks 
• Increased cardiac 
output and cardiac 
work 
Byrne, 
2017 [29] 
• Myocardial 
function and 
injury 
• Sprague-
Dawley rats 
• 
ischemia/reperfu
sion (I/R) 
• Canagliflozin 
(3ug/kg)/IV/5th 
min of ischemia 
• Reduced infarct size, 
increased efficiency 
during I/R 
Sayour, 
2019 [131] 
• Left ventricle 
function and 
injury 
• DIO-insulin 
resistant rats for 
4 weeks 
• 
ischemia/reperfu
sion (I/R) 
• Dapagliflozin 
(1mg/kg) daily 
by oral gavage 
for 4 weeks 
• Reduced infarct size 
and maintained stroke 
work during I/R 
Tanajak, 
2018 [146] 
• Myocardial 
ischemia/reperfu
sion injury in 
diabetic and 
non-diabetic 
hearts 
• Diabetic ZDF 
and non-diabetic 
ZL rats 
• high fat diet for 
32 weeks 
• Canagliflozin 
(300 mg) daily 
orally for 4 
weeks 
• Ischemia 
/reperfusion (IR) 
 
• Attenuated 
myocardial infarct size 
independent of 
glycemic status 
 
Lim, 2019 
[97] 
 
• Cardiac 
fibrosis and 
ventricular 
hemodynamics 
• Spontaneous 
Hypertensive 
Rats (SHR) 
• Empagliflozin 
(20 mg/kg) daily 
orally for 12 
weeks 
• Improved 
hemodynamics, 
attenuated cardiac 
fibrosis and 
normalized heart 
failure genes 
 
Lee, 2019 
[94] 
• Microvascular 
function and 
cardiac 
contractility 
• Lean and 
ob/ob -/- mice 
• Empagliflozin 
(1.5 mg/kg) daily 
for 10 weeks 
• Improved coronary 
flow reserve and 
fractional area change 
Adingupu, 
2019 [3] 
• Cardiac 
fibrosis and 
heart failure 
• Non-diabetic 
pigs 
• 2-hour balloon 
occlusion 
• Empagliflozin 
• Improved myocardial 
energetics, enhanced 
LV systolic function 
and ameliorated 
adverse LV 
remodeling 
Santos-
Gallego, 
2019 [130] 
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(10 mg) daily for 
8 weeks 
NHE • Cardiac NHE 
activity, 
hemodynamic 
and metabolic 
performance of 
isolated hearts 
tissues 
• Molecular 
docking 
simulations 
• Langendorff-
perfused mouse 
heart, perfused 
for 30 min 
• Empagliflozin 
(1 µM), 
dapagliflozin (1 
µM), or 
canagliflozin (3 
µM)  
• All SGLT2i exhibit a 
class effect by 
blocking NHE and 
reducing [Na+]c 
directly in the cardiac 
cell. Canagliflozin and 
empagliflozin induce 
vasodilation of the 
coronary circulation of 
the intact heart, and 
empagliflozin 
increases oxygen 
consumption 
Uthman et 
al., 2017 
[149] 
Atherosclerosi
s 
• Repetitive 
fluctuations in 
blood glucose 
concentrations 
and monocyte 
adhesion to the 
aortic 
endothelium 
• Male Goto-
Kakizaki rats 
• Phlorizin (100 
mg/kg injected 
subcutaneously 
twice daily) for 
12 weeks 
• Suppressed 
adhesion of 
monocytes on aortic 
endothelium 
Azuma et 
al., 2006 
[17] 
• Atherosclerosis  • Atherosclerosis 
model of male 
ApoE-/- mice 
• Empagliflozin 1 
mg/kg and 
empagliflozin 
3mg/ 
kg for 8 weeks 
• Decreased insulin 
resistance and 
circulating 
concentrations of 
TNF-alpha, IL-6, 
monocyte 
chemoattractant 
protein-1 (MCP-1), 
serum amyloid A and 
urinary microalbumin, 
and this significantly 
correlated with plaque 
size 
• Increased 
adiponectin levels 
Han et al., 
2017 [64] 
• Glycaemia and 
macrophage-
driven 
atherosclerosis 
• Glycaemia and 
macrophage-
driven 
atherosclerosis 
• Apolipoprotein 
E null (ApoE-/-) 
mice, 
streptozotocin-
induced diabetic 
ApoE-/- mice, 
and diabetic 
db/db mice 
• Dapagliflozin 
or ipragliflozin at 
the dose of 1.0 
• Attenuated the up-
regulation of gene 
expression of CD36 
and Lox-1, surface 
areas of 
atherosclerotic 
lesions, atheromatous 
plaque size, 
macrophage 
infiltration, and foam 
cell formation 
Terasaki et 
al., 2015 
[147] 
20 
mg/kg/day for 4 
weeks 
Modulation of 
neurohormone
s 
• Expression of 
biomarkers of 
heart failure and 
mortality 
• AA-induced 
heart failure 
model in 
developing 
cmlc2::GFP 
transgenic 
zebrafish 
embryos 
• Empagliflozin 
(0.1, 10 lM) 
• Modulated BNP and 
ANP signaling 
pathways, reduced the 
morphological and 
functional cardiac 
changes induced by 
AA, dampened AA-
enhanced expression 
of BNP and ANP, and 
reduced embryonic 
mortality 
Shi et al., 
2017 [140] 
Blood 
pressure  
• Efficacy and 
safety of 
canagliflozin 
compared with 
vildagliptin 
• Albino rats 
• Canagliflozin 
10 mg/kg 
• n = 12 
• Reduced mean blood 
pressure from 
baseline 
Abu Seif et 
al., 2017 
[2] 
• Regulation of 
vascular tone as 
well as NO-
induced 
vascular 
relaxation 
• Male 
streptozotocin-
induced 
C57BL/6 
diabetic mice 
• Canagliflozin 
(30 mg_10 mL-
1_kg body 
weight-1 via oral 
gavage daily) or 
vehicle (0.5% 
HPMC) for 4 
weeks. Mouse 
and human 
PAECs, human 
PASMCs, 
human CAECs, 
and human 
CASMCs were 
used in assays 
• Augmented sodium 
nitroprusside-
dependent relaxation 
in coronary arteries 
through induction of 
membrane 
hyperpolarization in 
smooth muscle cells, 
mediated by activation 
of potassium 
channels, but not in 
papaverine-induced 
model 
Han et al., 
2016 [65] 
• Blood glucose, 
SBP, GFR, 
urinary ACR, 
renal oxidative 
stress, 
angiotensinogen
, and Nrf2 
expression 
• Adult male 
Akita mice 
• Canagliflozin 
(0.3 mg/mL in 
drinking water) 
for 16 weeks 
• Improvements were 
not observed 
Chan et al., 
2016 [80] 
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Sympathetic 
nervous 
system 
• 
Cardioprotective 
effects via 
glucagon, which 
has inotropic 
effects on the 
heart 
• Male C57BL6 
mice 
• Canagliflozin 
(10 mg/kg/day 
for 4 weeks) 
• Reduced heart size, 
left ventricular dilation, 
and circulating 
glucagon 
concentration 
Kamihara 
et al., 2017 
[84] 
• Ventricular 
myocyte 
shortening and 
intracellular Ca2+ 
transport 
• Male Wistar 
STZ-induced 
diabetic rats 
• Freshly 
isolated 
ventricular 
myocytes 
perfused 
with 
dapagliflozin 
(10-5 M, 10-6 M, 
and 10-7 M) 
• Reduced the 
amplitude of 
ventricular myocytes 
shortening, calcium 
transient and L-type 
calcium current, 
suggesting that 
alteration in 
the mechanism(s) of 
calcium transport may 
partly explain the 
negative inotropic 
effects of 
SGLT2 inhibitors 
Hamouda 
et al., 2015 
[63] 
Oxidative 
stress  
• Endothelial 
dysfunction, 
oxidative stress, 
AGE/RAGE 
signaling and 
inflammation 
• Endothelial 
dysfunction, 
oxidative stress, 
AGE/RAGE 
signaling and 
inflammation 
• Male Wistar 
rats 
• Empagliflozin 
(10 mg/kg/day 
oral) or 
empagliflozin 
(30 mg/kg/day 
oral) for 8 weeks 
• Reduced blood 
glucose levels, 
normalized endothelial 
function and reduced 
oxidative stress in 
aortic vessels and in 
blood 
• Reversed the pro-
inflammatory 
phenotype and 
glucotoxicity 
(AGE/RAGE signaling) 
Oelze et 
al., 2014 
[117] 
Inflammation  • Activation of 
NLRP3 and 
inflammasome  
• Male BTBR 
ob/ob and WT 
mice 
• Dapagliflozin 
(1 mg/kg/day) 
for 8 weeks 
• Attenuated the 
activation of the 
nucleotide binding 
oligomerization 
domain (NOD)-like 
receptor 3 (NLRP3) 
inflammasome and 
upregulation of C-
reactive protein. The 
anti-inflammatory 
effect was AMPK-
dependent and 
SGLT1-independent 
Ye et al., 
2017 [162] 
Endoplasmic 
reticulum 
stress 
• Diabetic 
cardiomyopathy 
• Elucidate the 
related 
mechanism 
• Male 
streptozotocin-
induced Wistar 
rats 
• Empagliflozin 
(30 mg/kg/day 
oral); or 
empagliflozin 
• Improved mean 
pressure–volume 
relationships, 
ventricular contractility, 
histopathologic 
changes and ERS-
induced apoptosis of 
cardiomyocytes by 
Zhou et al., 
2017 [163] 
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(10 mg/kg/day) 
for 8 weeks 
downregulating 
proteins of the 
apoptosis pathways  
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Thrifty fuel hypothesis 
The “thrifty fuel hypothesis" [46, 111] proposes that the cardioprotective effects of 
SGLT2i are the result of a change in substrates utilized by the heart. The heart obtains 
the majority of its energy through mitochondrial oxidative phosphorylation [37]. Under 
normal conditions, the fuel source for the mitochondria is ~70% circulating free fatty acids 
and ~30% glucose [37, 101]. However, with myocardial ischemia or heart failure, and in 
the setting of diabetes, there is a preferential shift in fuel selection where the heart utilizes 
fatty acids almost exclusively [22, 101]. Oxidation of fatty acids requires more oxygen per 
unit of adenosine triphosphate (ATP) than other substrates (Figure 1.15) and an excess 
of fatty acid oxidation has been associated with reactive oxygen species generation [101], 
altered cellular ATP translocation from mitochondria inner membrane to the cytosol and 
increased mitochondrial uncoupling [25]. 
The “thrifty fuel hypothesis” suggests the 
anti-hyperglycemic actions of SGLT2i 
increases the glucagon to insulin ratio 
resulting in enhanced hepatic lipid 
mobilization and oxidation and a tonic 
increase in hepatic production of ketones 
(Figure 1.16). Ketones can serve as a fuel for myocardial ATP synthesis and do so with a 
more favorable ratio of ATP to oxygen [22] thus preventing negative effects associated 
with excessive fatty acid oxidation.  
  
Figure 1.15 ATP produced per oxygen 
consumed (P/O ratio) for various 
substrates.  [111] 
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Studies have been performed evaluating the effects of increased delivery of ketone 
bodies i.e. via a ketogenic diet or infusion of ketone bodies in pre-clinical animal and in 
human studies.  Horton et al. evaluated the effect of a ketogenic diet 1 week prior to a 
TAC/MI (transverse aortic constriction combined with a small apical myocardial infarction) 
procedure and for four weeks post TAC/MI procedure in mice.  Mice fed a ketogenic diet 
had increased circulating ketone levels compared to control chow fed mice.  They found 
no differences in ejection fraction between the two groups however, they did observe 
significant changes in left ventricular volumes.  Both left ventricular end diastolic and end 
systolic volumes were significantly lower in the animals on a ketogenic diet.  Additionally, 
Horton et al. performed studies in a canine tachypacing model of dilated cardiomyopathy 
which has myocardial alterations consistent with dilated congestive heart failure.  After 13 
Figure 1.16 The thrifty fuel hypothesis.   
Empagliflozin (EMPA) may result in an increase in a more energetically favorable 
substrate such as β-hydroxybutyrate (BHOB) and shift myocardial metabolism away 
from fatty acid utilization.  ADP, adenosine diphosphate; ANT, adenine nucleotide 
translocase; ATP, adenosine triphosphate; CPT-1/2, carnitine palmitoyltransferase 
type 1/2; ETC, electron transport chain; FAT/CD36, fatty acid translocase; GLUT1/4, 
glucose transporter 1/4; MCT, monocarboxylate transporter; NAD+/NADH, nicotine 
amide dinucleotide oxidized/reduced; PDH, pyruvate dehydrogenase; TAG, 
triacylglycerols; UCP 2/3, uncoupling proteins 2 and 3. [25] 
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days of over-pacing, the ketone body 3-hydroxybutyrate (3-OHB) was infused into the right 
ventricle for the remainder of the protocol (day 29 of pacing).  Infusion of 3-OHB prevented 
increases in left ventricular end diastolic pressure, a key parameter for identifying heart 
failure and evaluating its progression [77].  Horton et al. observed a 30% increase in 
myocardial mechanical energy efficiency (pressure-volume area/myocardial oxygen 
consumption) consistent with increased stroke work (pressure-volume area) as 
myocardial oxygen consumption remained unchanged compared to non-paced controls.   
Nielsen et al. evaluated the effect of 3-hydroxybutyrate (3-OHB) infusion in heart 
failure patients with reduced ejection fraction.  They demonstrated that circulating 3-OHB 
levels increased from 0.4 to 3.3 mM, which resulted in a significant increase in cardiac 
output, stroke volume, heart rate and left ventricular ejection fraction [115].  Gormsen et 
al.  evaluated Na-3-hydroxbutyrate (ketone) infusion in 8 healthy adults and observed 
reduced myocardial glucose uptake, increased myocardial blood flow and no change in 
free fatty acid oxidation with ketone infusion compared to saline infusion [58].  Together 
these data provide evidence of beneficial hemodynamic effect of increased ketones in 
heart failure animal models and in heart failure patients.  Clear evidence that SGLT2i 
treatment-induced shifts to ketones as a fuel source will improve or maintain cardiac 
function in ischemic heart disease does not yet exist. 
 
Sodium hypothesis 
Another proposed mechanism for the cardiovascular benefit is an off-target action 
of SGLT2i on the cardiac Na+/H+ exchanger, i.e. the “sodium hypothesis”. Studies in rat 
and rabbit cardiomyocytes have demonstrated the ability of SGLT2i to inhibit NHE-1 [19], 
the predominant isoform expressed in cardiac tissue [32, 125]. Under normal conditions, 
this exchanger is responsible for extruding protons from the myocyte and serving to 
regulate intracellular pH [154]. Intracellular acidosis is the major stimulus for NHE-1 
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activity.  Both activity and expression of NHE-1 [18] have been shown to be elevated in 
conditions of metabolic stress such as myocardial ischemia and heart failure.  This protein 
exchanges H+ for Na+ meaning that enhanced proton extrusion will result in increased Na+ 
uptake [25]. Studies in isolated cardiomyocytes have demonstrated that under conditions 
of hyperactive NHE-1, the resultant influx of Na+ is sufficient to affect the Na+/Ca2+ 
exchanger (NCX).  NCX transports Ca2+ out as Na+ enters (i.e. forward mode of NCX).  
However, under the condition of increased intracellular Na+, the NCX runs in reverse, 
thereby increasing intracellular Ca2+ [120].  SGLT2i blockade of NHE-1 would prevent the 
increase in cytoplasmic Na+ and by extension prevent intracellular accumulation of Ca2+ 
and the consequent pathological hypercontractility. The net effect of the “sodium 
hypothesis” is depicted in Figure 1.17.  
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Pre-clinical studies with NHE-1i have demonstrated positive cardiovascular 
effects.  Hartmann and Decking evaluated the NHE-1i cariporide in isolated guinea-pig 
hearts subjected to 15 minutes of ischemia and 30 minutes of reperfusion.  They observed 
significant reductions in ischemia-induced rise in intracellular Na+, improved post-ischemic 
contractile function and diminished contracture development with cariporide pre-treatment 
[67].  Fukuta et al. performed studies in open-chest swine pretreated with amiloride (NHE-
1i) and subjected to 30 minutes of regional ischemia followed by 180 minutes of 
reperfusion.  They demonstrated that pre-treatment with amiloride significantly reduced 
infarct size in the open-chest swine model of ischemia/reperfusion [53].  Additionally, 
Spitznagel et al. evaluated the effects of cariporide in a rat model of infarct-induced heart 
Figure 1.17 The sodium hypothesis.   
EMPA may protect failing cardiac myocytes by improving Na
+
 and Ca2
+
 handling via 
NHE inhibition. ADP, adenosine diphosphate; ATP, adenosine triphosphate; ETC, 
electron transport chain; MCU, mitochondrial Ca2
+
 uniporter; NAD
+ 
/ NADH, nicotine 
amide dinucleotide oxidized/reduced; NCX, sarcolemmal Na
+ 
/Ca2
+
 exchanger; NKA, 
Na+/K
+
 ATPase; IMM, inner mitochondrial membrane; OMM, outer mitochondrial 
membrane; RyR, ryanodine receptor; SERCA, sarcoplasmic reticulum Ca2
+
 ATPase 
[25] 
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failure.  They found that chronic treatment with cariporide decreased left ventricular end 
diastolic pressure and improved myocardial contractility [142].  These studies provide 
support for NHE-1 mediated cardioprotection during ischemia/heart failure.  Whether 
SGLT2i mediates NHE-1 activity during ischemia/heart failure as described by the “sodium 
hypothesis”, remains to be determined. 
 
Summary and proposed experimental aims  
At present, there is a paucity of data regarding the cardiovascular effects of SGLT2i in 
health or disease. Recent rodent studies support SGLT2i mediated improvements in 
cardiac function leading to improved cardiac efficiency during myocardial ischemia.  One 
such study by Sayour et al. demonstrated canagliflozin mediated improvements in cardiac 
efficiency compared to control animals in non-diabetic rats subjected to ischemia-
reperfusion injury [131].  Two plausible mechanisms for the observed cardiac effects 
include the “thrifty fuel hypothesis” and “the sodium hypothesis” however, the exact 
mechanisms responsible for these effects have not been delineated. Coincidently, both 
myocardial metabolism (“thrifty fuel hypothesis”) and Na+/Ca2+ handling (potentially 
mediated by inhibition of NHE-1, “the sodium hypothesis”) play an important role in 
determining cardiac efficiency (Figure 1.17).  Furthermore, SGLT2i have been reported to 
increase ketone levels [39, 46, 88] and inhibit NHE-1 in isolated rodent cardiomyocytes 
[19, 149]. 
Efficiency is defined as the relationship between work performed relative to the 
amount of energy consumed, simply put, for work to be done energy is required [79, 136].  
This holds true for the heart, for the heart to perform it’s pumping function (work) it requires 
energy.  The heart obtains most of its energy through mitochondrial oxidative 
phosphorylation [37]. Under normal conditions, the fuel source for the mitochondria is 
~70% circulating free fatty acids and ~30% glucose [37, 101].  However, in situations such 
29 
as myocardial ischemia or heart failure, and in the setting of diabetes, there is a 
preferential shift in fuel selection where the heart utilizes fatty acids almost exclusively [22, 
101]. Therefore, for simplicity when calculating cardiac efficiency myocardial oxygen 
consumption (MVO2) is used as a surrogate, regardless of what fuel source is being 
oxidized oxygen is being consumed [79, 136].   
In the heart, the left ventricular external work represents the work being done by 
the heart and is the product of stroke volume and mean arterial pressure.  Accordingly, 
the calculation for cardiac efficiency is stroke work / MVO2 or stroke volume x mean arterial 
pressure / coronary blood flow x arteriovenous oxygen difference.  As such, myocardial 
substrate selection plays an important role in determining cardiac efficiency.  Cardiac 
function is linked to oxygen supply such that cardiac function is proportionally impaired 
with reductions in oxygen supply [136].  However, the heart can use what oxygen is 
available more efficiently by altering which substrate is consumed (MVO2).  Ketones yield 
more ATP per oxygen consumed compared to other substrates (have a higher P/O ratio, 
number of phosphates for ATP generation per molecule of oxygen consumed, Figure 1.15) 
and therefore are a more efficient fuel source (Figure 1.16).  This generated ATP is then 
used for crossbridge cycling (contraction) and for ion transport (Na+ and Ca2+) as shown 
in Figure 1.18 [136]. Myocardial work depends on the ATP generated by oxidative 
phosphorylation such that cardiac efficiency is dependent on how efficient the heart is at 
converting ATP (by hydrolysis) to mechanical work [79].  The heart being able to maintain 
ATP generation or minimize the reduction of ATP generation during ischemia is critical to 
cardiac function and therefore cardiac efficiency. 
Na+/Ca2+ handling is also a major determining factor in myocardial work through 
regulation of excitation-contraction coupling and in modulating diastolic and systolic heart 
function [54].  Under normal conditions cardiac NHE-1 is quiescent and becomes active 
when intracellular pH is reduced as observed in ischemic conditions [18, 154].  The 
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increased activity of NHE-1 leads to an increased influx of Na+ and consequent 
dysfunctional Ca2+ handling ultimately leading to diastolic and systolic dysfunction [120].   
Inhibition of NHE-1 during ischemia prevents the dysregulation of Na+ and consequent 
Ca2+ overload thereby allowing the heart to maintain cardiac function and most importantly 
cardiac efficiency during ischemia and reperfusion (Figure 1.17).  Therefore, both the 
“thrifty fuel hypothesis” and the “sodium hypothesis” are plausible cardioprotective 
mechanisms and may not be mutually exclusive as energy levels are tied to Na+/Ca2+ 
handling and contraction (Figure 1.18).  However, neither hypothesis has been directly 
attributed to for SGLT2i cardioprotective effects. 
 
Figure 1.18 Schematic diagram of the proposed effects of SGLT2i on the primary 
determinants of cardiac efficiency.  
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The goal of this proposal is to examine the mechanisms of cardiovascular effects of 
SGLT2i in ischemia/reperfusion. This goal will be accomplished by addressing the 
following specific aims: 
 
1. Test the hypothesis that SGLT2i improves cardiac contractile function and efficiency 
and attenuates infarct size in response to ischemia/reperfusion injury via salutary 
effects on myocardial metabolism. Integrative in vivo studies in open-chest swine will 
evaluate the relationship between left ventricular pressure and volume, myocardial 
substrate selection and infarct size during regional ischemia/reperfusion injury in the 
absence and presence of the SGLT2i. Additional in vitro studies will investigate the 
extent of SGLT2 mRNA and protein expression in swine kidney vs. heart.   
 
2. Evaluate the hypothesis that NHE-1 contributes to the cardiac effects of SGLT2i in 
response to myocardial ischemia/reperfusion injury. In vivo studies in open-chest 
swine will evaluate the relationship between left ventricular pressure and volume 
during regional myocardial ischemia injury in the absence and presence of the NHE-
1i. In vitro studies will examine the effects of SGLT2i on NHE1 function.  
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Chapter 2:  Inhibition of Sodium Glucose Cotransporter-2 Preserves Cardiac 
Function During Regional Myocardial Ischemia Independent of Alterations in 
Myocardial Substrate Utilization 
 
Introduction 
The type 2 sodium-glucose co-transporter (SGLT2) is located in the S1 and S2 
segments of the renal proximal tubules and is responsible for ~90% of glucose 
reabsorption in the kidney. In chronic hyperglycemia, SGLT2 activity is increased as a 
result of upregulation, exacerbating increases in plasma glucose concentration [108]. 
Inhibitors of this co-transporter (SGLT2i) reduce glucose reabsorption in the kidneys, 
resulting in increased urinary glucose excretion and a reduction in plasma glucose levels 
[69]. Cardiovascular outcome studies have demonstrated that SGLT2i also significantly 
reduce major adverse cardiovascular events in subjects with type 2 diabetes mellitus 
(T2DM) [12, 114, 164]. These cardiovascular benefits do not appear to be mediated by 
direct effects of these agents on the SGLT2 transporter in cardiovascular tissues, as 
SGLT2 protein expression is not detected in the heart or vasculature [32, 65, 68]. These 
benefits are also not explained by improved glycemic control, as anti-diabetes agents in 
other classes have provided similar improvements in glucose without parallel beneficial 
cardiac effects [104, 114, 164]. Furthermore, SGLT2i have been shown to improve cardiac 
function and mitigate myocardial infarct size in metabolically normal animal models [97, 
129].  Improved arterial stiffness [33] and reduced blood pressure [34] have been reported 
with chronic SGLT2i treatment, however, it is unclear whether these effects are sufficient 
to explain the observed cardiovascular benefits.  
 In this context the ‘thrifty fuel’ hypothesis has been proposed to explain the 
cardiovascular benefits of SLGT2i [111]. In particular, inhibition of SGLT2 has been 
demonstrated to augment circulating ketone bodies via alterations in hepatic fuel 
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metabolism [48, 112]. Since ketone transport via the monocarboxyl transporter depends 
simply on the transmembrane gradient, increased ketone availability could serve to shift 
myocardial fuel utilization away from free fatty acids toward ketones, which require less 
oxygen per mole of ATP produced [22]. Some support for the plausibility of this ketone 
hypothesis in improving cardiac function and efficiency in response to pathologic stimuli 
such as ischemia has been presented [47]. However, studies to directly assess the effects 
of SGLT2i on myocardial substrate utilization during ischemia are presently lacking.  
The goal of the present study was to evaluate the effects of SGLT2i on cardiac 
contractile function, substrate utilization, and efficiency before and during regional 
myocardial ischemia/reperfusion injury in normal, metabolically healthy swine. This study 
tested the hypothesis that SGLT2i improves cardiac function and efficiency during 
ischemia/reperfusion injury via shifts in myocardial substrate selection toward ketone 
utilization. To exclude contributions of effects of chronic exposure, studies were performed 
following a very short-term (24 hr) exposure to SGLT2i.  Invasive methodologies were 
used to obtain high-quality and precise in vivo measures of hemodynamics and cardiac 
function, including gold standard measurements of contractility. Findings from this study 
provide novel insight in to the acute, cardioprotective effects of SGLT2i during ischemic 
injury.  
 
Methods 
Animal model and surgical preparation 
All experiments involving animals were approved by an Institutional Animal Care 
and Use Committee and performed in accordance with the Guide for the Care and Use of 
Laboratory Animals (National Institutes of Health Publication. No. 85-23, Revised 2011).  
Male domestic swine (~50 kg) were placed on a standard chow (5L80, Purina Test Diet, 
Richmond, IN, USA) and randomly assigned into Control or Treatment groups.  Treatment 
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animals were given canagliflozin (300 mg, oral) 24 hours prior to and approximately 2 
hours before the acute/terminal procedure. Control animals received no treatment. 
 
Left Circumflex Ischemia Protocol 
 Following an overnight fast (~16 hours), control (n = 7) and canagliflozin treated 
(n = 8) swine were anesthetized with telazol (5 mg/kg), ketamine (3 mg/kg), and xylazine 
(2.2mg/kg) cocktail (i.m.) and then anesthesia was maintained with morphine (3 mg/kg) 
and α-chloralose (100 mg/kg, i.v). Depth of anesthesia was monitored by observing 
continuous measurements of arterial blood pressure and heart rate as well as regular (15-
minute intervals) reflex tests (corneal, jaw, limb withdrawal), beginning after induction of 
anesthesia and continuing throughout the experimental protocol. Periodic 
supplementation with α-chloralose was performed every 1.5 hours to maintain a level, 
stage 3 plane of anesthesia. The right femoral artery and vein were isolated and 
catheterized to allow measurement of systemic arterial pressure and maintain venous 
access, respectively. The heart was exposed by a left lateral thoracotomy. The proximal 
region of both the left anterior descending artery (LAD) and left circumflex artery (LCX) 
were isolated for placement of perivascular flow probes (Transonic Systems Inc., Ithaca, 
NY) and a snare occluder was placed around the left circumflex artery.  A catheter was 
then placed in the intraventricular vein to allow sampling of coronary venous blood from 
the area supplied by the LAD. A Sci-Sense pressure/volume admittance catheter 
(Transonic Scisense, London Ontario, Canada) was passed through a hemostatic control 
valve placed directly into the left ventricle via a transmural stab near the base of the left 
ventricle and secured with a purse string suture.  Measurements were obtained at 
baseline, during a 30 minute complete occlusion of the LCX, and during a 2-hour 
reperfusion. At the beginning of the study, a total of 20 animals were enrolled (10 per 
group; randomized). Three swine from the control group and two swine from the 
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canagliflozin group fibrillated during the coronary occlusion portion of the protocol and 
were thus not included in the study.  
 
Metabolic Analysis 
Arterial (5 mL) and coronary venous (5 mL) blood samples were collected 
simultaneously into untreated syringes, immediately sealed, and placed on ice. These 
samples were collected every 15 minutes during baseline and the coronary occlusion, and 
every 30 minutes during reperfusion; total blood samples across the 2-3-hour 
experimental protocol summed to <100 mL from an estimated ~4-5 L total circulating blood 
volume. The samples were analyzed immediately upon collection for pH, PCO2, PO2, O2 
content, glucose, lactate and hematocrit with an Instrumentation Laboratories automatic 
blood gas analyzer (GEM Premier 4000). Free fatty acids (NEFA- Non-Esterified Fatty 
Acids) were measured colorimetrically (WAKO Life Sciences, City State) and ketones 
were analyzed with a chemistry analyzer (Roche Hitachi Modular P, Indianapolis IN), 
reporting concentrations of -hydroxybutyrate and acetone as total ketone measure. 
Myocardial oxygen consumption (MvO2; μl O2/min/g) was calculated using the Fick 
principle [coronary blood flow × (arterial O2 content – coronary venous O2 content)]. For 
these calculations, LAD perfusion territory was estimated to be 30% of total heart weight, 
as previously described [45].  The Fick principle was also used to calculate substrate 
uptake (glucose, lactate, free fatty acids, and ketone), [coronary blood flow × (arterial 
substrate content – coronary venous substrate content)]. Accordingly, the term “uptake” 
refers to the result of the Fick calculation and it should be recognized that this variable 
does not account for the degree to which substrate production by the tissue (e.g. lactate) 
contributes to the reported value. Cardiac efficiency was calculated as cardiac work 
(product of cardiac output and mean arterial pressure) divided by MvO2. 
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Infarct protocol 
Additional studies to assess the effects of SGLT2i on myocardial infarct size were 
also performed in control (n = 8) and canagliflozin treated (n = 8) swine. Owing to the fact 
that historic attempts at proximal occlusions of the LCX have resulted in high mortality 
rates with prolonged ischemic duration as well as variable access to distal LCX territories, 
these studies were performed in the distal LAD region, as previously described [55, 56]. 
In these experiments, the distal LAD was subjected to a 60 minute occlusion followed by 
2 hours of reperfusion. Durations of ischemia and reperfusion were selected based on 
literature support indicating that the stimulus would be adequate and appropriate for 
induction of regional myocardial infarction [55, 56]. Four swine fibrillated during the LAD 
coronary occlusion portion of this protocol (n = 2 in each group) and thus were not included 
in infarct analyses. Therefore, for infarct analyses, the final n = 6 for each group.  
Hemodynamic data were collected in these animals as well. However, due to a 
failure of the pressure volume catheter, pressure volume loops for two animals in the 
infarct study (n = 1 per group) were unreliable. As a result, the n for metrics associated 
with the pressure-volume catheter (left ventricular pressures, volumes and derived 
measures) is 5 per group. 
 
Infarct Quantification  
At the completion of each experiment, hearts were fibrillated by direct application 
of a 9V battery and excised.  Hearts were then sliced into 1-cm-thick sections and 
incubated in 1% 2, 3,5-triphenyltetrazolium chloride (TTC) solution for 20 minutes at 37°C.  
Following incubation with TTC solution, a digital image of each heart slice was captured 
by a Canon Eos-Rebel sl1 with an associated 18-55mm lens, capturing 18.0 MP images 
in RAW format. No measurable infarct was detected in animals subjected to LCX occlusion 
regardless of treatment (control n = 3; SGLT2i n = 4) and those animals are, accordingly, 
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not included in infarct analyses. Measurable infarct was present and consistent in animals 
who received the longer (60 minute) occlusion of the distal LAD. In those animals, 
quantification of infarct area (unstained) versus viable myocardium (stained) was 
performed using ImageJ software (National Institutes of Health). Each heart slice was 
evaluated by three separate investigators who were blinded to experimental treatment 
group. Data are presented as averaged area for left ventricle (stained) and infarct area 
(unstained); the coefficient of variation between the three investigators was 7% for the left 
ventricle and 9% for the infarcted area. 
 
RNA Isolation and cDNA synthesis 
Tissue mRNA was prepared using a miRNeasy Mini Kit (Qiagen Cat#1038703). 
Flash frozen (500 mg) pig heart (n = 5) and kidney (n = 5) samples from domestic swine 
were homogenized in 2 mL Qiazol with a Polytron homogenizer (Kinematica Model 
PT3100) at 1000 rpm until clear homogenate was observed (1-2 min in cold room on ice 
bath). The homogenate was vigorously shaken for 15 seconds with 380 µL chloroform. 
Total RNA was isolated from the upper aqueous phase according to the kit protocol using 
on-column DNA digestion.  cDNA was synthesized from 500 ng total RNA in a 20 µL 
reaction using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems 
Cat#4368814). 
 
RT PCR 
The pig SGLT1 RT PCR assay was obtained from ThermoFisher (Applied 
Bioscience catalog # Ss03374377_m1). The SGLT2 assay was designed on the basis of 
whole genome shotgun sequence published in NCBI (Reference Sequence: 
NC_010445.4) and made by Integrated DNA Technologies, Inc. (Skokie, Illinois) as a 
custom assay. Primer/Probe sequences were: Pig SGLT2- Assay 1, reverse primer GAA 
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TCC AGC TGA GCC ACT C, forward primer GGG AAG CGA TAC TGT CAG ATC, probe 
TGG AAA AGGACC CCT CTG GAT TTG G. The pig SGLT2-Assay 2, reverse primer 
GGA CAG GTA GAG GCG AAT G, forward primer CTC TTC GTG CCA GTG TAC C, 
probe CGC CGG TGTCAT TAC CAT GCC. cDNA was diluted 1:5 and RT-PCR was 
accomplished with Taqman 2X Universal PCR Master Mix (Applied Biosytems, catalog # 
4304437) in ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Cycles 
for SGLT1 and 2 were normalized to housekeeping gene, peptidylpropyl isomerase A.  
 
Statistical Analyses 
Data were analyzed using the SigmaPlot statistical package (version 11 Systat 
Software Inc, San Jose, CA) and SPSS (version 22 IBM, Chicago, IL, USA). Data are 
presented as mean ± standard error. Comparisons were assessed by t-test or two-way 
ANOVA; [Factor A = treatment (time control/SGLT2i); Factor B = condition 
(baseline/occlusion/reperfusion)] as appropriate. When significance was established with 
ANOVA, Student–Newman–Keuls post-hoc testing was performed to identify pairwise 
differences between treatment groups and conditions.   Statistical significance was 
declared when P < 0.05. 
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Results 
mRNA expression of SGLT-1 vs. SGLT-2 in swine heart and kidney  
Determination of the relative abundance of SLC5A1 transcript (the gene encoding 
SGLT1 protein) and SLC5A2 transcript (the gene encoding SGLT2 protein) was assessed 
by qPCR in kidney and left ventricular biopsies from domestic swine (n = 5). These 
analyses detected the presence of SGLT1 (Figure 2.1A) and SGLT2 (Figure 2.1B) mRNA 
in both heart and kidney. However, the abundance of both of these transcripts was 
approximately 100-fold higher in kidney tissue than that of heart tissue.    
Systemic effects of SGLT-2i during ischemia/reperfusion injury of the LCX   
Hemodynamic and blood gas data for control (n = 7) and canagliflozin (n = 8) 
treated swine at rest and during LCX ischemia/reperfusion injury are provided in Table 
2.1. The 24-hour exposure to canagliflozin did not significantly affect baseline resting 
systolic arterial pressure (P = 0.16), diastolic arterial pressure (P = 0.93) or coronary blood 
flow (P = 0.56) (Table 2.1). Although canagliflozin-related decreases in arterial pH (P < 
0.001) and hematocrit (P < 0.001) and increases in arterial PO2 (P < 0.001) were detected 
by ANOVA, values of these variables remained within physiologic limits throughout the 
experimental protocol (Table 2.1).   
B A 
Figure 2.1 qPCR for SGLT1 (Panel A) and SGLT2 (Panel B) in kidney (n = 5) vs. 
heart (n = 5) biopsies from domestic swine. [20] 
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Mean arterial pressure decreased from ~85 ± 5 mmHg at baseline to ~70 ± 5 
mmHg following 30 minute ischemia/reperfusion injury in control and canagliflozin treated 
swine (Figure 2.2A; Condition: P = 0.03; Treatment: P = 0.53). Heart rate averaged ~75 
beats/min throughout the entire protocol in both untreated and treated swine (Figure 2.2B; 
Condition: P = 0.98; Treatment group: P = 0.80). None of the hemodynamic or blood gas 
parameters were significantly affected by 30 minute ischemia/reperfusion (Table 2.1).   
 
Effects of SGLT2i on cardiac contractile function during ischemia/reperfusion injury of the 
LCX 
Under baseline conditions canagliflozin had no effect on left ventricular end 
diastolic volume (P = 0.69), end systolic volume (P = 0.47) stroke volume (P = 0.76) or 
cardiac output (P = 0.92) (Figure 2.3). However, following the onset of regional myocardial 
ischemia (LCX occlusion), canagliflozin treatment was associated with a significant and 
acute increase in left ventricular end-diastolic volume (Figure 2.3A; P = 0.002) and left 
ventricular end-systolic volume (Figure 2.3B; P = 0.03). These changes in cardiac volumes 
corresponded with a maintenance of stroke volume (Figure 2.3C; P = 0.03) and cardiac 
output (Figure 2.3D; P = 0.05) throughout the ischemic time period and were not observed 
in control animals. Canagliflozin did not affect load-dependent measures of cardiac 
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Figure 2.2 Effects of ischemia/reperfusion injury on mean blood pressure (Panel A) 
and heart rate (Panel B) in Control (n = 7) and SGLT2i (canagliflozin) treated (n = 8) 
swine. [20] 
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function, including ejection fraction (P = 0.14), dP/dtmax (P = 0.06), dP/dtmin (P = 0.30), or 
Tau½ (P = 0.31) (Table 2.1). MvO2 of the non-occluded anterior coronary vascular bed was 
unaffected by canagliflozin or by 30 minute ischemia/reperfusion in either group (Table 
2.1).    
 
 Schematic representations of average steady-state left ventricular pressure-
volume loops illustrating the effect of regional myocardial ischemia in control vs. 
canagliflozin treated swine are provided in Figure 2.4.  In control swine these pressure-
volume relationships demonstrate an expected modest reduction of left ventricular end-
diastolic volume and systolic pressure generation during regional ischemia (Figure 2.4A).  
This was notably different in the canagliflozin-treated animals, which showed a substantial 
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Figure 2.3 Effect of ischemia/reperfusion injury on end diastolic volume (Panel A), 
end systolic volume (Panel B), stroke volume (Panel C) and cardiac output (Panel D) 
in Control (n = 7) and SGLT2i (canagliflozin) treated (n = 8) swine. * P < 0.05 vs. 
Control (same time point), † P < 0.05 vs. baseline value (same treatment). [20] 
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right shift of the pressure-volume relationship (Figure 2.4B).  Comparisons of the 
relationship between stroke volume vs. end-diastolic volume and cardiac output vs. end-
diastolic volume (Frank-Starling relationship) during ischemia in control and canagliflozin 
treated swine are provided in Figure 2.4. These plots reveal that canagliflozin-mediated 
increases in stroke volume (Figure 2.4C) and cardiac output (Figure 2.4D) were directly 
related to increases in end-diastolic volume (preload). Left ventricular end diastolic 
pressure was unaffected by 30 minute ischemia/reperfusion or SGLT2i with canagliflozin 
(Table 1). 
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Stroke work (stroke volume (mL) x mean arterial pressure (mmHg)) and efficiency 
(cardiac output (mL/min) × mean arterial pressure (mmHg)) / MvO2 (μl O2/min/g) were 
unaffected by canagliflozin treatment under baseline conditions (Figure 2.5). However, 
stroke work (Figure 2.5A; P < 0.001) and efficiency (Figure 2.5B; P = 0.03) were 
significantly increased by canagliflozin administration during regional myocardial ischemia 
compared to control swine.  
 
Effects of SGLT2i on myocardial substrate selection during ischemia/reperfusion injury of 
the LCX 
Administration of canagliflozin augmented arterial free fatty acid concentration 
(Table 2.2; P = 0.017). However, circulating concentrations of other cardiac substrates 
including glucose (P = 0.087), lactate (P = 0.336) and total ketone bodies (acetoacetone 
and 3-hydroxybutyrate) (P = 0.74) were unaffected by SGLT2i (Table 2.2). Canagliflozin 
did not significantly influence myocardial uptake of glucose (P = 0.75), lactate (P = 0.26), 
ketones (P = 0.41) or free fatty acids (P = 0.31) (Figure 2.6), under resting conditions, 
during the 30 min ischemia, or during reperfusion.  
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Figure 2.5 Effects of ischemia/reperfusion injury on cardiac stroke work (Panel A) and 
efficiency (Panel B) in Control (n = 7) and SGLT2i (canagliflozin) treated (n = 8) 
swine. * P < 0.05 vs. Control (same time point). [20] 
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Effect of SGLT2i on myocardial infarct size and cardiac function in response to 60-minute 
LAD occlusion 
No evidence of myocardial infarction was detected in either control (n = 3) or 
SGLT2i (n = 4) treated hearts following the 30 minute LCX occlusion protocol. Therefore, 
to better assess potential effects on magnitude of myocardial infarction, a 60 minute 
occlusion with 2-hour reperfusion was performed in a separate cohort of animals in the 
distal LAD region. The rationale for a change in perfusion territory was based on historic 
attempts at longer term proximal occlusions of the LCX which resulted in marked 
increases in mortality [55, 56]. Therefore, our additional cohort of animals, was modeled 
0 30 60 90 120 150
0.00
0.05
0.10
0.15
0.20
Time (min)
G
lu
c
o
s
e
 U
p
ta
k
e
 (

m
o
l/
m
in
/g
)
15
Ischemia Reperfusion
Condition P = 0.47
Treatment P = 0.74
Control
SGLT2i
0 30 60 90 120 150
0.0
0.2
0.4
0.6
Time (min)
L
a
c
ta
te
 U
p
ta
k
e
 (

m
o
l/
m
in
/g
)
15
Ischemia Reperfusion
Condition P = 0.14
Treatment P = 0.25
0 30 60 90 120 150
0
5
10
15
20
Time (min)
K
e
to
n
e
 U
p
ta
k
e
 (
n
m
o
l/
m
in
/g
)
15
Ischemia Reperfusion
Condition P = 0.27
Treatment P = 0.41
A B 
C D 
0 30 60 90 120 150
0.00
0.01
0.02
0.03
0.04
0.05
Time (min)
F
F
A
 U
p
ta
k
e
 (
n
m
o
l/
m
in
/g
)
15
Ischemia Reperfusion
Condition P = 0.58
Treatment P = 0.31
Figure 2.6 Effect of ischemia/reperfusion injury on myocardial uptake of glucose 
(Panel A), lactate (Panel B), ketones (Panel C) and free fatty acids (FFA) (Panel D) 
in Control (n = 7) and SGLT2i (canagliflozin) treated (n = 8) swine. [20] 
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after established protocols demonstrating reliable induction of myocardial infarction with 
higher survival rates following 60 minute occlusion of the distal LAD in swine [55, 56]. 
 In contrast to data from the 30 minute LCX occlusion, TTC staining of hearts from 
the 60 minute LAD occlusion protocol revealed that treatment with canagliflozin (n = 6) 
significantly reduced infarct size by ~60% compared to control (n = 6) swine (Figure 2.7; 
P = 0.03).  Additionally, canagliflozin treatment produced similar effects following the onset 
(15 and 30 minute) of the distal LAD occlusion, including a significant increase in left 
ventricular end-diastolic volume and stroke volume (Appendix B; P = 0.01) compared to 
control swine. Heart rate was significantly lower in the SGLT2i group at the later ischemic 
time points (≥ 30 minute occlusion) (Appendix A). However, this reduction was not 
associated with alterations in end diastolic volume or stroke volume at either 45 or 60min 
occlusion.   
 
 
 
 
Figure 2.7 Images in Panel A show representative transmural sections of left 
ventricular slices from control (n = 6) and canagliflozin (n = 6) treated swine. 
Quantification of total infarct area relative to total left ventricular area is presented in 
Panel B. * P < 0.05 vs. control. [20] 
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Discussion 
There is a growing body of evidence supporting beneficial cardiovascular effects 
of SGLT2i in the setting of obesity/type 2 diabetes [12, 114, 164] and in normal, 
metabolically healthy animal models [97, 129]. However, there was no a priori reason to 
expect such beneficial effects of these glucosuric agents, and the mechanisms 
underpinning these unexpected effects are unknown. As such, whether effects of SGLT2i 
are the result of direct action on cardiomyocytes or other cardiac cells or, are secondary 
to extra-cardiac effects of SGLT2i remains undetermined. A proposed mechanism to 
explain SGLT2i-associated improvements in major adverse cardiovascular events as well 
as reductions in myocardial infarct size [12, 97] centers around the “thrifty fuel hypothesis” 
[22, 49, 112, 143]. This hypothesis is based on a recognized effect of SGLT2i to induce 
ketone production, which by providing ketones to the heart may improve cardiac efficiency 
by shifting myocardial substrate utilization away from free fatty acids [22, 47]. Accordingly, 
this study was designed to evaluate the effects of the SGLT2i canagliflozin on cardiac 
contractile function, substrate utilization, and efficiency before and during regional 
myocardial ischemia/reperfusion injury in normal, metabolically healthy swine. Effects of 
canagliflozin to augment cardiac function during regional myocardial ischemia and reduce 
myocardial infarct size were observed in this study, but these effects were independent of 
alterations myocardial substrate utilization.  These observations argue against 
contributions of ketone-induced shifts in fuel selection to the cardioprotective effects of 
SGLT2i.  
 
Cardiac effects of SGLT2i  
Here, shown for the first time that SGLT2i produces a prominent and sustained 
increase in left ventricular volumes during regional myocardial ischemia in otherwise 
normal, metabolically healthy swine. There was no evidence of these effects under 
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baseline conditions, and they abated during reperfusion (Figure 2.4).  Further, these 
effects were not associated with any changes in arterial blood pressure (afterload) or heart 
rate (ventricular filling time) (Figure 2.2). These data are consistent with recent rodent 
investigations which demonstrate that SGLT2i was able to preserve cardiac function in 
pressure-overload induced heart failure mice independent of changes in afterload, as 
cardioprotection was evident both in vivo and in subsequent isolated heart studies [29].  
Significant increases in end diastolic volume could be interpreted as potentially 
deleterious, as volume overload is commonly associated with dilated cardiomyopathy 
and/or exacerbation of myocardial infarction. In this study, however, changes in ventricular 
volume handling were seen only during ischemia and reversed with relief of ischemia, at 
least under these acute exposure conditions. The timeline of the ischemia in this study 
(minutes) would not allow for the necessary remodeling associated with a dilated 
cardiomyopathy phenotype. Further, interpretation of this study is simplified as effects 
were evident in the absence of measurable myocardial infarction, as measured by TTC 
staining in the 30 minute LCX occlusion study.  The lack of myocardial infarction following 
a 30 minute coronary occlusion is consistent with previously published studies in swine 
[55, 71, 72, 132]. Therefore, changes in ventricular volume handling must occur 
independent of ventricular remodeling and/or infarction. The observations of unchanged 
end diastolic pressure suggest that SGLT2i enhanced ventricular compliance; however, 
no significant differences in global indices of diastolic function (dP/dtmin, Tau) were noted.  
Although any evidence of myocardial infarction following the 30 minute LCX 
occlusion protocol were not observed, insights into potential infarct mitigating behavior of 
SGLT2i are fundamentally valuable. Therefore, additional studies were performed in a 
separate cohort of animals wherein conditionally identical swine were subjected to a 60 
minute coronary artery occlusion.  The LAD was occluded during these experiments as 
longer duration LCX occlusion is associated with decreased survivability [55]. In these 
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animals, a significant SGLT2i associated reduction in infarct size was demonstrated 
(Figure 2.7). This finding is consistent with prior studies in rodent models which 
documented reductions in myocardial infarct size in response to ischemia/reperfusion 
injury [12, 97].   
Small amounts of SGLT1 and SGLT2 mRNA were detected from swine myocardial 
samples (Figure 2.1), consistent with observations in human samples [32, 65, 68]. 
However, it is unclear whether the SGLT2i mediated effects in this study are the result of 
direct and/or indirect actions on the heart. As initial dosing was 24 hours prior to the acute 
study, so the potential for paracrine/humoral mediation exists.  The 300 mg oral dosing 
regimen utilized in this study was selected to directly parallel the “high-dose” utilized 
clinically.  Prior studies indicate that a single oral dose of canagliflozin (300 mg) achieves 
a plasma Cmax of 3,480 ng/mL (7.67 µM) in humans with a tmax of 1.5 hours and a half-life 
of 14.9 hours [41, 42, 133]. We estimate (using allometric scaling) that the maximal plasma 
concentration of canagliflozin in ~50 kg swine such as those used in the present study to 
be ~3757 ng/mL (assuming no plasma protein binding), which is comparable to exposure 
in humans [41, 42, 133]. Given the present observations of clear effects of canagliflozin 
on myocardial function it seems plausible that a myocardial receptor system might exist 
that is responsive to this agent but not from the SGLT2 protein family; one potential target, 
the sodium hydrogen exchanger-1 (NHE-1) is discussed below. Therefore, further studies 
to determine dose-dependence and direct vs. indirect actions of SGLT2i are needed. 
 
Potential mechanisms underlying cardiac effects of SGLT2i 
 SGLT2i therapies have been demonstrated to augment circulating ketone bodies 
in type 2 diabetes thereby suggesting the “thrifty fuel hypothesis” of cardioprotection. In 
this study canagliflozin increased free fatty acid concentrations modestly but did not affect 
arterial levels of lactate or ketone bodies (Table 2.2). Arterial glucose levels tended to be 
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lower in the treatment group (P = 0.08) however, ischemia/reperfusion status had no effect 
on glucose levels on either group (P = 1.0).  These data are consistent with prior studies 
of SGLT2i treatment in metabolically healthy humans who also exhibited no change in 
fasting plasma glucose or ketone concentrations [7]. Despite the modest changes in 
circulating substrate concentration that we observed, no changes in myocardial uptake of 
glucose, lactate, ketones, or free fatty acid were seen (Figure 2.6). Thus, while 
interventions such as insulin and malonyl CoA inhibition have been shown to improve 
contractile function during ischemia via promotion of the utilization of thrifty fuels [49, 90, 
144], this does not appear to be the explanation for the currently observed effects of 
SGLT2i. A caveat of the present study is that findings were made in a metabolically normal 
animal model, under conditions of acute and controlled ischemia.  Therefore, whether 
these findings extend to the setting of chronic treatment in patients with type 2 diabetes 
with or without acute ischemia merits future study. 
 It is well recognized that SGLT2i influence circulating blood volume, promoting 
osmotic diuresis and natriuresis and reductions in plasma volume [33, 86].  Although did 
plasma volume was not directly measured, there was a modest but significant decrease 
in hematocrit in SGLT2i treated swine which runs counter to anticipated effects of diuresis. 
Further, the current observations are not consistent with beneficial effects of diuresis, as 
any reduction in plasma volume would be expected to reduce overall ventricular filling 
volumes, in contrast to our observed ~50% increase in end diastolic volume during 
ischemia. Also, no differences in hemodynamics or cardiac volumes were noted at 
baseline or during the reperfusion period (Figure 2.3). Cardiovascular benefits associated 
with diuretic-induced reductions in plasma volume are understood to result from preload 
lowering and associated decreased wall tension within the ventricle and direct reductions 
in Frank-Starling mediated cardiac force generation [36], again in contrast to what was 
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observed. Together, these data argue against a role of diuresis in the observed effects of 
canagliflozin following short term (single-day) therapy and acute ischemic insult. 
 An alternate hypothesis to potentially explain SLGT2i mediated cardioprotection is 
the “sodium hypothesis”. Recent evidence suggests that the SGLT2i mediated effects 
could work via direct inhibition of NHE-1 as has been demonstrated in isolated 
cardiomyocytes from rats and rabbits [19, 149]. In conditions leading to cellular acidosis 
such as myocardial ischemia, NHE-1 has been shown to be activated resulting in a 
reversal of the Na+/Ca2+ exchanger and increase intracellular calcium [116, 120]. By 
extension, inhibition of NHE-1 would act to lessen Ca2+ overload in cardiomyocytes during 
myocardial ischemia. Improvement in cytosolic Ca2+ handling also produces myriad effects 
on regulatory and contractile proteins within the cardiomyocyte [9, 59, 102, 128, 155]. As 
the interplay between developed tension and resting cardiomyocyte length can determine 
Starling effects [110], a mechanism that directly alters intracellular Ca2+ handling could 
potentially contribute to the effects seen in this investigation. Previous studies have 
demonstrated a reduction in infarct size in a swine model of ischemia/reperfusion with 
NHE-1 inhibitors [89]. These data are directionally consistent with our present 
observations and suggest a direction for further systematic in vivo and in vitro studies to 
explore the potential mechanisms of SGLT2i-mediated cardioprotection.  
 
Conclusion 
Data from these studies demonstrate that canagliflozin preserves cardiac 
contractile function and efficiency during acute regional myocardial ischemia through 
acute effects on cardiac volume regulation that cannot be explained by myocardial fuel 
switching. Further, SGLT2i reduces infarct size following 60 minutes of ischemia. Findings 
from this study highlight the therapeutic potential for SGLT2i in metabolically normal 
subjects [129] and demonstrate the need for further investigations to both elucidate the 
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mechanisms responsible for improvements in cardiac function during ischemia and to 
extend these studies into metabolically deranged cohorts as well as cohorts with normal 
glucose metabolism but abnormal cardiac function. 
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Table 2.1 
 
Effects of canagliflozin on systemic hemodynamics, cardiac contractile function and blood gas parameters 
Parameter Treatment 
Condition 
Condition 
P-value 
Treatment 
P-value 
Interaction 
P-value 
Baseline Ischemia Reperfusion 
0 min 15 min 30 min 60 min 90 min 120 min 150 min 
Arterial pH 
Control 
7.57 ± 
0.01 
7.56 ± 
0.01 
7.55 ±0 
.01 
7.54 ± 
0.01 
7.53 ± 
0.01 
7.55 ± 
0.01 
7.55 ± 0.10 
0.753 <0.001 0.895 
SGLT2i 
7.52 ± 
0.01 
7.52 ± 
0.01 
7.52 ± 
0.01 
7.49 ± 
0.02 
7.52 ± 
0.02 
7.52 ± 
0.01 
7.50 ± 0.03 
† 
Arterial PCO2 
(mmHg) 
Control 38 ± 2 38 ± 2 39 ± 2 40 ± 2 41 ± 2 39 ± 2 39 ± 2 
0.993 0.953 0.907 
SGLT2i 40 ± 1 39 ± 1 39 ± 1 39 ± 1 38 ± 1 38 ± 1 41 ± 1 
Arterial PO2 
(mmHg) 
Control 143 ± 12 143 ± 11 143 ± 11 136 ± 9 138 ± 10 139 ± 10 134 ± 9 
0.978 <0.001 0.873 
SGLT2i 159 ± 11 164 ± 9 167 ± 10 163 ± 7 168 ± 7 155 ± 13 179 ± 15 † 
Coronary 
Venous PO2 
(mmHg) 
Control 16 ± 1 14 ± 2 15 ± 1 15 ± 2 15 ± 2 15 ± 2 15 ± 1 
0.982 0.132 1.000 
SGLT2i 16 ± 1 15 ± 1 16 ± 1 17 ± 1 17 ± 1 16 ± 1 17 ± 2 
HCT (%) 
Control 34 ± 1 35 ± 1 35 ± 1 35 ± 1 35 ± 1 34 ± 1 34 ± 1 
0.978 <0.001 0.988 
SGLT2i 32 ± 1 32 ± 1 32 ± 1 33 ± 1 32 ± 1 33 ± 1 33 ± 1 
Arterial O2 
Content 
(mL/dL) 
Control 15 ± 1 15 ± 1 15 ± 1 16 ± 1 15 ± 1 15 ± 1 15 ± 1 
0.637 0.774 0.710 
SGLT2i 15 ± 1 15 ± 1 15 ± 1 16 ± 1 15 ± 1 15 ± 1 16 ± 1 
Coronary 
Venous O2 
Content 
(mL/dL) 
Control 3.4 ± 0.4 2.9 ± 0.4 3. 0 ± 0.4 3.1 ± 0.5 3.1 ± 0.5 3.2 ± 0.5 3.2 ± 0.5 
0.907 0.292 0.975 
SGLT2i 3.3 ± 0.3 2.9 ± 0.3 3.0 ± 0.2 3.8 ± 0.9 3.9 ± 0.9 3.6 ± 0.7 3.6 ± 0.8 
Myocardial 
Oxygen 
Consumption 
(µL O2/min/g) 
Control 47 ± 5 49 ± 5 43 ± 5 43 ± 6 44 ± 6 41 ± 5 39 ± 5 
0.673 0.214 1.000 
SGLT2i 50 ± 7 53 ± 6 48 ± 6 47 ± 6 45 ± 6 45 ± 6 43 ± 4 
Systolic 
Pressure 
(mmHg) 
Control 105 ± 7 94 ± 8 87 ± 8 88 ± 7 91 ± 8 90 ± 7 89 ± 7 
0.362 0.02 0.989 
SGLT2i 127 ± 17 111 ± 14 106 ± 14 103 ± 14 101 ± 11 99 ± 11 95 ± 10 
Diastolic 
Pressure 
(mmHg) 
Control 71 ± 4 64 ± 5 58 ± 5 60 ± 4 61 ± 4 60 ± 4 59 ± 4 
0.095 0.468 0.995 
SGLT2i 71 ± 3 67 ± 5 63 ± 5 62 ± 3 63 ± 5 63 ± 5 57 ± 4 
Systemic 
Vascular 
Resistance 
(mmHgxmin/mL) 
Control 
0.02 ± 
0.00 
0.03 ± 
0.00 
0.04 ± 
0.00 
0.03 ± 
0.00 
0.03 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 0.00 
0.832 0.03 0.557 
SGLT2i 
0.03 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 0.00 
Coronary Blood 
Flow (ml/min/g) 
Control 
0.40 ± 
0.05 
0.38 ± 
0.05 
0.34 ± 
0.05 
0.35 ± 
0.05 
0.35 ± 
0.05 
0.34 ± 
0.05 
0.33 ± 0.05 
0.673 0.063 1.000 
SGLT2i 
0.44 ± 
0.06 
0.44 ± 
0.05 
0.40 ± 
0.05 
0.40 ± 
0.04 
0.39 ± 
0.04 
0.39 ± 
0.03 
0.36 ± 0.03 
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Ejection 
Fraction (%) 
Control 59 ± 3 45 ± 5 47 ± 7 49 ± 7 48 ± 5 52 ± 4 52 ± 5 
0.069 0.146 0.984 
SGLT2i 64 ± 4 50 ± 6 48 ± 4 50 ± 5 56 ± 3 57 ± 4 55 ± 4 
Left Ventricular 
End Diastolic 
Pressure 
(mmHg) 
Control 14 ± 2 16 ± 2 16 ± 2 15 ± 2 15 ± 2 14 ± 2 13 ± 2 
0.886 0.624 0.999 
SGLT2i 13 ± 2 16 ± 2 15 ± 2 14 ± 2 13 ± 2 14 ± 2 14 ± 3 
dP/dtmax 
(mmHg/s) 
Control 
1748 ± 
138 
1358 ± 
191 
2296 ± 
895 
1368 ± 
158 
1330 ± 
143 
1405 ± 
131 
1322 ± 112 
0.120 0.066 0.487 
SGLT2i 
1522 ± 
191 
1307 ± 
140 
1235 ± 
125 
1212 ± 
134 
1264 ± 
125 
1262 ± 
131 
1336 ± 99 
dP/dtmin 
(mmHg/s) 
Control 
-1613 ± 
168 
-1251 ± 
168 
-1162 ± 
131 
-1246 ± 
229 
-1164 ± 
171 
-1161 ± 
192 
-1101 ± 163 
0.031 0.641 0.446 
SGLT2i 
-1708 ± 
183 
-1471 ± 
109 
-1199 ± 
109 
-1127 ± 
102 
-1111 ± 
109 
-1155 ± 
133 
-999 ± 102 
Tau1/2 (ms) 
Control 30 ± 3 38 ± 5 41 ± 5 37 ± 5 40 ± 8 43 ± 9 45 ±10 
0.234 0.414 0.857 
SGLT2i 31 ± 3 30 ± 1 34 ± 3 39 ± 4 39 ± 5 35 ± 5 37 ± 3 
Tau 1/e (ms) 
Control 21 ± 2 25 ± 3 28 ± 4 25 ± 3 28 ± 6 30 ± 7 32 ± 8 
0.214 0.382 0.870 
SGLT2i 21 ± 2 20 ± 1 23 ± 2 27 ± 3 27 ± 3 24 ± 3 26 ± 2 
   Values are mean ± SE for Control (n = 7) and SGLT2i (canagliflozin) (n = 8). † P < 0.05 vs. baseline value (same treatment) [23] 
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Table 2.2 
    Effects of canagliflozin on circulating substrate concentrations                                                                                                               
    Values are mean ± SE for Control (n = 7) and SGLT2i (canagliflozin) (n = 8). * P < 0.05 vs. control (same time point) [23] 
 
 
 
 
Parameter Treatment 
Condition 
Condition 
P-value 
Treatment 
P-value 
Interaction 
P-value 
Baseline Ischemia Reperfusion 
0 min 15 min 30 min 60 min 90 min 120 min 150 min 
Arterial 
Glucose 
(mg/dL) 
Control 104 ± 14 110 ± 21 105 ± 19 120±24 119 ± 26 112 ± 21 109 ± 20 
1.000 0.087 0.990 
SGLT2i 102 ± 25 96 ± 20 93 ± 20 91±20 84 ± 18 89 ± 20 89 ± 19 
Arterial 
Lactate 
(mmol/L) 
Control 2.0 ± 0.4 2.5 ± 0.7 2.8 ± 0.9 3.1 ± 0.9 3.0 ± 0.8 2.7 ± 0.7 2.4 ± 0.6 
0.754 0.336 1.000 
SGLT2i 1.8 ± 0.4 2.1 ± 0.5 2.2 ± 0.5 2.8 ± 0.8 2.5 ± 0.7 2.5 ± 0.6 2.2 ± 0.5 
Arterial 
Ketone 
(µmol/L) 
Control 31 ± 5 41 ± 8 48 ± 10 47 ± 8 50 ± 9 53 ± 8 59 ± 10 
0.002 0.74 0.953 
SGLT2i 31 ± 4 34 ± 5 37 ± 6 46 ± 6 49 ± 6 59 ± 7 63 ± 8 * 
Arterial 
FFA 
(mmol/L) 
Control 
0.32 ± 
0.06 
0.32 ± 
0.05 
0.31 ± 
0.05 
0.34 ± 0.06 0.34 ± 0.05 
0.35 ± 
0.06 
0.36 ± 0.05 
0.995 0.017 0.999 
SGLT2i 
0.43 ± 
0.05 
0.41 ± 
0.05 
0.44 ± 
0.05 
0.44 ± 0.06 0.47 ± 0.06 
0.49 ± 
0.07 
0.50 ± 0.08 
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Chapter 3:  Inhibition of Sodium Glucose Cotransporter-2 Improves Cardiac 
Efficiency During Regional Myocardial Ischemia Independent of Sodium/Hydrogen 
Exchanger-1  
 
Introduction  
Sodium glucose co-transporter 2 inhibitors (SGLT2i) are a class of anti-
hyperglycemic agents that reduce circulating blood glucose levels by increasing urinary 
glucose excretion [69]. Recent clinical outcome studies demonstrated unexpected and 
significant decreases in major adverse cardiac events (MACE) with SGLT2i therapy, 
independent of effects on HbA1c [114, 158, 164]. Notably, SGLT2i therapy is associated 
with decreases in heart failure related hospitalization, non-fatal myocardial infarction and 
cardiovascular death [114, 158, 164]. Moreover, this effect is not limited to a single 
compound in the category as is demonstrable by the results of the study of 10,142 
participants in the Canagliflozin Cardiovascular Assessment Study (CANVAS) [114] and 
7,020 participants in the multicenter Empagliflozin, Cardiovascular Outcomes, and 
Mortality in Type 2 Diabetes trial (EMPA-REG) [164]. However, the specific effects and 
mechanisms by which SGLT2i potentially influence the cardiovascular system remain 
poorly defined. 
Multiple mechanisms to explain the cardiovascular benefits of SGLT2i have been 
proposed. At present the two most plausible are the “thrifty fuel hypothesis” and the 
“sodium hypothesis” which propose an SGLT2i mediated shift in myocardial substrate 
utilization toward ketone bodies vs. the direct inhibition of the sodium hydrogen 
exchanger-1 (NHE-1) respectively. Recent data from our investigative team demonstrated 
that SGLT2i augments ventricular filling, maintains myocardial efficiency, and attenuates 
infarct size in response to acute ischemia-reperfusion injury independent of alterations in 
myocardial substrate selection, volume loading, or afterload in lean healthy swine [20]. 
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These findings are consistent with investigations from other groups [29, 96, 131] and 
argue against a requisite role for ketone utilization as the sole mechanism for SGLT2i-
mediated improvements in cardiovascular function in the acute ischemia setting. 
Alternatively, recent evidence in isolated cardiomyocytes has demonstrated that NHE-1 
activity is directly inhibited by SGLT2i [19, 149].  While prior studies support NHE-1i 
improves post-ischemic contractile dysfunction [67] and attenuates myocardial infarct size 
[53], there are at present a paucity of data to address the extent to which SGLT2i-mediated 
cardioprotection occurs via effects on NHE-1. 
The goal of the present study was to test the hypothesis that NHE-1 contributes to 
the cardiac effects of SGLT2i in response to myocardial ischemia-reperfusion injury. 
Experiments evaluated whether acute administration of the SGLT2i canagliflozin (30 µM) 
vs. the NHE-1i cariporide (1 µM) influence cardiac contractile function and efficiency in a 
directionally consistent manner. Studies were performed in lean, metabolically healthy 
open-chest swine with high fidelity pressure-volume admittance catheters.  
Complementary fluorometric NHE-1 activity assays were also were performed in wild-type 
CHO (AP-1) cells transfected with human NHE-1.  Findings from this study provide novel 
mechanistic insight into the acute, cardioprotective effects of SGLT2i and NHE-1i in the 
setting of myocardial ischemia-reperfusion injury. 
 
Methods 
Animal model and surgical preparation 
All experiments involving animals were approved by an Institutional Animal Care 
and Use Committee and performed in accordance with the Guide for the Care and Use of 
Laboratory Animals (National Institutes of Health Publication. No. 85-23, Revised 2011).  
Male domestic swine (~50 kg) were placed on a standard chow (5L80, Purina Test Diet, 
Richmond, IN, USA) and randomly assigned into control or treatment groups.  Control 
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swine received a 15-30-minute infusion of vehicle (DMSO; n = 6), the treatment animals 
received a 15-30-minute infusion of either SGLT2i Canagliflozin (30 µM; n = 6), or the 
NHE-1 inhibitor Cariporide (1 µM; n = 6) immediately prior to total occlusion of the left 
circumflex artery. 
 
Left Circumflex Ischemia Protocol 
  Following an overnight fast (~16 hours), swine were anesthetized with telazol (5 
mg/kg), ketamine (3 mg/kg), and xylazine (2.2 mg/kg) cocktail (i.m.) and then anesthesia 
was maintained with morphine (3 mg/kg) and α-chloralose (100 mg/kg, i.v). Depth of 
anesthesia was monitored by observing continuous measurements of arterial blood 
pressure and heart rate as well as regular (15-minute intervals) reflex tests (corneal, jaw, 
limb withdrawal), beginning after induction of anesthesia and continuing throughout the 
experimental protocol. Periodic supplementation with α-chloralose was performed every 
1.5 hours to maintain a level, stage 3 plane of anesthesia. The right femoral artery and 
vein were isolated and catheterized to allow measurement of systemic arterial pressure 
and maintain venous access, respectively. The heart was exposed by a left lateral 
thoracotomy. The proximal region of both the left anterior descending artery (LAD) and 
left circumflex artery (LCX) were isolated for placement of perivascular flow probes 
(Transonic Systems Inc., Ithaca, NY) and a snare occluder was placed around the left 
circumflex artery.  A catheter was then placed in the intraventricular vein to allow sampling 
of coronary venous blood from the area supplied by the LAD. A Sci-Sense 
pressure/volume admittance catheter (Transonic Scisense, London Ontario, Canada) was 
passed through a hemostatic control valve placed directly into the left ventricle via a 
transmural stab near the base of the left ventricle and secured with a purse string suture.  
Measurements were obtained at baseline, during a 60 min complete occlusion of the LCX, 
and during a 2-hour reperfusion. At the beginning of the study, a total of 23 animals were 
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enrolled.  Three swine died during instrumentation independent of treatment and two 
animals from the control group fibrillated during the coronary occlusion portion of the 
protocol and were thus not included in the study. Therefore, a total of n = 18 animals were 
included in the study (n = 6 per group, randomized). 
 
Metabolic Analysis 
Arterial (5 mL) and coronary venous (5 mL) blood samples were collected 
simultaneously into untreated syringes, immediately sealed, and placed on ice. These 
samples were collected every 15 minutes during baseline and the coronary occlusion, and 
every 30 minute during reperfusion; total blood samples across the 2-3-hour experimental 
protocol summed to <100 mL from an estimated ~4-5 L total circulating blood volume. The 
samples were analyzed immediately upon collection for pH, PCO2, PO2, O2 content, 
glucose, lactate and hematocrit with an Instrumentation Laboratories automatic blood gas 
analyzer (GEM Premier 4000). Free fatty acids (NEFA- Non-Esterified Fatty Acids) were 
measured in a colorimetric assay (WAKO Life Sciences, City State) and ketones were 
analyzed with a chemistry analyzer (Roche Hitachi Modular P, Indianapolis IN), reporting 
concentrations of -hydroxybutyrate and acetone as total ketone measured. Myocardial 
oxygen consumption (MvO2; μl O2/min/g) was calculated using the Fick principle [coronary 
blood flow × (arterial O2 content – coronary venous O2 content)]. For these calculations, 
LAD perfusion territory was estimated to be 30% of total heart weight, as previously 
described [45].  Cardiac efficiency was calculated as cardiac stroke work [stroke volume 
(mL) x mean arterial pressure (mmHg)] divided by MvO2. 
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NHE-1 Activity Assay in Wild type NHE-1 transfected AP-1 cells 
 Wild type NHE-1 transfected AP-1 cells (a mutant cell line derived from Chinese 
hamster ovarian cells that that lack an endogenous Na+/H+ exchanger) were cultured and 
grown at 37oC on glass cover slips until confluent. Double pulse fluorometric assays using 
PTI Delta Scan 4000 fluorometers were then used to test for NHE activity [11]. The assays 
first involved a 20-minute incubation of the cover slips at 37oC in serum free growth 
medium with the addition of 3 μM of BCECF-AM which is used as an indicator of cytosolic 
pH. Intracellular pH was then measured with a PTI (Photon Technologies International) 
Delta-scan spectrofluorometer placed in a thermostatically controlled chamber. Coverslips 
containing cells were placed in 2.5 ml Na+ normal buffer (135 mM NaCl, 5 mM KCl, 1.8 
mM CaCl2, 1.0 mM MgSO4, 5.5 mM Glucose, 10 mM Hepes, pH: 7.3) for 3 minutes to 
stabilize the pHi. Dual excitation at 440 nm and 502.5 nm as well as emission at 528.7 nm 
during the assays (2,3) were used to give pH measurements that were independent of dye 
concentration or cell number. To test the effect of inhibitors, a dual pulse assay was used 
in which two acid loads were created and recovered from consecutively, in the same set 
of cells (3). The rate of recovery of the second pulse plus or minus SGLT2i or NHE1i, was 
compared to the first pH measurement. Each NHE recovery activity was measured after 
a 3-minute acid load using 50 mM NH4Cl and a 30 second exposure to sodium free buffer 
(135 mM N-Methyl-D-glucamine, 5.0mM KCl, 1.8 mM CaCl2, 1.0 mM MgSO4, 5.5 mM 
glucose, 10 mM Hepes, solution pH: 7.3) for 10 – 20 seconds at 37°C.  Cells were allowed 
to recover from the acid load by incubating them in Na+ normal buffer for 3 – 4 minutes.  
Each drug was added directly into the Na+ containing recovery buffer (second recovery) 
and the rates of pH change per second with and without the drug were compared for each 
trial. The drugs were added upon the second pulse and so the rate of recovery 2 (ROR2) 
contained drug while the first pulse (ROR1) contained no drug. Six replicates were 
performed for each concentration of each drug tested. The following concentrations were 
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tested: 1, 3, 10, 30, 100, and 300 μM for CANA. and 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 μM 
for cariporide. A negative control was performed using the same volume of DMSO solvent 
added to the Na+ containing buffer with the drugs as it was used to dissolve the drugs for 
testing. NHE-1 activity was calculated by taking the change in cytosolic pH/s (slope) from 
the drug exposed recovery and dividing it by the Na+ buffer only recovery for each trial. 
This was performed using the ROR slopes derived from the raw graphical data of the 
assays. These calculations are represented as rate of recovery 2/ rate of recovery 1 
(ROR2/ROR1). The resulting NHE activities were then standardized with the negative 
control (0 μM of drug, DMSO only) acting as 100% activity for comparison across all 
concentrations. For every pH assay, a calibration curve was done at 3 successive pH’s 
using nigericin as described earlier [10]. 
 
NHE-1 Activity Assay in iCell™ human IPSc-derived cardiomyocytes 
Cryopreserved iCell™ human IPSc-derived cardiomyocytes (Cellular Dynamics 
International, Inc) were thawed, plated, and maintained following the manufacturer’s 
protocol. Briefly, 20,000 cardiomyocytes/well were attached to 0.1% Gelatin (StemCell 
Technologies) coated 96-well plates for 48 hrs in iCell™ Cardiomyocytes Plating Medium 
and maintained for 14 days in iCell™ Cardiomyocytes Maintenance Medium.  To facilitate 
intracellular pH (pHi) measurement, the iCell™ cardiomyocytes were incubated with 5 µM 
fluorescent pH indicator dye BCECF AM (Invitrogen) (Live Cell Imaging Solution, pH 7.4, 
Thermofisher Scientific) for 15 minutes, followed by a subsequent wash with HEPES 
buffered Ringer Solution (pH7.4) containing 140 mM NaCl, 5 mM KCl, 1mM MgCl2, 1 mM 
CaCl2, 5 mM glucose, 10 mM N‐2‐hydroxyethylpiperazin‐N′‐2‐ethanesulfonic acid 
(HEPES).  IPSc-derived cardiomyocytes were then treated with vehicle (DMSO 0.1% in 
HBRS, pH 7.4), cariporide or canagliflozin.  The following concentrations of both cariporide 
and canagliflozin were tested: 0.12, 0.37, 1.1, 3.3, and 10 μM.   HEPES buffered Ringer 
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Solution (pH 7.4), cells were exposed to HEPES buffered Ringer Solution (pH 7.4) for 5 
minutes after which the buffer was then replaced by HEPES buffered Ringer Solution (pH 
6.4) for 5 minutes to obtain intracellular acidification.  Subsequent intracellular re-
alkalinization was induced by replacing HBRS (pH 6.4) with HBRS (pH 7.4).  Respective 
treatments were present during each step. Successive images of four fields per well under 
10x objective (excitation at 405nm and 488 nm, emission at 500-550 nm) were captured 
immediately after each treatment was added and serial images were acquired every 1.5 
minutes thereafter.  Images were captured with a temperature‐controlled (37°C) Opera 
Phenix™ High Content Screening System (PerkinElmer).  Intracellular pH calibrations were 
performed at the end of each experiment with an Intracellular pH Calibration Buffer Kit 
(Thermofisher Scientific), fluorescence ratio of 488nm/405nm was calibrated to reflect pHi.  
 
Statistical Analyses 
Data were analyzed using the SigmaPlot statistical package (version 11 Systat 
Software Inc, San Jose, CA) and SPSS (version 22 IBM, Chicago, IL, USA). Data are 
presented as mean ± standard error. Comparisons were assessed by t-test or two-way 
ANOVA with repeated measures; [Factor A = treatment (time control/SGLT2i); Factor B = 
condition (baseline/occlusion/reperfusion)] as appropriate. When significance was 
established with ANOVA, Student–Newman–Keuls post-hoc testing was performed to 
identify pairwise differences between treatment groups and conditions.  Statistical 
significance was declared when P < 0.05.  Multiple linear regression and analysis of 
covariance were used to compare the slopes and intercepts of the relationships between 
stroke volume vs. end-diastolic volume, and stroke work vs. myocardial oxygen 
consumption. 
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Results 
Systemic effects of SGLT-2i and NHE-1i during ischemia/reperfusion injury 
Blood gas and hemodynamic data for control (n = 6), canagliflozin (n = 6) and 
cariporide (n = 6) treated swine at rest and during LCX ischemia/reperfusion injury are 
provided in Table 3.1 and Table 3.2 respectively. The 15-30-minute acute infusion of 
canagliflozin or cariporide did not significantly affect baseline resting systolic arterial 
pressure, diastolic arterial pressure or coronary blood flow (Table 3.2).  Mean arterial 
pressure decreased from ~91 ± 3 mmHg at baseline to ~62 ± 3 mmHg following 60 min 
ischemia/reperfusion injury in control, canagliflozin and cariporide treated swine (Table 
3.2; Condition: P < 0.001; Treatment: P = 0.36). Heart rate averaged ~78 beats/min at 
baseline and throughout the ischemic period, however, SGLT2i significantly increased 
heart rate during reperfusion compared to control and NHE-1i treated swine (Table 3.2; 
Condition: P <0.001; Treatment: P = 0.006). None of the blood gas (Table 3.1) or 
hemodynamic parameters (Table 3.2) were significantly affected by 60 minutes ischemia 
or 2 hours of reperfusion.  In addition, canagliflozin and cariporide had no effect on 
circulating concentrations of cardiac substrates including glucose (P = 0.66), lactate (P = 
0.46), free fatty acids (P = 0.12) and total ketone bodies (acetoacetone and 3-
hydroxybutyrate) (P = 0.77) compared to control at any time during the study (Table 3.3). 
 
Effects of SGLT2i and NHE-1i on cardiac contractile function during ischemia/reperfusion 
injury 
Under baseline conditions canagliflozin and cariporide had no effect on left 
ventricular end diastolic volume, end systolic volume, stroke volume, or cardiac output 
(Figure 3.1). However, following the onset of regional myocardial ischemia (LCX 
occlusion), canagliflozin treatment was associated with a significant increase in left 
ventricular end diastolic volume (Figure 3.1A; P = 0.02). This SGLT2i-mediated increase 
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in cardiac filling volume corresponded with a significant increase in stroke volume relative 
to control animals (Figure 3.1C; P = 0.03), however, no significant differences in cardiac 
output were detected (Figure 3.1D; P = 0.33).  Heart rate averaged ~78 beats/min at 
baseline and throughout the ischemic period, however, SGLT2i significantly increased 
heart rate during reperfusion compared to control and NHE-1i treated swine (Table 3.2).  
Left ventricular end diastolic volume and stroke volume were not significantly different 
throughout the experimental protocol in either the control or cariporide treated animals.  
Neither canagliflozin nor cariporide influenced load-dependent measures of cardiac 
function, including ejection fraction (P = 0.77), dP/dtmax (P = 0.92), dP/dtmin (P = 0.97), or 
Tau½ (P = 0.18) (Table 3.2).  MvO2 of the non-occluded LAD coronary vascular bed was 
unaffected by canagliflozin or cariporide treatment. (Table 3.1).    
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Schematic representations of average steady-state left ventricular pressure-
volume loops illustrating the effect of regional myocardial ischemia in control, canagliflozin 
and cariporide treated swine are provided in Figure 3.2.  Comparisons of the Frank-
Starling relationship between stroke volume vs. end diastolic volume during ischemia 
reveal canagliflozin-mediated increases in stroke volume were directly related to increases 
in end-diastolic volume (preload) (Figure 3.2D; P = 0.004). This effect was not present in 
cariporide treated animals as demonstrated in Figure 3.2E.  Left ventricular end diastolic 
pressure were unaffected by 60 minutes of ischemia/reperfusion or by SGLT2i 
canagliflozin or NHE-1i cariporide (Table 3.1). 
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Figure 3.1 Effect of ischemia/reperfusion injury on end diastolic volume (Panel A), end 
systolic volume (Panel B), stroke volume (Panel C) and cardiac output (Panel D) in 
Control (n = 6), SGLT2i (canagliflozin) treated (n = 6) and NHE-1i(cariporide) treated 
(n = 6) swine. * P < 0.05 vs. Control (same time point), † P < 0.05 vs. baseline value 
(same treatment), ^ P < 0.05 vs. NHE-1i (same time point). 
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Stroke work [stroke volume (mL) x mean arterial pressure (mmHg)] and efficiency 
(stroke work / MvO2 (μl O2/min/g)) were unaffected by canagliflozin or cariporide treatment 
under baseline conditions (Figure 3.3). However, canagliflozin significantly increased 
stroke work (Figure 3.3A; P = 0.025) and cardiac efficiency (Figure 3.3B; P = 0.008) during 
regional myocardial ischemia compared to control swine. Cariporide did not alter stroke 
work (P = 0.37) or cardiac efficiency (P = 0.15) at any time point.  Comparisons of the 
relationship between stroke work and MvO2 during ischemia reveal a canagliflozin-
mediated increase in stroke work occurred independent of any changes in MvO2 (Figure 
3.3C).  Cariporide had no effect on this relationship as demonstrated in Figure 3.3D. 
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Figure 3.2 Representative pressure-volume loops of average steady state conditions 
at baseline and during regional myocardial ischemia in Control (n = 6) (Panel A), 
SGLT2i (canagliflozin) (n = 6) treated (Panel B) and NHE-1i (cariporide) (n = 6) treated 
(Panel C) swine. Relationship between stroke volume and end diastolic volume during 
ischemia in Control (n = 6) (R
2 
= 0.7) and SGLT2i (canagliflozin) (n = 6) (R
2 
= 0.9)  
(Panel D) and Control (n = 6) and NHE-1i (cariporide) (n = 6) (R
2 
= 0.3)  (Panel E) 
treated swine. 
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Effect of SGLT2i on NHE-1 activity in wild type AP-1cells transfected with NHE-1 
Fluorometric activity assays in wild type AP-1 cells transfected with NHE-1 
demonstrated concentration-dependent inhibition of NHE-1 activity by cariporide 
beginning at 0.03 μM continuing to a plateau to near zero % activity at 3μM (Figure 3.4A). 
The IC50 value of cariporide was 0.11μM.  In contrast, canagliflozin did not cause 
significant changes of NHE-1 activity, with mean values of % activity ranging from 90.8% 
to 109.9% (Figure 3.4B). IC50 values for canagliflozin were not calculated due to the lack 
of adequate inhibitory effects.  
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Figure 3.3 Effects of ischemia/reperfusion injury on cardiac stroke work (Panel A) and 
efficiency (Panel B) in Control (n = 6), SGLT2i (canagliflozin) treated (n = 6) and NHE-
1i (cariporide) treated (n = 6) swine. Relationship between stroke work and myocardial 
oxygen consumption during ischemia in Control (n = 6) (R
2 
= 0.16) and SGLT2i 
(canagliflozin) (n = 6) (R
2 
= 0.13) (Panel D) and Control (n = 6) and NHE-1i (cariporide) 
(n = 6) (R
2 
= 0.02) (Panel E) treated swine. † P < 0.05 vs. Control (same time point).   
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Effect of SGLT2i on NHE-1 Activity Assay in iCell™ human IPSc-derived cardiomyocytes 
The fluorometric activity assays demonstrated concentration-dependent inhibition 
of NHE-1 activity by cariporide beginning at 1.1 μM and reaching near zero % activity at 
10μM (Figure 3.5A).  In contrast, canagliflozin had no inhibitory effect on NHE-1 (Figure 
3.5B).  
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Figure 3.5 Effect of cariporide (Panel A) and canagliflozin (Panel B) on NHE1 activity 
in iCell™ human IPSc-derived cardiomyocytes. 
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Discussion 
This study was designed to test the hypothesis that NHE-1 contributes to the 
cardiac effects of acute SGLT2i in response to myocardial ischemia-reperfusion injury. 
Consistent with recent findings from our laboratory [20], 15-30 minutes pre-treatment with 
canagliflozin increased left ventricular end diastolic volume, stroke work and improved 
cardiac work efficiency relative to untreated control hearts during the ischemic period. In 
contrast, cariporide did not significantly affect ventricular diastolic filling, stroke volume or 
work efficiency at any time point. Additionally, the observed cardiac effects of canagliflozin 
were independent of any change in circulating substrate concentration compared to 
control at any time during the study protocol.  The distinct physiologic effects of SGLT2i 
vs. NHE-1i in vivo were corroborated by in vitro activity assays in which canagliflozin failed 
to affect NHE-1 activity of AP-1 cells transfected with human NHE-1 or in human IPSc 
derived cardiomyocytes. Taken together, these findings fail to support the hypothesis that 
the acute cardiac effects of SGLT2i are mediated via an NHE-1 dependent pathway. 
 
Cardiac effects of SGLT2i and NHE-1i 
The rationale for the so-called “sodium hypothesis” is based primarily on recent 
evidence in isolated cardiomyocytes which demonstrated that NHE-1 activity is directly 
inhibited by SGLT2i [19, 149].  Inhibition of NHE-1 under conditions of cellular acidification, 
such as ischemia, would prevent the increase in cytoplasmic Na+ and by extension prevent 
intracellular accumulation of Ca2+ and the consequent pathological hypercontractility. 
While prior studies support NHE-1i improves post-ischemic contractile dysfunction [67] 
and attenuates myocardial infarct size [53], the extent to which SGLT2i-mediated 
cardioprotection occurs via effects on NHE-1 remains poorly defined. Here for the first 
time a head to head comparison of the cardiac effects of SGLT2i (canagliflozin) and NHE-
1i (cariporide) in response to myocardial ischemia/reperfusion injury in normal, 
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metabolically healthy swine is provided.  Consistent with prior data from our laboratory, 
significant and sustained increases in left ventricular end diastolic volume during 
myocardial ischemia with an acute administration (15-30 minutes pre-treatment) of 
canagliflozin were demonstrated (Figure 3.1A).  This increased cardiac filling in SGLT2i 
treated animals was directly related to increased stroke work and improved efficiency as 
shown in Figure 3.3. These observed findings were only evident during the ischemic 
period and returned to baseline levels upon reperfusion.  Additionally, these effects were 
in absence of any alteration of arterial blood pressure (afterload) or heart rate (ventricular 
filling time) during ischemia.  The expectation would be if SGLT2i was involved with 
cardiac NHE-1 inhibition then treatment with an NHE-1i would demonstrate similar cardiac 
effects during myocardial ischemia/reperfusion. However, 15-30 minutes pre-treatment 
with cariporide did not alter ventricular filling volume, cardiac output or work efficiency at 
any time point during the study period.  One could argue that the lack of observed effects 
with cariporide could be to be related to the chosen dose.  In the present study a plasma 
concentration of ~1 µM was chosen based on published data demonstrating that this 
concentration is sufficient for effective inhibition of NHE activity in cardiac ventricular 
myocytes [15, 89]. Furthermore, prior studies have established that 1 µM cariporide 
reduced ischemia induced arrhythmias in rats and mitigates myocardial infarct size in both 
rabbits and pigs  [16, 89, 100].  
 
SGLT2i effects on NHE-1 activity 
To further investigate the hypothesis that the cardiac effects of SGLT2i occur via inhibition 
of NHE-1, cellular studies evaluating the effect of canagliflozin on NHE-1 activity in 
response to acid loading conditions (which resemble conditions in cardiomyocytes during 
ischemia) were conducted.  To circumvent the confounding effects of endogenous 
exchangers, wild type NHE-1 gene was transfected in antiport-deficient (AP-1) cells [141]. 
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This approach allowed for evaluation of a direct effect of canagliflozin on NHE-1 activity.  
The NHE-1 activity studies demonstrated a dose-dependent inhibition of NHE-1 activity 
by cariporide as expected.  Conversely, canagliflozin at all concentrations tested did not 
significantly attenuate NHE-1 activity (Figure 3.4). Similar studies also failed to show an 
effect of SGLT2i on NHE-1 activity human IPSc derived cardiomyocytes (Figure 3.5).  It 
has previously been demonstrated that SGLT2i (empagliflozin, canagliflozin and 
dapagliflozin) reduced pH recovery following an acid load (measure of NHE-1 activity) in 
rabbit and mouse cardiomyocytes by binding NHE-1 [19, 149].  This finding contrasts with 
the present pig experimental data where canagliflozin and cariporide demonstrate 
different cardiac effects during ischemia and the NHE-1 activity assay data demonstrating 
no effect of canagliflozin on NHE-1 activity.  Reasons for these discrepant findings remain 
unclear but are likely related to underlying differences between species, cell types utilized, 
and/or experimental conditions.  Nevertheless, the cardiac findings in the present study 
are consistent with data from the NHE-1 activity assays in both the wild type NHE-1 
transfected AP-1 cells and the IPSc derived cardiomyocytes.  Furthermore, despite assay 
format differences, both the wild type NHE-1 transfected AP-1 cells and the IPSc derived 
cardiomyocytes demonstrate a concentration-dependent inhibition of NHE-1 activity with 
cariporide while canagliflozin had no effect on NHE-1 activity at any concentration tested. 
 
Conclusion and Implications 
The findings from this study fail to support the hypothesis that the acute cardiac 
effects of SGLT2i are mediated via an NHE-1 dependent pathway. Multiple mechanisms 
to explain the benefits have been proposed, including anti-hypertensive effects [103, 105], 
sodium and fluid loss [13, 138], enhanced arterial compliance [50, 94, 150], and anti-
inflammatory capacity [28, 70, 161]. However, based on the acute nature of SGLT2i 
administration in this study (15-30 minutes) these mechanisms are unlikely to explain the 
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Frank-Starling effect of SGLT2i observed during ischemia.  Furthermore, data from our 
recent study as well as the present investigation argue against a requisite role for either 
ketones or NHE-1 in mediating cardiac effects of SGLT2i in normal metabolically healthy 
swine.  These findings contrast prior evidence for ketone utilization in obese heart failure 
suggesting mechanisms of SGLT2i may differ depending the on duration of treatment, 
underlying pathophysiologic conditions and metabolic status, all of which should be further 
explored. Regardless, the acute SGLT2i-mediated preservation of cardiac function in the 
absence of changes in substrate utilization or evidence of NHE-1 activity strongly suggest 
the involvement of other pathways that are independent of SGLT2 as neither its mRNA 
nor protein have been detected in cardiac tissue [32, 43].    
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Table 3.1 
 
Effects of canagliflozin and cariporide on blood gas parameters 
Parameter Treatment 
Condition 
Condition 
P-value 
Treatment 
P-value 
Interaction 
P-value 
Baseline Ischemia Reperfusion 
   
0 min 15 min 30 min 45 min 60 min 30 min 60 min 90 min 120 min 
Arterial pH 
Control 
7.49 ± 
0.00 
7.44 ± 
0.03 
7.45 ± 
0.03 
7.44 ± 
0.03 
7.44 ± 
0.02 
7.46 ± 
0.02 
7.46 ± 
0.02 
7.47 ± 
0.02 
7.47 ± 
0.03 
0.08 0.65 0.97 SGLT2i 
7.46 ± 
0.03 
7.45 ± 
0.03 
7.45 ± 
0.03 
7.45 ± 
0.01 
7.46 ± 
0.01 
7.47 ± 
0.01 
7.46 ± 
0.01 
7.45 ± 
0.02 
7.46 ± 
0.03 
NHE-1i 
7.45 ± 
0.03 
7.46 ± 
0.03 
7.47 ± 
0.03 
7.47 ± 
0.02 
7.47 ± 
0.01 
7.48 ± 
0.02 
7.50 ± 
0.02 
7.49 ± 
0.03 
7.49 ± 
0.03 
Arterial PCO2 
(mmHg) 
Control 46 ± 2 49 ± 5 45 ± 3 48 ± 4 45 ± 2 44 ± 2 44 ± 3 43 ± 1 44 ± 2 
0.20 0.55 0.58 SGLT2i 46 ± 4 45 ± 3 44 ± 2 43 ± 2 44 ± 3 45 ± 4 44 ± 4 46 ± 4 44 ± 4 
NHE-1i 42 ± 2 44 ± 2 42 ± 1 42 ± 1 42 ± 1 42 ± 1 40 ± 3 40 ± 2 42 ± 3 
Arterial PO2 
(mmHg) 
 
Control 110 ± 11 
103 ± 
11 
113 ± 9 101 ± 11 108 ± 9 111 ± 6 107 ± 5 110 ± 4 105 ± 5 
0.01 0.23 0.21 SGLT2i 122 ± 10 125 ± 6 129 ± 10 131 ± 8 129 ± 9 
121 ± 
12 
115 ± 10 104 ± 8 
112 ± 
13 
NHE-1i 123 ± 10 132 ± 9 133 ± 9 130 ± 9 130 ± 3 
126 ± 
10 
127 ± 10 122 ± 8 119 ± 7 
Coronary 
Venous PO2 
(mmHg) 
Control 20 ± 1 22 ± 2 23 ± 2 26 ± 5* 22 ± 2 20 ± 2 21 ± 2 20 ± 1 19 ± 1 
0.02 0.17 0.46 SGLT2i 18 ± 2 17 ± 1 18 ± 2 18 ± 2† 17 ± 2 17 ± 2 16 ± 2 17 ± 2 15 ± 2 
NHE-1i 19 ± 2 20 ± 2 18 ± 2 18 ± 2† 18 ± 2 17 ± 2 17 ± 2 17 ± 2 17 ± 2 
HCT (%) 
Control 31 ± 2 34 ± 3 33 ± 3 34 ± 3 32 ± 3 31 ± 2 31 ± 2 30 ± 2 32 ± 2 
0.46 0.61 0.90 SGLT2i 30 ± 1 31 ± 1 31 ± 2 31 ± 2 31 ± 2 30 ± 2 31 ± 2 31 ± 3 30 ± 3 
NHE-1i 32 ± 2 33 ± 2 32 ± 1 34 ± 1 33 ± 1 33 ± 2 33 ± 2 33 ± 2 35 ± 2 
Arterial O2 
Content 
(mL/dL) 
Control 15 ± 1 16 ± 1 16 ± 1 16 ± 1 15 ± 1 15 ± 1 15 ± 1 15 ± 1 15 ± 1 
0.59 0.59 0.98 SGLT2i 15 ± 1 15 ± 1 15 ± 1 15 ± 1 15 ± 1 15 ± 1 15 ± 1 15 ± 1 14 ± 1 
NHE-1i 16 ± 1 16 ± 1 16 ± 1 16 ± 1 16 ± 1 16 ± 1 16 ± 1 16 ± 1 16 ± 1 
Coronary 
Venous O2 
Content 
(mL/dL) 
Control 3.6 ± 0.5 
4.4 ± 
0.7 
4.7 ± 0.8 5.9 ± 2.0 4.3 ± 0.7 
3.5 ± 
0.5 
3.8 ± 0.6 
3.3 ± 
0.2 
3.2 ± 
0.3 
0.08 0.43 0.41 
SGLT2i 3.5 ± 0.6 
3.1 ± 
0.5 
3.5 ± 0.6 3.4 ± 0.6 3.3 ± 0.5 
3.3 ± 
0.4 
3.4 ± 0.5 
3.2 ± 
0.5 
3.0 ± 
0.5 
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NHE-1i 3.7 ± 0.5 
3.9 ± 
1.0 
3.4 ± 0.6 3.4 ± 0.4 3.2 ± 0.3 
3.1 ± 
0.4 
3.2 ± 0.2 
3.0 ± 
0.2 
3.1 ± 
0.2 
Myocardial 
Oxygen 
Consumption 
(mL 
O2/min/g) 
Control 61 ± 7 65 ± 12 53 ± 7 46 ± 6 48 ± 4 49 ± 6 48 ± 6 47 ± 7 50 ± 6 
0.01 0.56 0.20 SGLT2i 41 ± 4 45 ± 5 42 ± 3 42 ± 4 44 ± 5 38 ± 3 43 ± 7 49 ± 9 50 ± 6 
NHE-1i 66 ± 18 71 ± 21 39 ± 2* 45 ± 5 46 ± 7 59 ± 13 54 ± 9 51 ± 9 51 ± 9 
Values are mean ± SE for Control (n = 6), SGLT2i (canagliflozin) (n = 6) and NHE-1 (cariporide) (n = 6). * P < 0.05 vs. baseline value 
(same treatment), † P < 0.05 vs. Control (same time point).   
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Table 3.2 
Effects of canagliflozin and cariporide on systemic hemodynamics and cardiac contractile function                                                                                
Parameter Treatment 
Condition 
Condition 
P-value 
Treatment 
P-value 
Interaction 
P-value 
Baseline Ischemia Reperfusion 
   
0 min 15 min 30 min 45 min 60 min 30 min 60 min 90 min 120 min 
Systolic 
Pressure 
(mmHg) 
Control 115 ± 8 98 ± 7* 91 ± 7* 88 ± 4* 83 ± 5* 80 ± 2* 81 ± 4* 79 ± 4* 77 ± 6* 
<0.001 0.33 0.60 SGLT2i 110 ± 5 97 ± 9* 93 ± 9* 93 ± 10* 89 ± 9* 80 ± 7*^ 67 ± 6* 70 ± 5* 80 ± 5* 
NHE-1i 119 ± 8 
 108 ± 
8* 
100 ± 
10* 
99 ± 6* 100 ± 6* 93 ± 6* 92 ± 6* 84 ± 6* 83 ± 7* 
Systemic 
Diastolic 
Pressure 
(mmHg) 
Control 77 ± 7 69 ± 7* 63 ± 5* 61 ± 4* 57 ± 5* 55 ± 2* 54 ± 4* 52 ± 4* 50 ± 5* 
<0.001 0.39 0.31 SGLT2i 81 ± 4 71 ± 6* 67 ± 7* 68 ± 8* 64 ± 7* 55 ± 5* 45 ± 4* 47 ± 3* 52 ± 3* 
NHE-1i 81 ± 6 74 ± 5 69 ± 6 69 ± 8 69 ± 4 65 ± 5* 66 ± 5* 59 ± 5* 57 ± 5* 
Mean 
Pressure 
(mmHg) 
Control 89 ± 7 79 ± 7* 72 ± 6* 70 ± 4* 66 ± 5* 64 ± 2* 63 ± 4* 61 ± 4* 60 ± 5* 
<0.001 0.36 0.43 SGLT2i 91 ± 5 80 ± 7* 76 ± 7* 77 ± 8* 73 ± 7* 63 ± 6* 52 ± 5*^ 55 ± 4* 62 ± 4* 
NHE-1i 94 ± 7 85 ± 6 79 ± 7 79 ± 9 79 ± 4 74 ± 4* 74 ± 6* 67 ± 5* 65 ± 5* 
Heart Rate 
(beats/min) 
Control 83 ± 8 87 ± 6 83 ± 7 83 ± 5 81 ± 6 92 ± 8 91 ± 5 91 ± 5 94 ± 6 
<0.001 0.01 0.02 SGLT2i 79 ± 3 78 ± 5 73 ± 3 83 ± 5 82 ± 5 98 ± 7 113 ± 4*†^ 
118 ± 
6*†^ 
113 ± 
3*†^ 
NHE-1i 68 ± 6 69 ± 6 65 ± 5 74 ± 7 77 ± 10 80 ± 4 86 ± 5 83 ± 4 84 ± 3 
Systemic 
Vascular 
Resistance 
(mmHgxmin/m
L) 
Control 
0.03 ± 
0.00 
0.03 ± 
0.01 
0.02 ± 
0.01 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.01 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.57 0.22 0.76 SGLT2i 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.01 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
NHE-1i 
0.03 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.03 ± 
0.02 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
Coronary 
Blood Flow 
(µl/min/g) 
Control 
0.53 ± 
0.06 
0.57 ± 
0.09 
0.48 ± 
0.06 
0.49 ± 
0.05 
0.44 ± 
0.05 
0.44 ± 
0.06 
0.45 ± 
0.07 
0.44 ± 
0.06 
0.42 ± 
0.06 
0.005 0.55 0.07 SGLT2i 
0.37 ± 
0.07 
0.37 ± 
0.03 
0.36 ± 
0.03 
0.36 ± 
0.04 
0.37 ± 
0.05 
0.36 ± 
0.05 
0.37 ± 
0.07 
0.40 ± 
0.06 
0.44 ± 
0.05 
NHE-1i 
0.57 ± 
0.16 
0.61 ± 
0.20 
0.33 ± 
0.03* 
0.35 ± 
0.04* 
0.36 ± 
0.06* 
0.47 ± 
0.10* 
0.43 ± 
0.07* 
0.39 ± 
0.07 
0.38 ± 
0.06 
Ejection 
Fraction (%) 
Control 64 ± 4 49 ± 4 48 ± 5 51 ± 3 61 ± 6 64 ± 4 63 ± 5 62 ± 5 59 ± 5 
0.17 0.77 0.04 
SGLT2i 66 ± 5 64 ± 3 65 ± 3 66 ± 3 64 ± 5 62 ± 9 55 ± 7 61 ± 5 60 ± 4 
  
 
7
5
 
NHE-1i 68 ± 4 50 ± 6 58 ± 7 56 ± 7 55 ± 8 61 ± 8 60 ± 7 65 ± 4 64 ± 7 
dP/dtmax 
(mmHg/s) 
Control 
1853 ± 
138 
1644 ± 
301 
1051 ± 
214* 
1365 ± 
68 
1325 ± 
93 
1408 ± 
75 
1339 ± 57 
1623 ± 
200 
1661 ± 
245 
<0.001 0.92 0.26 SGLT2i 
1711 ± 
176 
1356 ± 
200 
1449 ± 
156 
1381 ± 
181 
1564 ± 
119 
1440 ± 
66 
1249 ± 
116 
1456 ± 
128 
1641 ± 
114 
NHE-1i 
1892 ± 
111 
1495 ± 
103 
1305 ± 
120* 
1507 ± 
114 
1377 ± 
150* 
1335 ± 
47* 
1371 ± 73* 
1301± 
84* 
1309 ± 
130* 
dP/dtmin 
(mmHg/s) 
Control 
-1754 ± 
157 
-1182 ± 
134* 
-872 ± 
192* 
-1124 ± 
116* 
-1091 ± 
123* 
-1108 ± 
54* 
-1031 ± 
118* 
-1096 ± 
131* 
-1069 ± 
147* 
<0.001 0.97 0.054 SGLT2i 
-1500 ± 
78 
-1225 ± 
129 
-1191 ± 
132 
-1225 ± 
154 
-1249 ± 
131 
-1073 ± 
105* 
-900 ± 
131* 
-1039 ± 
163* 
-1238 ± 
149* 
NHE-1i 
-1466 ± 
106 
-1221 ± 
116 
-1109 ± 
100 
-1328 ± 
135 
-1161 ± 
85 
-1048 ± 
77* 
-1144 ± 
113 
-1005 ± 
81* 
-982 ± 
103* 
Tau1/2 (ms) 
Control 33 ± 4 45 ± 13 27 ± 6 34 ± 4 34 ± 4 38 ± 10 29 ± 2 29 ± 1 27 ± 2 
<0.001 0.18 0.62 SGLT2i 35 ± 3 35 ± 4 38 ± 5 33 ± 5 30 ± 5 26 ± 3 19 ± 4 21 ± 2 20 ± 2 
NHE-1i 39 ± 3 51 ± 12 40 ± 4 42 ± 5 38 ± 3 32 ± 3 30 ± 3 35 ± 5 33 ± 3 
Tau 1/e (ms) 
Control 23 ± 3 31 ± 8 19 ± 4 23 ± 3 23 ± 3 27 ± 8 20 ± 2 20 ± 1 18 ± 1 
<0.001 0.21 0.61 
SGLT2i 24 ± 2 24 ± 3 24 ± 3 23 ± 3 20 ± 4 17 ± 2 13 ± 2 14 ± 1 14 ± 1 
NHE-1i 27 ± 3 32 ± 6 27 ± 3 25 ± 2 26 ± 2 22 ± 2 21 ± 2 22 ± 2 22 ± 2 
Values are mean ± SE for Control (n = 6), SGLT2i (canagliflozin) (n = 6) and NHE-1 (cariporide) (n = 6). * P < 0.05 vs. baseline value 
(same treatment), † P < 0.05 vs. Control (same time point).   
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Table 3.3 
Effects of canagliflozin and cariporide on circulating substrate concentrations  
Parameter Treatment 
Condition 
Condition 
P-value 
Treatment 
P-value 
Interaction 
P-value 
Baseline Ischemia Reperfusion 
   
0 min 15 min 30 min 45 min 60 min 30 min 60 min 90 min 120 min 
Arterial 
Glucose 
(mg/dL) 
Control 114 ± 30 148 ± 40 143 ± 37 124 ± 32 139 ± 33 133 ± 36 128 ± 28 146± 32 146 ± 29 
0.07 0.66 0.02 SGLT2i 159 ± 24 151 ± 28 140 ± 22 135 ± 19 128 ± 13 135 ± 16 137 ± 18 143 ± 16 145 ± 19 
NHE-1i 163 ± 13  184 ± 21 171 ± 17 175 ± 18 179 ± 25 153 ± 11 151 ± 20 155 ± 19 153 ± 17 
Arterial 
Lactate 
(mmol/L) 
Control 1.8 ± 0.4 3.4 ± 0.9* 3.6 ± 0.9* 
3.6 ± 
0.9* 
3.9 ± 
0.9* 
3.6 ± 0.8 
3.4 ± 
0.8* 
3.2 ± 0.8* 2.7 ± 0.5 
<0.001 0.46 0.97 SGLT2i 3.5 ± 0.9 4.1 ± 1.2 4.5 ± 1.4 5.0 ± 1.2 4.6 ± 0.9 4.6 ± 1.0 4.3 ± 1.0 4.4 ± 1.2 4.0 ± 1.3 
NHE-1i 2.6 ± 0.5 3.1 ± 0.5 3.1 ± 0.5 3.4 ± 0.7 3.5 ± 0.8 3.0 ± 0.7 2.8 ± 0.5 2.7 ± 0.5 2.5 ± 0.4 
Arterial 
Ketone 
(µmol/L)) 
Control 66 ± 15 94 ± 17 101 ± 21* 91 ± 19* 
103 ± 
21* 
102 ± 
18* 
109 ± 
16* 
123 ± 19* 133 ± 24* 
<0.001 0.12 0.63 SGLT2i 57 ± 13 75 ± 19 75 ± 17 80 ± 18 80 ± 16 90 ± 17* 92 ± 16* 89 ± 11* 94 ± 12* 
NHE-1i 35 ± 5 49 ± 7 46 ± 5 50 ± 6 58 ± 9 54 ± 6 65 ± 9* 66 ± 7* 79 ± 13* 
Arterial 
FFA 
(mmol/L) 
Control 0.7 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 0.8 ±0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 
0.18 0.77 0.98 SGLT2i 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.7 ± 0. 0.7 ± 0.1 0.6 ± 0.1 
NHE-1i 0.8± 0.2 0.8 ± 0.2 0.8 ± 0.1 0.8 ± 0.1 0.9 ± 0.2 0.8 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 
Values are mean ± SE for Control (n = 6), SGLT2i (canagliflozin) (n = 6) and NHE-1 (cariporide) (n=6). * P < 0.05 vs. baseline value 
(same treatment), † P < 0.05 vs. Control (same time point).   
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Chapter 4:  Discussion 
 
Summary of Findings 
Cardiovascular disease is a major health concern worldwide.  Contributing to the 
cardiovascular burden is the continued epidemic of obesity and the increased prevalence 
of type 2 diabetes.  The combination of obesity and type 2 diabetes are associated with 
several complicated and distinct cardiovascular pathophysiological changes. Treating 
dysmetabolic patients has become problematic as several anti-hyperglycemic agents 
have shown worsening or no improvements on cardiovascular outcomes.  Recent 
cardiovascular outcome trials evaluating the SGLT2i class of anti-hyperglycemic agents 
has demonstrated surprising and unexpected improvements in cardiovascular outcomes.  
SGLT2i were designed to reduce blood glucose levels by inhibiting glucose reabsorption 
in kidney by inhibiting the SGLT2 in the proximal tubules.   SGLT2i were never expected 
to have cardioprotective effects especially since SGLT2 protein expression has not been 
detected in the human heart.  Therefore, the mechanism behind their cardiovascular 
action remains a mystery.   
There have been several proposed hypotheses for the SGLT2i mediated 
cardioprotective effects, but uncertainty remains.  The goal of this application was to test 
the two main hypotheses for the observed effects in the acute ischemia reperfusion 
porcine model, first the “thrifty fuel” hypothesis and second the “sodium” hypothesis.  
SGLT2i therapy has been demonstrated to augment circulating ketone bodies via 
alterations in hepatic metabolism [48, 112]. This “thrifty fuel” effect could serve to shift 
myocardial substrate utilization away from free fatty acids toward ketones, which require 
less oxygen per mole of ATP produced [22].  Alternatively, recent evidence also suggests 
that the SGLT2i mediate cardiac protection via direct inhibition of the sodium hydrogen 
exchanger-1 (NHE-1), i.e. “the sodium hypothesis” [19, 149]. In conditions such as 
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myocardial ischemia, intracellular acidosis activates NHE-1 leading to myocyte sodium 
accumulation and calcium overload.  Inhibition of NHE-1 during myocardial ischemia could 
potentially improve calcium handling and preserve cardiomyocyte function and efficiency. 
Although prior studies have demonstrated improved cardiac function with 
increased ketones [58, 77, 115] or the administration of an NHE-1i [53, 67, 142], a direct 
link to SGLT2i mediated improvements in cardiac function via increased ketones or 
inhibition of NHE-1 has not been established.  Accordingly, the goal of this investigation 
was to test the hypothesis that SGLT2i therapy enhances cardiac function and mitigates 
myocardial infarct size via indirect effects on NHE-1 and/or a shift in myocardial substrate 
utilization.  The findings of the Specific Aims are summarized below: 
 
Aim 1:  Test the hypothesis that SGLT2i improves cardiac contractile function and 
efficiency and attenuates infarct size in response to ischemia/reperfusion injury via 
salutary effects on myocardial metabolism. 
 
 
↑ 
SGLT2i → 
? 
Figure 4.1 Schematic diagram of the proposed ketone effects of SGLT2i on the primary 
determinants of cardiac efficiency.  
  
? 
? 
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The goal of the initial study was to evaluate the effects of SGLT2i on cardiac 
contractile function, substrate utilization, and efficiency before and during regional 
myocardial ischemia/reperfusion injury in normal, metabolically healthy swine (Figure 4.1).  
This study was designed to evaluate short-term effects of SGLT2i (24 hour exposure) 
thereby excluding contributions of effects of chronic SGLT2i exposure (i.e. weight loss, 
reduced blood pressure, etc.).  The initial study revealed that treatment with SGLT2i 
produced significant increases in end diastolic volume at the onset of ischemia and that 
this increased volume returned to baseline values upon reperfusion (Figure 2.3).  This 
canagliflozin mediated increase in end diastolic volume was directly associated with 
increased stroke volume and stroke work relative to controls during ischemia (Figure 2.5). 
Taken together, the increased stroke work and unaltered myocardial oxygen consumption 
(Table 2.1) led to improved cardiac work efficiency during ischemia in the SGLT2i treated 
group compared to the control group.  Additionally, no differences in myocardial uptake of 
glucose, lactate, free fatty acids or ketones, were noted between treatment groups at any 
time (Figure 2.6).  
Additional studies were designed to evaluate the effect of SGLT2i on infarct size 
in response to ischemia/reperfusion injury.  These studies used a longer (60 minute) 
coronary occlusion and a 2-hour reperfusion period.  Canagliflozin increased both end 
diastolic volume and stroke volume as observed in the initial studies (Appendix B).  
Canagliflozin treatment also produced significant reductions in infarct size relative to 
control animals (Figure 2.7).  These data demonstrate that SGLT2i with canagliflozin 
preserves cardiac contractile function and efficiency during regional myocardial ischemia 
and provides ischemia protection independent of alterations in myocardial substrate 
utilization.  Collectively, these observations argue against contributions of ketone-induced 
shifts in fuel selection (“thrifty fuel hypothesis”) to the cardioprotective effects of SGLT2i 
in normal, metabolically healthy swine (Figure 4.2).   
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SGLT2i could preserve cardiac contractile function during regional myocardial 
ischemia via activation of the Frank-Starling mechanism, increase in cardiac output via an 
increase in end diastolic volume as was demonstrated in Aim 1 (Figure 2.4 C and D).  
Studies have shown the giant protein titin contributes to this mechanism which brings us 
to the question could SGLT2i alter titin’s contribution to the Frank-Starling mechanism  [5, 
52, 93].  Titin functions as a “molecular spring” and is the primary source of “passive” 
tension in cardiomyocytes (sarcomeres) [62].  Additionally, studies have demonstrated 
that changes in titin, (i.e. differences titin isoforms N2B and N2BA, increases in N2B cause 
the heart to become more rigid) and PTM of titin N2B and N2BA isoforms have been 
observed during ischemia/reperfusion contributing to contractile dysfunction in the heart 
[8, 27, 91].   
Figure 4.2 Schematic diagram of the experimental outcomes of SGLT2i effects on the 
primary determinants of cardiac efficiency.  
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Altered function of cardiac ion channels, transporters and/or exchangers are often 
the consequence of an ischemic event which can lead to improper Ca2+ handling [21, 30].  
Dysfunctional Ca2+ handling is detrimental to the mechanical and electrical properties of 
the heart (diastolic and systolic dysfunction, arrhythmias) [30, 120]. It has been suggested 
that SGLT2i could play a role in Ca2+ handling in cardiomyocytes.  Baartscheer and 
Uthman have suggested that SGLT2i inhibits NHE-1 activity thereby preventing increased 
intracellular Na+ and consequentially intracellular Ca2+ overload during ischemia and that 
this is how SGLT2i improve cardiovascular outcomes during ischemia [19, 149].  This 
hypothesis is discussed and addressed in Aim 2 of this investigation.  Additionally, Lee et 
al [94] suggests empagliflozin attenuates Na+ and Ca2+ dysregulation in streptozotocin-
induced diabetic rats, a model of diabetes mellitus (DM) cardiomyopathy.  They concluded 
that empagliflozin significantly altered Ca2+ regulation, late Na+ and NHE currents and 
electrophysical properties of DM cardiomyopathy, therefore proposing this as the 
mechanism for the reported SGLT2i cardioprotection [94].  While Lee et al. demonstrated 
improvements in Na+ and Ca2+ handling in DM cardiomyopathy, the question for whether 
SGLT2i influence Na+ and Ca2+ handling in normal glycemic hearts during ischemia 
remains. 
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Aim 2:  Evaluate the hypothesis that NHE-1 contributes to the cardiac effects of SGLT2i 
in response to myocardial ischemia/reperfusion injury.  
 
 
The goal of Aim 2 was to evaluate the effects of SGLT2i and NHE-1i on cardiac 
contractile function and efficiency (Figure 4.3) in response to a regional myocardial 
ischemia/reperfusion injury in normal, metabolically healthy swine. Additionally, this study 
was designed to evaluate acute effects of SGLT2i (15-30 min, I.V. infusion) thereby 
excluding contributions of additional pleiotropic effects beyond those that are directly 
affecting the heart (i.e. weight loss, reduced blood pressure, etc.).  Our initial study 
revealed that acute treatment with SGLT2i produced significant increases in end diastolic 
volume at the onset of ischemia and that this increased volume returned to baseline values 
upon reperfusion (Figure 3.1).  This canagliflozin mediated increase in end diastolic 
volume was directly associated with increased stroke work and improved cardiac 
↑ 
SGLT2i → 
? 
Figure 4.3 Schematic diagram of the proposed NHE-1 effects of SGLT2i on the primary 
determinants of cardiac efficiency.  
  
↑ 
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efficiency compared to controls during ischemia (Figure 3.3).  In contrast to canagliflozin, 
cariporide did not alter ventricular filling volume, cardiac output or work efficiency at any 
time point during the study period.   
To further examine effects of SGLT2i on NHE-1 a cellular approach was utilized 
(in parallel to the in vivo studies).  The initial NHE-1 activity studies evaluated SGLT2i 
(canagliflozin and dapagliflozin) in WT human NHE-1 in transfected CHO (AP-1) cells.  
This allowed evaluation of whether SGLT2i had a direct effect on NHE-1 activity.  The data 
from the WT human NHE-1 in transfected CHO (AP-1) cell studies failed to show an effect 
of SGLT2i on NHE-1 activity, specifically SGLT2i did not inhibit NHE-1 in response to an 
acid load (similar to the acidic conditions in cardiomyocytes during ischemia).   It has been 
proposed that the SGTL2i mediated cardiovascular protection was at least in part due to 
SGLT2i inhibition of NHE-1 activity (“sodium hypothesis”) however, findings from these 
studies do not support this hypothesis (Figure 4.4).   
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It has been reported that both canagliflozin and cariporide have in infarct mitigating 
effects [20, 89, 131].  Nevertheless, canagliflozin and cariporide had very different cardiac 
contractile and efficiency responses to ischemia.  This would suggest that SGLT2i and 
NHE-1i are working through different mechanisms (i.e. SGLT2i does not affect NHE-1 
activity).  It has also been reported that the infarct mitigating effects of cariporide are only 
present when dosed prior to or at the time of ischemia but the effect is lost if dosed after 
the onset of ischemia suggesting a localized effect (i.e. NHE-1i needs to be present within 
the area at risk prior to the ischemic event)  [89].  Whereas, in addition to infarct mitigation 
properties, canagliflozin also demonstrated a more “global” cardiac response to ischemia 
(i.e. increased cardiac filling volumes, stroke work and cardiac output).   Studies published 
by Sayour et. al provide further support for a more “global” response with SGLT2i as they 
demonstrated cardiac effects and infarct mitigation when canagliflozin was administered 
Figure 4.4 Schematic diagram of the experimental outcomes of the proposed NHE1 
effects of SGLT2i on the primary determinants of cardiac efficiency.  
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5 minutes into ischemia [131].  Together these data suggest that SGLT2i have a cardiac 
effect that exists outside of the ischemic territory but is triggered by an ischemic event.  
These data further suggest SGLT2i could be mediating the activity of a cardiac ion 
channel, exchanger or some other mechanism directly involved in the myocardium’s 
immediate response to ischemia.   
 
Implications 
 Findings from this investigation provides support that the SGLT2i canagliflozin 
preserves cardiac contractile function and efficiency during regional myocardial ischemia 
and provides ischemia protection independent of alterations in myocardial substrate 
utilization or NHE-1 activity.  The findings from these studies demonstrate an acute action 
of SGLT2i on cardiac function at the onset of ischemia and for the duration of the ischemic 
period.  Canagliflozin had no effect on cardiac function at baseline and returned to 
baseline levels at the beginning of the reperfusion.  These data suggest SGLT2i could be 
mediating the activity of a cardiac ion channel, exchanger or some other mechanism 
directly involved in the myocardium’s immediate response to ischemia. The observed 
cardiac effects of SGLT2i in the initial study are consistent with the activation of a Frank-
Starling mechanism.  The Frank-Starling law states that as cardiac filling increases (left 
ventricular end diastolic volume) there is a proportionate increase in stroke volume [40].  
Despite over 100 years of research, the precise mechanism responsible for this 
fundamental physiologic response remains a contested mystery.  Recent studies indicate 
that the giant protein titin, a major component of the contractile apparatus, contributes to 
the activation of the Frank-Starling mechanism [99] by acting as an adjustable “molecular 
spring” which allows the heart to quickly balance ventricular stroke volume relative to 
diastolic filling volume on a relative beat-to-beat basis  [62, 91, 113].  In particular, titin 
phosphorylation has been observed during ischemia/reperfusion and in heart failure 
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contributing to contractile dysfunction in the heart [62, 66, 78, 126].  A recent study 
reported direct effects of empagliflozin on cardiac muscle resulting in improved diastolic 
function in human and mouse heart failure myocardium [118].  The improved diastolic 
function was suggested to be the result of empagliflozin mediated increases in titin 
phosphorylation.  Additionally, these data were evident after acute (15-60 minute) 
empagliflozin treatment and were independent of any changes in systolic contractility or 
cytosolic Ca2+.  Together these data support a potential role for SGLT2i in modulating titin 
phosphorylation which could explain the observed cardiac effects of the present study and 
warrant further investigation. Additional findings support that that SGLT2i attenuates 
myocardial infarct size (Figure 2.7).  The infarct mitigating properties of canagliflozin 
suggest SGLT2i plays a role in myocardial survival during ischemia/reperfusion (i.e. 
STAT3, SAFE pathway, mitochondrial transition pore) [12].  While there are many 
proposed mechanisms for the observed SGLT2i mediated effects on cardiac function 
there are few answers.  The findings from these studies begin to answer some those 
questions thereby allowing us to identify and better understand the mechanisms behind 
the SGLT2i mediated cardioprotection.  Additionally, the findings of this investigation 
further support a role for SGLT2i use in non-diabetic individuals at risk for ischemic heart 
disease. 
 
Future Directions and Proposed Studies 
While these studies answer mechanistic questions regarding SGLT2i role in 
cardioprotection during myocardial ischemia/reperfusion injury in a metabolically normal 
animal, the question remains as to whether this holds true in the setting of diabetes where 
metabolic flexibility is often compromised. Therefore, future studies are needed to 
evaluate cardiac effects of SGLT2i during ischemia/reperfusion in obese diabetic animals 
as well as metabolically normal and diabetic heart failure models.  With the reported 
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improvements in heart failure outcomes in the SGLT2i clinical trials, we also propose that 
future studies should include evaluating the hypothesis that SGLT2i attenuates the 
progression of heart failure in the setting of obesity.  
Unfortunately, relevant large animal models representing diabetic heart failure are 
currently lacking.  However, our lab has completed preliminary heart failure model 
development studies in Ossabaw swine.  Ossabaw swine, when fed a high fat/ high 
cholesterol diet become obese, develop insulin resistance/impaired glucose tolerance, 
dyslipidemia and atherosclerosis have a similar phenotype as to what is observed in 
“metabolic syndrome” (MetS).  We have established that rapid ventricular pacing (~180 
beats/min for ~4-5 weeks) of obese Ossabaw swine induces marked increases in left 
ventricular end diastolic pressure (> 20 mmHg), moderate increases in end diastolic and 
end systolic volume, but without changes in ejection fraction; i.e. mimicking the clinical 
phenotype of heart failure with preserved ejection fraction (HFpEF) (Figure 4.5).   
 
Figure 4.5 Representative pressure-volume loops for lean, obese and obese heart 
failure Ossabaw swine.  
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This obese pacing-induced heart failure model now gives us the opportunity to 
specifically evaluate the distinct physiologic, pathophysiologic and metabolic changes 
associated with this dysmetabolic state (metabolomic and proteomic analysis, histology to 
evaluate structural changes,  hemodynamic analysis including chronic telemetric 
assessment of left ventricular pressure, volume, coronary blood flow, arterial pressure at 
rest and during interventions such as graded treadmill exercise, ischemia-reperfusion 
injury). This model will allow us to perform studies to evaluate the effects of SGLT2i on 
cardiac function in the setting of obese heart failure.  
   It has been reported that SGLT2 expression is not present in the human heart 
[32, 43, 153] and, data from our lab have demonstrated similar results in pig hearts (Figure 
2.1).  The expression data would indicate that SGLT2i should not have a direct effect on 
the heart as SGLT2 protein expression isn’t present.  However, the data generated by our 
lab demonstrate cardiac effects with acute administration (15 minute intravenous infusion, 
immediately prior to ischemia) and raise the possibility that SGLT2i are having a direct 
effect on the heart.  This would indicate that SGLT2i has off-target molecular effects either 
during ischemia.  Therefore, we propose studies to investigate molecular targets that 
SGLT2i could potentially be interacting with in the myocardium in the presence/absence 
of ischemia.  These studies would be a collaborative effort and involve a chemoproteomics 
approach (via click chemistry) to identify proteins from myocardial lysates and cardiac 
myocytes under normal and ischemic conditions that bind to SGLT2i.   
 Click chemistry describes the bioconjugation reaction between an azide with an 
alkyne group to form a covalent bond under a Cu(I) catalyzed condition (Figure 4.6) [160].    
The overall process is as follows:  
1. Canagliflozin and a structurally similar but SGLT2 inactive compound will be 
incubated separately with cells (either under normal or hypoxic conditions) and/or 
porcine myocardial lysates. 
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2. Samples will be exposed to UV light to crosslink canagliflozin compounds to 
protein binding targets.   
3. Biotin-azide or biotin-alkyne and CuAAC will be added to initiate the click reaction. 
4. Tagged proteins will be purified using streptavidin beads. 
5. Protein identification will be done by mass spectrometry proteomics. 
6. The negative control compound will be used to eliminate non-specific binding 
proteins. 
7. Samples with free canagliflozin compound will be spiked into additional samples 
to serve as an additional negative control. 
This analysis could potentially identify additional novel protein ligands of SGLT2i that may 
lead to new pathways for cardiac protection. 
 
Figure 4.6 Schematic diagram of the proposed chemical proteomics study to identify 
binding partners/targets.  [160] 
  
compound Compound-
inspired probe 
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Concluding Remarks 
Obesity and type 2 diabetes are highly prevalent diseases that are significant 
contributors to the increasing cardiovascular disease burden.  Furthermore, the 
combination of obesity and type 2 diabetes is associated with increased prevalence and 
severity of cardiovascular disease.  To date many type 2 diabetes therapies have either 
failed to reduce adverse cardiovascular outcomes or have been associated with 
worsening of heart disease.  Together this highlights the need for new therapeutic options 
for treating cardiovascular disease in dysmetabolic individuals.  Recent clinical trials 
EMPA-REG, CANVAS, DECLARE-TIMI, demonstrated that empagliflozin, canagliflozin 
and dapagliflozin improved cardiovascular outcomes in patients with type 2 diabetes. 
These SGLT2 inhibitors are a new class of anti-hyperglycemic agent, which produced 
unexpected reductions of sudden cardiac death and heart failure hospitalizations.  While 
these inhibitors provide a valuable treatment option for dysmetabolic individuals with 
cardiovascular disease, little is known regarding their cardioprotective mechanism of 
action.  The goal of this work was to investigate the two main hypotheses for the observed 
effects, the “thrifty fuel” hypothesis and the “sodium” hypothesis in the setting of acute 
cardiac ischemia and reperfusion.  Findings from this investigation provides support that 
the SGLT2i canagliflozin preserves cardiac contractile function and efficiency during 
regional myocardial ischemia and provides ischemia protection independent of alterations 
in myocardial substrate utilization or NHE-1 activity.  The findings from these studies 
demonstrate an acute action of SGLT2i on cardiac function at the onset of ischemia and 
for the duration of the ischemic period.  While there are still many questions regarding 
SGLT2i cardioprotective mechanisms, this investigation has provided valuable information 
for two of the most prevalent hypotheses.  Furthermore, the acute nature of SGLT2i 
mediated cardiac effects identified in this body of work emphasizes the need to focus on 
mechanisms directly associated with the myocardium (i.e. cardiac ion channels, 
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exchangers, mitochondrial preservation).  Additionally, the findings of this investigation 
further support a role for SGLT2i use in non-diabetic individuals at risk for ischemic heart 
disease. 
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Appendices 
Appendix A: Supplemental Table 
  
Parameter Treatment 
Condition 
Condition 
P-value 
Treatment 
P-value 
Interaction 
P-value Baseline Ischemia Reperfusion 
0 min 15 min 30 min 45 min 60 min 90 min 120 min 150 min 180 min 
Arterial pH 
Control 7.53 ± 
0.58 
7.52 ± 
0.06  
7.53 ± 
0.06  
7.51 ± 
0.04 
7.49 ± 
0.03  
7.49 ± 
0.03 
7.50 ± 
0.04 
7.50 ± 
0.05 
7.49 ± 
0.05 0.815 
  
0.899 
  
0.908 
  
SGLT2i 7.51 ± 
0.07 
7.50 ± 
0.06 
7.51 ± 
0.05 
7.51 ± 
0.04  
7.51 ± 
0.04  
7.51 ± 
0.05 
7.51 ± 
0.04 
7.48 ± 
0.04  
7.51 ± 
0.05  
Arterial PCO2 
(mmHg) 
Control 38 ± 5 38 ± 5 37 ± 5 40 ± 3 40 ± 3 40 ± 3 39 ± 4 39 ± 5 39 ± 5 0.995 
  
0.004 
  
0.800 
  SGLT2i 43 ± 7 * 43 ± 6 * 42 ± 6 42 ± 3 41 ± 3 40 ± 4 40 ± 3 41 ± 4 40 ± 3 
Arterial PO
2
 
(mmHg) 
Control 169 ± 
24 
168 ± 
23 
168 ± 
29 
164 ± 
37 
169 ± 
23 171 ± 19 165 ± 26 165 ± 25 
161 ± 
26 0.988 
  
0.468 
  
0.998 
  
SGLT2i 166 ± 
32 
168 ± 
31 
171 ± 
29 
166 ± 
32 
165 ± 
32 156 ± 32 160 ± 31 153 ± 40 
156 ± 
37 
HCT (%) Control 33 ± 4 33 ± 3 33 ± 4 34 ± 3 35 ± 3 34 ± 2 34 ± 2 33 ± 5 33 ± 3 0.993 
  
0.592 
  
0.942 
  SGLT2i 33 ± 3 34 ± 4 34 ± 4 34 ± 4 34 ± 3 33 ± 3 33 ± 3 35 ± 2 35 ± 4 
Mean Blood 
Pressure 
(mmHg) 
Control 75 ± 11 75 ± 8 70 ± 12 73 ± 13 73 ± 14 70 ± 16 65 ± 19 63 ± 20 65 ± 14 
0.272 
  
0.470 
  
0.999 
  SGLT2i 76 ± 17 75 ± 14   73 ± 16 68 ± 18 70 ± 16 64 ± 17 61 ± 14  60 ± 15  62 ± 14  
Heart Rate 
(beats/minute) 
Control 83 ± 21  78 ± 18 85 ± 13 91 ± 10 88 ± 13  86 ± 14 85 ± 12 87 ± 10 82 ± 7 
0.483 
  
<0.001 
  
0.262 
  SGLT2i 67 ± 20 66 ± 14 62 ±16 
*  
61 ± 15 
*  
60 ± 13 
* 82 ± 24 82 ± 30 76 ± 22 82 ± 7 
Effects of canagliflozin on systemic hemodynamics and blood gas parameters 
Values are mean ± SE for saline (n = 6) and canagliflozin (n = 6). *p<0.05 vs. time control. [23] 
  
 
9
3
 
Appendix B: Supplemental Figure 
 
0 30 60 90 120 150 180
0
50
100
150
Time
E
n
d
 D
ia
s
to
li
c
 V
o
lu
m
e
 (
m
L
)
Control
SGLT2i
15 45
Ischemia Reperfusion
Condition P = <0.001
Treatment P = 0.74
*
*
† † † †
0 30 60 90 120 150 180
0
25
50
75
100
Time
S
tr
o
k
e
 V
o
lu
m
e
 (
m
L
)
15 45
Ischemia Reperfusion
Condition P = <0.001
Treatment P = 0.17
*
*
†
† † †
A B C 
0 50 100 150
0
20
40
60
80
100
120
End Diastolic Volume (mL)
S
tr
o
k
e
 V
o
lu
m
e
 (
m
L
)
Effect of ischemia/reperfusion injury on end diastolic volume (Panel A), stroke volume (Panel B) and the relationship between stroke 
volume and end diastolic volume during ischemia in Control (n = 5) and SGLT2i (canagliflozin) treated (n = 5) swine. * P < 0.05 vs. 
Control (same time point), † P < 0.05 vs. baseline value (same treatment). [23] 
 94 
REFERENCES 
 
1. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA (2016) SGLT2 Inhibitors and 
Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. 
Diabetes Care 39:717-725 doi:10.2337/dc16-0041 
 
2. Abu Seif AM SH, Awad AY, El-Kotby HM. (2017) Efficacy and safety of 
canagliflozin compared to vildagliptin in treatment of experimentally induced 
diabetes in albino rats. Diabetic Medicine 34  
 
3. Adingupu DD, Gopel SO, Gronros J, Behrendt M, Sotak M, Miliotis T, Dahlqvist U, 
Gan LM, Jonsson-Rylander AC (2019) SGLT2 inhibition with empagliflozin 
improves coronary microvascular function and cardiac contractility in prediabetic 
ob/ob(-/-) mice. Cardiovasc Diabetol 18:16 doi:10.1186/s12933-019-0820-6 
 
4. Administration FaD (2018) Diabetes Mellitus -- Evaluating Cardiovascular Risk in 
New Antidiabetic Therapies to Treat Type 2 Diabetes. In: Research CfDEa (ed) 
 
5. Ait-Mou Y, Hsu K, Farman GP, Kumar M, Greaser ML, Irving TC, de Tombe PP 
(2016) Titin strain contributes to the Frank-Starling law of the heart by structural 
rearrangements of both thin- and thick-filament proteins. Proc Natl Acad Sci U S 
A 113:2306-2311 doi:10.1073/pnas.1516732113 
 
6. Al-Goblan AS, Al-Alfi MA, Khan MZ (2014) Mechanism linking diabetes mellitus 
and obesity. Diabetes Metab Syndr Obes 7:587-591 doi:10.2147/DMSO.S67400 
 
7. Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo RA, Abdul-
Ghani M (2017) Determinants of the increase in ketone concentration during 
SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab 19:809-
813 doi:10.1111/dom.12881 
 
8. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R (2010) Titin is a target 
of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion 
injury. Circulation 122:2039-2047 doi:10.1161/CIRCULATIONAHA.109.930222 
 
9. Amende I, Bentivegna L, Morgan JP (1992) Ventricular function and calcium 
handling during ischemia. J Cardiovasc Pharmacol 20 Suppl 5:S42 
doi:10.1097/00005344-199206205-00007 
 
10. Amith SR, Wilkinson JM, Fliegel L (2016) Assessing Na(+)/H(+) exchange and cell 
effector functionality in metastatic breast cancer. Biochim Open 2:16-23 
doi:10.1016/j.biopen.2016.01.001 
 
11. Amith SR, Wilkinson JM, Fliegel L (2016) KR-33028, a potent inhibitor of the 
Na(+)/H(+) exchanger NHE1, suppresses metastatic potential of triple-negative 
breast cancer cells. Biochem Pharmacol 118:31-39 doi:10.1016/j.bcp.2016.08.010 
 
12. Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou 
CA, Nikolaou PE, Maratou E, Lambadiari V, Ikonomidis I, Kostomitsopoulos N, 
Brizzi MF, Dimitriadis G, Iliodromitis EK (2017) Empagliflozin Limits Myocardial 
 95 
Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox 
Aspects. Front Physiol 8:1077 doi:10.3389/fphys.2017.01077 
 
13. Ansary TM, Nakano D, Nishiyama A (2019) Diuretic Effects of Sodium Glucose 
Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. 
Int J Mol Sci 20 doi:10.3390/ijms20030629 
 
14. Asleh R, Sheikh-Ahmad M, Briasoulis A, Kushwaha SS (2018) The influence of 
anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in 
patients with type 2 diabetes mellitus. Heart Fail Rev 23:445-459 
doi:10.1007/s10741-017-9666-8 
 
15. Avkiran M, Marber MS (2002) Na(+)/H(+) exchange inhibitors for cardioprotective 
therapy: progress, problems and prospects. J Am Coll Cardiol 39:747-753 
doi:10.1016/s0735-1097(02)01693-5 
 
16. Aye NN, Xue YX, Hashimoto K (1997) Antiarrhythmic effects of cariporide, a novel 
Na+-H+ exchange inhibitor, on reperfusion ventricular arrhythmias in rat hearts. 
Eur J Pharmacol 339:121-127 doi:10.1016/s0014-2999(97)01371-x 
 
17. Azuma K, Kawamori R, Toyofuku Y, Kitahara Y, Sato F, Shimizu T, Miura K, Mine 
T, Tanaka Y, Mitsumata M, Watada H (2006) Repetitive fluctuations in blood 
glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. 
Arterioscler Thromb Vasc Biol 26:2275-2280 
doi:10.1161/01.ATV.0000239488.05069.03 
 
18. Baartscheer A, Schumacher CA, Belterman CN, Coronel R, Fiolet JW (2003) 
[Na+]i and the driving force of the Na+/Ca2+-exchanger in heart failure. 
Cardiovasc Res 57:986-995 doi:10.1016/s0008-6363(02)00848-9 
 
19. Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, 
Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na(+) 
through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. 
Diabetologia 60:568-573 doi:10.1007/s00125-016-4134-x 
 
20. Baker HE, Kiel AM, Luebbe ST, Simon BR, Earl CC, Regmi A, Roell WC, Mather 
KJ, Tune JD, Goodwill AG (2019) Inhibition of sodium-glucose cotransporter-2 
preserves cardiac function during regional myocardial ischemia independent of 
alterations in myocardial substrate utilization. Basic Res Cardiol 114:25 
doi:10.1007/s00395-019-0733-2 
 
21. Baumeister P, Quinn TA (2016) Altered Calcium Handling and Ventricular 
Arrhythmias in Acute Ischemia. Clin Med Insights Cardiol 10:61-69 
doi:10.4137/CMC.S39706 
 
22. Bayeva M, Gheorghiade M, Ardehali H (2013) Mitochondria as a therapeutic target 
in heart failure. J Am Coll Cardiol 61:599-610 doi:10.1016/j.jacc.2012.08.1021 
 
23. Bell RM, Yellon DM (2017) SGLT2 inhibitors: hypotheses on the mechanism of 
cardiovascular protection. Lancet Diabetes Endocrinol doi:10.1016/S2213-
8587(17)30314-5 
 96 
24. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, 
Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind 
MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, 
Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, 
Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, 
Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, 
Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, 
Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS, American Heart 
Association Council on E, Prevention Statistics C, Stroke Statistics S (2019) Heart 
Disease and Stroke Statistics-2019 Update: A Report From the American Heart 
Association. Circulation 139:e56-e528 doi:10.1161/CIR.0000000000000659 
 
25. Bertero E, Prates Roma L, Ameri P, Maack C (2018) Cardiac effects of SGLT2 
inhibitors: the sodium hypothesis. Cardiovasc Res 114:12-18 
doi:10.1093/cvr/cvx149 
 
26. Bhupathiraju SN, Hu FB (2016) Epidemiology of Obesity and Diabetes and Their 
Cardiovascular Complications. Circ Res 118:1723-1735 
doi:10.1161/CIRCRESAHA.115.306825 
 
27. Bogomolovas J, Gasch A, Bajoras V, Karciauskaite D, Serpytis P, Grabauskiene 
V, Labeit D, Labeit S (2016) Cardiac specific titin N2B exon is a novel sensitive 
serological marker for cardiac injury. Int J Cardiol 212:232-234 
doi:10.1016/j.ijcard.2016.03.045 
 
28. Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue 
low-grade inflammation: The potential contribution to diabetes complications and 
cardiovascular disease. Diabetes Metab 44:457-464 
doi:10.1016/j.diabet.2018.09.005 
 
29. Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, Fedak 
PWM, Verma S, Dyck JRB (2017) Empagliflozin Prevents Worsening of Cardiac 
Function in an Experimental Model of Pressure Overload-Induced Heart Failure. 
JACC Basic Transl Sci 2:347-354 doi:10.1016/j.jacbts.2017.07.003 
 
30. Carmeliet E (1999) Cardiac ionic currents and acute ischemia: from channels to 
arrhythmias. Physiol Rev 79:917-1017 doi:10.1152/physrev.1999.79.3.917 
 
31. Chao EC, Henry RR (2010) SGLT2 inhibition--a novel strategy for diabetes 
treatment. Nat Rev Drug Discov 9:551-559 doi:10.1038/nrd3180 
 
32. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN (2010) 
Quantitative PCR tissue expression profiling of the human SGLT2 gene and 
related family members. Diabetes Ther 1:57-92 doi:10.1007/s13300-010-0006-4 
 
33. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle 
HJ, von Eynatten M, Broedl UC (2014) The effect of empagliflozin on arterial 
stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes 
mellitus. Cardiovasc Diabetol 13:28 doi:10.1186/1475-2840-13-28 
 
 97 
34. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE 
(2015) Effects of empagliflozin on blood pressure and markers of arterial stiffness 
and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 
17:1180-1193 doi:10.1111/dom.12572 
 
35. Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, Wang 
BH, Liew D (2019) Potential mechanisms underlying the cardiovascular benefits 
of sodium glucose cotransporter 2 inhibitors: a systematic review of data from 
preclinical studies. Cardiovasc Res 115:266-276 doi:10.1093/cvr/cvy295 
 
36. Chow MS (1993) Assessing the treatment of congestive heart failure: diuretics, 
vasodilators, and angiotensin-converting enzyme inhibitors. Pharmacotherapy 
13:82S-87S  
 
37. Christiansen LB, Dela F, Koch J, Hansen CN, Leifsson PS, Yokota T (2015) 
Impaired cardiac mitochondrial oxidative phosphorylation and enhanced 
mitochondrial oxidative stress in feline hypertrophic cardiomyopathy. Am J Physiol 
Heart Circ Physiol 308:H1237-1247 doi:10.1152/ajpheart.00727.2014 
 
38. Cornier MA, Marshall JA, Hill JO, Maahs DM, Eckel RH (2011) Prevention of 
overweight/obesity as a strategy to optimize cardiovascular health. Circulation 
124:840-850 doi:10.1161/CIRCULATIONAHA.110.968461 
 
39. Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo 
RA, Norton L, Abdul-Ghani M (2016) Dapagliflozin Enhances Fat Oxidation and 
Ketone Production in Patients With Type 2 Diabetes. Diabetes Care 39:2036-2041 
doi:10.2337/dc15-2688 
 
40. Delicce AV, Basit H, Makaryus AN (2019) Physiology, Frank Starling Law. In: 
StatPearls. Treasure Island (FL) 
 
41. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg 
PL (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium 
glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin 
Pharmacol 53:601-610 doi:10.1002/jcph.88 
 
42. Devineni D, Polidori D (2015) Clinical Pharmacokinetic, Pharmacodynamic, and 
Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 
Inhibitor. Clin Pharmacokinet 54:1027-1041 doi:10.1007/s40262-015-0285-z 
 
43. Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi 
M, Mannucci E (2017) Sodium-dependent glucose transporters (SGLT) in human 
ischemic heart: A new potential pharmacological target. Int J Cardiol 243:86-90 
doi:10.1016/j.ijcard.2017.05.032 
 
44. Diseases NIoDaDaK (2017) Overweight & Obesity Statistics.   
 
45. Feigl EO, Neat GW, Huang AH (1990) Interrelations between coronary artery 
pressure, myocardial metabolism and coronary blood flow. J Mol Cell Cardiol 
22:375-390  
 
 98 
46. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, 
Pieber TR, Muscelli E (2016) Shift to Fatty Substrate Utilization in Response to 
Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and 
Patients With Type 2 Diabetes. Diabetes 65:1190-1195 doi:10.2337/db15-1356 
 
47. Ferrannini E, Mark M, Mayoux E (2016) CV Protection in the EMPA-REG 
OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 39:1108-1114 
doi:10.2337/dc16-0330 
 
48. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle 
HJ (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 
2 diabetic patients. J Clin Invest 124:499-508 doi:10.1172/JCI72227 
 
49. Fillmore N, Lopaschuk GD (2014) Malonyl CoA: A promising target for the 
treatment of cardiac disease. IUBMB Life 66:139-146 doi:10.1002/iub.1253 
 
50. Fitchett D (2019) A safety update on sodium glucose co-transporter 2 inhibitors. 
Diabetes Obes Metab 21 Suppl 2:34-42 doi:10.1111/dom.13611 
 
51. Fitchett DH, Udell JA, Inzucchi SE (2017) Heart failure outcomes in clinical trials 
of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 19:43-53 
doi:10.1002/ejhf.633 
 
52. Fukuda N, Terui T, Ohtsuki I, Ishiwata S, Kurihara S (2009) Titin and troponin: 
central players in the frank-starling mechanism of the heart. Curr Cardiol Rev 
5:119-124 doi:10.2174/157340309788166714 
 
53. Fukuta M, Wakida Y, Iwa T, Uesugi M, Kobayashi T (1996) Role of Na(+)-H+ 
exchange on reperfusion related myocardial injury and arrhythmias in an open-
chest swine model. Pacing Clin Electrophysiol 19:2027-2033 doi:10.1111/j.1540-
8159.1996.tb03275.x 
 
54. Gambardella J, Trimarco B, Iaccarino G, Santulli G (2018) New Insights in Cardiac 
Calcium Handling and Excitation-Contraction Coupling. Adv Exp Med Biol 
1067:373-385 doi:10.1007/5584_2017_106 
 
55. Garcia-Dorado D, Theroux P, Elizaga J, Galinanes M, Solares J, Riesgo M, Gomez 
MJ, Garcia-Dorado A, Fernandez Aviles F (1987) Myocardial reperfusion in the pig 
heart model: infarct size and duration of coronary occlusion. Cardiovasc Res 
21:537-544  
 
56. Gent S, Skyschally A, Kleinbongard P, Heusch G (2017) lschemic preconditioning 
in pigs: a causal role for signal transducer and activator of transcription 3. Am J 
Physiol Heart Circ Physiol 312:H478-H484 doi:10.1152/ajpheart.00749.2016 
 
57. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, 
Pfeffer MA, Yusuf S, Investigators CP (2008) The hemoglobin A1c level as a 
progressive risk factor for cardiovascular death, hospitalization for heart failure, or 
death in patients with chronic heart failure: an analysis of the Candesartan in Heart 
failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. 
Arch Intern Med 168:1699-1704 doi:10.1001/archinte.168.15.1699 
 99 
58. Gormsen LC, Svart M, Thomsen HH, Sondergaard E, Vendelbo MH, Christensen 
N, Tolbod LP, Harms HJ, Nielsen R, Wiggers H, Jessen N, Hansen J, Botker HE, 
Moller N (2017) Ketone Body Infusion With 3-Hydroxybutyrate Reduces 
Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron 
Emission Tomography Study. J Am Heart Assoc 6 doi:10.1161/JAHA.116.005066 
 
59. Gorski PA, Ceholski DK, Hajjar RJ (2015) Altered myocardial calcium cycling and 
energetics in heart failure--a rational approach for disease treatment. Cell Metab 
21:183-194 doi:10.1016/j.cmet.2015.01.005 
 
60. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, 
Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, 
Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, Group TS 
(2015) Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl 
J Med 373:232-242 doi:10.1056/NEJMoa1501352 
 
61. Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, 
Rector RS, Whaley-Connell A, DeMarco VG (2017) Sodium glucose transporter 2 
(SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a 
female rodent model of diabetes. Cardiovasc Diabetol 16:9 doi:10.1186/s12933-
016-0489-z 
 
62. Hamdani N, Herwig M, Linke WA (2017) Tampering with springs: phosphorylation 
of titin affecting the mechanical function of cardiomyocytes. Biophys Rev 9:225-
237 doi:10.1007/s12551-017-0263-9 
 
63. Hamouda NN, Sydorenko V, Qureshi MA, Alkaabi JM, Oz M, Howarth FC (2015) 
Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in 
ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem 
400:57-68 doi:10.1007/s11010-014-2262-5 
 
64. Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, Choi SH, Jang HC, Lee HS, 
Park KS, Kim YB, Lim S (2017) The beneficial effects of empagliflozin, an SGLT2 
inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet. Diabetologia 
60:364-376 doi:10.1007/s00125-016-4158-2 
 
65. Han Y, Cho YE, Ayon R, Guo R, Youssef KD, Pan M, Dai A, Yuan JX, Makino A 
(2015) SGLT inhibitors attenuate NO-dependent vascular relaxation in the 
pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol 
309:L1027-1036 doi:10.1152/ajplung.00167.2015 
 
66. Han YS, Ogut O (2011) Force relaxation and thin filament protein phosphorylation 
during acute myocardial ischemia. Cytoskeleton (Hoboken) 68:18-31 
doi:10.1002/cm.20491 
 
67. Hartmann M, Decking UK (1999) Blocking Na(+)-H+ exchange by cariporide 
reduces Na(+)-overload in ischemia and is cardioprotective. J Mol Cell Cardiol 
31:1985-1995 doi:10.1006/jmcc.1999.1029 
 
68. Hediger MA, Kanai Y, You G, Nussberger S (1995) Mammalian ion-coupled solute 
transporters. J Physiol 482:7S-17S  
 100 
69. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium 
Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: 
Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical 
Applications. Circulation 134:752-772 
doi:10.1161/CIRCULATIONAHA.116.021887 
 
70. Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G 
(2019) Canagliflozin reduces inflammation and fibrosis biomarkers: a potential 
mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney 
disease. Diabetologia 62:1154-1166 doi:10.1007/s00125-019-4859-4 
 
71. Heusch G, Skyschally A, Schulz R (2011) The in-situ pig heart with regional 
ischemia/reperfusion - ready for translation. J Mol Cell Cardiol 50:951-963 
doi:10.1016/j.yjmcc.2011.02.016 
 
72. Heyndrickx GR, Amano J, Patrick TA, Manders WT, Rogers GG, Rosendorff C, 
Vatner SF (1985) Effects of coronary artery reperfusion on regional myocardial 
blood flow and function in conscious baboons. Circulation 71:1029-1037  
 
73. Hiatt WR, Kaul S, Smith RJ (2013) The cardiovascular safety of diabetes drugs--
insights from the rosiglitazone experience. N Engl J Med 369:1285-1287 
doi:10.1056/NEJMp1309610 
 
74. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan 
JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati 
NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Group ES (2017) 
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 
Diabetes. N Engl J Med 377:1228-1239 doi:10.1056/NEJMoa1612917 
 
75. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones 
NP, Komajda M, McMurray JJ, Team RS (2009) Rosiglitazone evaluated for 
cardiovascular outcomes in oral agent combination therapy for type 2 diabetes 
(RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135 
doi:10.1016/S0140-6736(09)60953-3 
 
76. Hoogwerf BJ, Manner DH, Fu H, Moscarelli E, Gaydos BL, Heine RJ (2016) 
Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment 
in the Pharmaceutical Development of Glucose-Lowering Medications. Diabetes 
Care 39 Suppl 2:S219-227 doi:10.2337/dcS15-3025 
 
77. Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, 
Petucci C, Lewandowski ED, Crawford PA, Muoio DM, Recchia FA, Kelly DP 
(2019) The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. 
JCI Insight 4 doi:10.1172/jci.insight.124079 
78. Hudson B, Hidalgo C, Saripalli C, Granzier H (2011) Hyperphosphorylation of 
mouse cardiac titin contributes to transverse aortic constriction-induced diastolic 
dysfunction. Circ Res 109:858-866 doi:10.1161/CIRCRESAHA.111.246819 
 
79. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD (2011) Targeting fatty 
acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic 
 101 
and failing heart. Biochim Biophys Acta 1813:1333-1350 
doi:10.1016/j.bbamcr.2011.01.015 
 
80. John S.D. Chan IC, Anindya Ghosh, Chin-Han Wu, Chao-Sheng Lo, Shuiling 
Zhao, Jean-Louis Chiasson, Janos G. Filep, Julie R Ingelfinger, Shao-Ling Zhang 
(2016) CANAGLIFLOZIN, A SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT-
2) BLOCKER, NORMALIZES BLOOD GLUCOSE WITHOUT AFFECTING 
SYSTEMIC BLOOD PRESSURE, OXIDATIVE STRESS, INTRARENAL 
ANGIOTENSINOGEN GENE EXPRESSION AND KIDNEY INJURY IN TYPE 1 
DIABETIC MICE. Nephrology Dialysis Transplantation 31:i214  
 
81. Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, Dollet L, Le May 
C, Toumaniantz G, Manrique A, Charpentier F, Staels B, Magre J, Cariou B, Prieur 
X (2017) The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents 
Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. Diabetes 66:1030-
1040 doi:10.2337/db16-0733 
 
82. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin 
resistance and type 2 diabetes. Nature 444:840-846 doi:10.1038/nature05482 
 
83. Kalra S, Jain A, Ved J, Unnikrishnan AG (2016) Sodium-glucose cotransporter 2 
inhibition and health benefits: The Robin Hood effect. Indian J Endocrinol Metab 
20:725-729 doi:10.4103/2230-8210.183826 
 
84. Kamihara T BY, Nishiura K, Yasheng R, Kawase H, Murohara T. (2017) Impact of 
SGLT2 inhibitor on diabetic cardiomyopathy-role of glucagon-insulin axis. J Card 
Fail 23  
 
85. Kaplan A, Abidi E, El-Yazbi A, Eid A, Booz GW, Zouein FA (2018) Direct 
cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Fail 
Rev doi:10.1007/s10741-017-9665-9 
 
86. Kawasoe S, Maruguchi Y, Kajiya S, Uenomachi H, Miyata M, Kawasoe M, 
Kubozono T, Ohishi M (2017) Mechanism of the blood pressure-lowering effect of 
sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. 
BMC Pharmacol Toxicol 18:23 doi:10.1186/s40360-017-0125-x 
 
87. Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, Sweis RN, Lloyd-
Jones DM (2018) Association of Body Mass Index With Lifetime Risk of 
Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol 3:280-287 
doi:10.1001/jamacardio.2018.0022 
 
88. Kim JH, Lee M, Kim SH, Kim SR, Lee BW, Kang ES, Cha BS, Cho JW, Lee YH 
(2018) Sodium-glucose cotransporter 2 inhibitors regulate ketone body 
metabolism via inter-organ crosstalk. Diabetes Obes Metab 
doi:10.1111/dom.13577 
 
89. Klein HH, Pich S, Bohle RM, Lindert-Heimberg S, Nebendahl K (2000) Na(+)/H(+) 
exchange inhibitor cariporide attenuates cell injury predominantly during ischemia 
and not at onset of reperfusion in porcine hearts with low residual blood flow. 
Circulation 102:1977-1982 doi:10.1161/01.cir.102.16.1977 
 102 
90. Klein LJ, Visser FC (2010) The effect of insulin on the heart: Part 2: Effects on 
function during and post myocardial ischaemia. Neth Heart J 18:255-259 
doi:10.1007/bf03091772 
 
91. Koser F, Loescher C, Linke WA (2019) Posttranslational modifications of titin from 
cardiac muscle: how, where, and what for? FEBS J 286:2240-2260 
doi:10.1111/febs.14854 
 
92. Lahnwong S, Chattipakorn SC, Chattipakorn N (2018) Potential mechanisms 
responsible for cardioprotective effects of sodium-glucose co-transporter 2 
inhibitors. Cardiovasc Diabetol 17:101 doi:10.1186/s12933-018-0745-5 
 
93. Lee EJ, Peng J, Radke M, Gotthardt M, Granzier HL (2010) Calcium sensitivity 
and the Frank-Starling mechanism of the heart are increased in titin N2B region-
deficient mice. J Mol Cell Cardiol 49:449-458 doi:10.1016/j.yjmcc.2010.05.006 
 
94. Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, 
Chen YF, Lee AS (2019) The sodium-glucose co-transporter 2 inhibitor 
empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics 
in hypertensive heart failure rats. Cardiovasc Diabetol 18:45 doi:10.1186/s12933-
019-0849-6 
 
95. Lee TM, Chang NC, Lin SZ (2017) Dapagliflozin, a selective SGLT2 Inhibitor, 
attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 
signaling in infarcted rat hearts. Free Radic Biol Med 104:298-310 
doi:10.1016/j.freeradbiomed.2017.01.035 
 
96. Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM (2019) SGLT2 
Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and 
Nondiabetic Heart. JACC Basic Transl Sci 4:15-26 
doi:10.1016/j.jacbts.2018.10.002 
 
97. Lim VG, Robert M. Bell, S. Arjun, Maria Kolatsi-Joannou, David A. Long and Derek 
M. Yellon (2019) SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction 
in the Diabetic and Nondiabetic Heart. JACC: Basic to Translational Science 
doi:10.1016/j.jacbts.2018.10.002 
 
98. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa 
T, Kusaka H, Kim-Mitsuyama S (2014) Glycemic control with empagliflozin, a novel 
selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive 
dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 13:148 
doi:10.1186/s12933-014-0148-1 
 
99. Linke WA, Hamdani N (2014) Gigantic business: titin properties and function 
through thick and thin. Circ Res 114:1052-1068 
doi:10.1161/CIRCRESAHA.114.301286 
 
100. Linz W, Albus U, Crause P, Jung W, Weichert A, Scholkens BA, Scholz W (1998) 
Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 
inhibitor cariporide (HOE 642). Clin Exp Hypertens 20:733-749  
 
 103 
101. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial 
fatty acid metabolism in health and disease. Physiol Rev 90:207-258 
doi:10.1152/physrev.00015.2009 
 
102. Lou Q, Janardhan A, Efimov IR (2012) Remodeling of calcium handling in human 
heart failure. Adv Exp Med Biol 740:1145-1174 doi:10.1007/978-94-007-2888-
2_52 
 
103. Lovshin JA, Gilbert RE (2015) Are SGLT2 inhibitors reasonable antihypertensive 
drugs and renoprotective? Curr Hypertens Rep 17:551 doi:10.1007/s11906-015-
0551-3 
 
104. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, 
Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, Group CPC (2018) Canagliflozin 
for Primary and Secondary Prevention of Cardiovascular Events: Results From the 
CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 
137:323-334 doi:10.1161/CIRCULATIONAHA.117.032038 
 
105. Majewski C, Bakris GL (2015) Blood pressure reduction: an added benefit of 
sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. 
Diabetes Care 38:429-430 doi:10.2337/dc14-1596 
 
106. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, 
Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman 
B, Bergenstal RM, Buse JB, Committee LS, Investigators LT (2016) Liraglutide and 
Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375:311-322 
doi:10.1056/NEJMoa1603827 
 
107. Martens (2017) Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and 
Beyond. Curr Treat Options Cardio Med 19  
 
108. Martens P, Mathieu C, Verbrugge FH (2017) Promise of SGLT2 Inhibitors in Heart 
Failure: Diabetes and Beyond. Curr Treat Options Cardiovasc Med 19:23 
doi:10.1007/s11936-017-0522-x 
 
109. McMurray JJV (2018) Renin-angiotensin system inhibition-it's been a long but 
fruitful journey. Eur J Heart Fail 20:687-688 doi:10.1002/ejhf.1155 
 
110. Moss RL, Fitzsimons DP (2002) Frank-Starling relationship: long on importance, 
short on mechanism. Circ Res 90:11-13  
 
111. Mudaliar S, Alloju S, Henry RR (2016) Can a Shift in Fuel Energetics Explain the 
Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying 
Hypothesis. Diabetes Care 39:1115-1122 doi:10.2337/dc16-0542 
 
112. Mudaliar S, Polidori D, Zambrowicz B, Henry RR (2015) Sodium-Glucose 
Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From 
Bench to Bedside. Diabetes Care 38:2344-2353 doi:10.2337/dc15-0642 
 
 104 
113. Muller AE, Kreiner M, Kotter S, Lassak P, Bloch W, Suhr F, Kruger M (2014) Acute 
exercise modifies titin phosphorylation and increases cardiac myofilament 
stiffness. Front Physiol 5:449 doi:10.3389/fphys.2014.00449 
 
114. Neal B, Perkovic V, Matthews DR (2017) Canagliflozin and Cardiovascular and 
Renal Events in Type 2 Diabetes. N Engl J Med 377:2099 
doi:10.1056/NEJMc1712572 
 
115. Nielsen R, Moller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, Harms 
HJ, Frokiaer J, Eiskjaer H, Jespersen NR, Mellemkjaer S, Lassen TR, Pryds K, 
Botker HE, Wiggers H (2019) Cardiovascular Effects of Treatment With the Ketone 
Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation 139:2129-
2141 doi:10.1161/CIRCULATIONAHA.118.036459 
 
116. Odunewu-Aderibigbe A, Fliegel L (2014) The Na(+) /H(+) exchanger and pH 
regulation in the heart. IUBMB Life 66:679-685 doi:10.1002/iub.1323 
 
117. Oelze M, Kroller-Schon S, Welschof P, Jansen T, Hausding M, Mikhed Y, Stamm 
P, Mader M, Zinssius E, Agdauletova S, Gottschlich A, Steven S, Schulz E, Bottari 
SP, Mayoux E, Munzel T, Daiber A (2014) The sodium-glucose co-transporter 2 
inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the 
streptozotocin diabetes rat model by interfering with oxidative stress and 
glucotoxicity. PLoS One 9:e112394 doi:10.1371/journal.pone.0112394 
 
118. Pabel S, Wagner S, Bollenberg H, Bengel P, Kovacs A, Schach C, Tirilomis P, 
Mustroph J, Renner A, Gummert J, Fischer T, Van Linthout S, Tschope C, 
Streckfuss-Bomeke K, Hasenfuss G, Maier LS, Hamdani N, Sossalla S (2018) 
Empagliflozin directly improves diastolic function in human heart failure. Eur J 
Heart Fail 20:1690-1700 doi:10.1002/ejhf.1328 
 
119. Packer M (2018) Heart Failure: The Most Important, Preventable, and Treatable 
Cardiovascular Complication of Type 2 Diabetes. Diabetes Care 41:11-13 
doi:10.2337/dci17-0052 
 
120. Perez NG, de Hurtado MC, Cingolani HE (2001) Reverse mode of the Na+-Ca2+ 
exchange after myocardial stretch: underlying mechanism of the slow force 
response. Circ Res 88:376-382 doi:10.1161/01.res.88.4.376 
 
121. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, 
Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, 
Solomon SD, Tardif JC, Investigators E (2015) Lixisenatide in Patients with Type 
2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373:2247-2257 
doi:10.1056/NEJMoa1509225 
122. prevention Cfdca (2017) Heart Disease Fact Sheet. In: 
 
123. Qiu H, Novikov A, Vallon V (2017) Ketosis and diabetic ketoacidosis in response 
to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes 
Metab Res Rev 33 doi:10.1002/dmrr.2886 
 
 105 
124. Reaven G (2005) Insulin resistance, type 2 diabetes mellitus, and cardiovascular 
disease: the end of the beginning. Circulation 112:3030-3032 
doi:10.1161/CIRCULATIONAHA.105.504670 
 
125. Rehring TF, Shapiro JI, Cain BS, Meldrum DR, Cleveland JC, Harken AH, 
Banerjee A (1998) Mechanisms of pH preservation during global ischemia in 
preconditioned rat heart: roles for PKC and NHE. Am J Physiol 275:H805-813 
doi:10.1152/ajpheart.1998.275.3.H805 
 
126. Robison P, Caporizzo MA, Ahmadzadeh H, Bogush AI, Chen CY, Margulies KB, 
Shenoy VB, Prosser BL (2016) Detyrosinated microtubules buckle and bear load 
in contracting cardiomyocytes. Science 352:aaf0659 doi:10.1126/science.aaf0659 
 
127. Roth GA (2018) Global Burden of Disease Collaborative Network. Global Burden 
of Disease Study 2017 (GBD 2017) Results. Seattle, United States: Institute for 
Health Metrics and Evaluation (IHME), 2018. The Lancet 392:1736-1788  
 
128. Saini HK, Dhalla NS (2005) Defective calcium handling in cardiomyocytes isolated 
from hearts subjected to ischemia-reperfusion. Am J Physiol Heart Circ Physiol 
288:H2260-2270 doi:10.1152/ajpheart.01153.2004 
 
129. Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, 
Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster 
V, Badimon JJ (2019) Rationale and Design of the EMPA-TROPISM Trial (ATRU-
4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic 
Activity? Cardiovasc Drugs Ther doi:10.1007/s10557-018-06850-0 
 
130. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe 
S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon 
JJ (2019) Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in 
Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol 
73:1931-1944 doi:10.1016/j.jacc.2019.01.056 
 
131. Sayour AA, Korkmaz-Icoz S, Loganathan S, Ruppert M, Sayour VN, Olah A, Benke 
K, Brune M, Benko R, Horvath EM, Karck M, Merkely B, Radovits T, Szabo G 
(2019) Acute canagliflozin treatment protects against in vivo myocardial ischemia-
reperfusion injury in non-diabetic male rats and enhances endothelium-dependent 
vasorelaxation. J Transl Med 17:127 doi:10.1186/s12967-019-1881-8 
 
132. Schaper W, Gorge G, Winkler B, Schaper J (1988) The collateral circulation of the 
heart. Prog Cardiovasc Dis 31:57-77  
 
133. Scheen AJ (2014) Evaluating SGLT2 inhibitors for type 2 diabetes: 
pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 
10:647-663 doi:10.1517/17425255.2014.873788 
134. Scheepers A, Joost HG, Schurmann A (2004) The glucose transporter families 
SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J 
Parenter Enteral Nutr 28:364-371 doi:10.1177/0148607104028005364 
 
135. Scherer PE, Hill JA (2016) Obesity, Diabetes, and Cardiovascular Diseases: A 
Compendium. Circ Res 118:1703-1705 doi:10.1161/CIRCRESAHA.116.308999 
 106 
136. Schipke JD (1994) Cardiac efficiency. Basic Res Cardiol 89:207-240 
doi:10.1007/bf00795615 
 
137. Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, Skrha J, Valensi P, 
Ceriello A (2019) Report from the 4th Cardiovascular Outcome Trial (CVOT) 
Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. 
Cardiovasc Diabetol 18:30 doi:10.1186/s12933-019-0822-4 
 
138. Schork A, Saynisch J, Vosseler A, Jaghutriz BA, Heyne N, Peter A, Haring HU, 
Stefan N, Fritsche A, Artunc F (2019) Effect of SGLT2 inhibitors on body 
composition, fluid status and renin-angiotensin-aldosterone system in type 2 
diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc 
Diabetol 18:46 doi:10.1186/s12933-019-0852-y 
 
139. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, 
Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, 
Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, Committee S-TS, 
Investigators (2013) Saxagliptin and cardiovascular outcomes in patients with type 
2 diabetes mellitus. N Engl J Med 369:1317-1326 doi:10.1056/NEJMoa1307684 
 
140. Shi X, Verma S, Yun J, Brand-Arzamendi K, Singh KK, Liu X, Garg A, Quan A, 
Wen XY (2017) Effect of empagliflozin on cardiac biomarkers in a zebrafish model 
of heart failure: clues to the EMPA-REG OUTCOME trial? Mol Cell Biochem 
433:97-102 doi:10.1007/s11010-017-3018-9 
 
141. Slepkov ER, Rainey JK, Li X, Liu Y, Cheng FJ, Lindhout DA, Sykes BD, Fliegel L 
(2005) Structural and functional characterization of transmembrane segment IV of 
the NHE1 isoform of the Na+/H+ exchanger. J Biol Chem 280:17863-17872 
doi:10.1074/jbc.M409608200 
 
142. Spitznagel H, Chung O, Xia Q, Rossius B, Illner S, Jahnichen G, Sandmann S, 
Reinecke A, Daemen MJ, Unger T (2000) Cardioprotective effects of the 
Na(+)/H(+)-exchange inhibitor cariporide in infarct-induced heart failure. 
Cardiovasc Res 46:102-110 doi:10.1016/s0008-6363(99)00428-9 
 
143. Staels B (2017) Cardiovascular Protection by Sodium Glucose Cotransporter 2 
Inhibitors: Potential Mechanisms. Am J Med 130:S30-S39 
doi:10.1016/j.amjmed.2017.04.009 
 
144. Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism 
in the normal and failing heart. Physiol Rev 85:1093-1129 
doi:10.1152/physrev.00006.2004 
145. Sun J, Zhou W, Gu T, Zhu D, Bi Y (2018) A retrospective study on association 
between obesity and cardiovascular risk diseases with aging in Chinese adults. 
Sci Rep 8:5806 doi:10.1038/s41598-018-24161-0 
 
146. Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, 
Chattipakorn SC, Chattipakorn N (2018) Cardioprotection of dapagliflozin and 
vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol 236:69-84 
doi:10.1530/JOE-17-0457 
 
 107 
147. Terasaki M, Hiromura M, Mori Y, Kohashi K, Nagashima M, Kushima H, Watanabe 
T, Hirano T (2015) Amelioration of Hyperglycemia with a Sodium-Glucose 
Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through 
Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic 
Mice. PLoS One 10:e0143396 doi:10.1371/journal.pone.0143396 
 
148. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ (2017) Cardiovascular 
consequences of metabolic syndrome. Transl Res 183:57-70 
doi:10.1016/j.trsl.2017.01.001 
 
149. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, 
Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ (2018) Class effects 
of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) 
exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61:722-726 
doi:10.1007/s00125-017-4509-7 
 
150. Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit 
GY, Mayoux E, Lehrke M, Marx N, Lopaschuk GD (2018) Empagliflozin Increases 
Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart 
Failure Benefits of SGLT2 Inhibitors. JACC Basic Transl Sci 3:575-587 
doi:10.1016/j.jacbts.2018.07.006 
 
151. Vijayakumar S, Vaduganathan M, Butler J (2018) Glucose-Lowering Therapies 
and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, 
and Future Directions. Circulation 137:1060-1073 
doi:10.1161/CIRCULATIONAHA.117.032099 
 
152. Vlotides G, Mertens PR (2015) Sodium-glucose cotransport inhibitors: 
mechanisms, metabolic effects and implications for the treatment of diabetic 
patients with chronic kidney disease. Nephrol Dial Transplant 30:1272-1276 
doi:10.1093/ndt/gfu299 
 
153. Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, Radovic N, 
Jadrijevic S, Aleksic I, Walles T, Sauvant C, Sabolic I, Koepsell H (2015) 
Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human 
kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 
467:1881-1898 doi:10.1007/s00424-014-1619-7 
 
154. Wakabayashi S, Ikeda T, Iwamoto T, Pouyssegur J, Shigekawa M (1997) 
Calmodulin-binding autoinhibitory domain controls "pH-sensing" in the Na+/H+ 
exchanger NHE1 through sequence-specific interaction. Biochemistry 36:12854-
12861 doi:10.1021/bi9715472 
155. Wehrens XH, Lehnart SE, Reiken SR, Marks AR (2004) Ca2+/calmodulin-
dependent protein kinase II phosphorylation regulates the cardiac ryanodine 
receptor. Circ Res 94:e61-70 doi:10.1161/01.RES.0000125626.33738.E2 
 
156. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA (1992) Cloning of a 
human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J 
Physiol 263:F459-465 doi:10.1152/ajprenal.1992.263.3.F459 
 
 108 
157. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez 
AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, 
Investigators E (2013) Alogliptin after acute coronary syndrome in patients with 
type 2 diabetes. N Engl J Med 369:1327-1335 doi:10.1056/NEJMoa1305889 
 
158. Wiviott SD, Raz I, Sabatine MS (2019) Dapagliflozin and Cardiovascular 
Outcomes in Type 2 Diabetes. Reply. N Engl J Med 380:1881-1882 
doi:10.1056/NEJMc1902837 
 
159. Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose 
transporters. Physiol Rev 91:733-794 doi:10.1152/physrev.00055.2009 
 
160. Wright MH, Sieber SA (2016) Chemical proteomics approaches for identifying the 
cellular targets of natural products. Nat Prod Rep 33:681-708 
doi:10.1039/c6np00001k 
 
161. Yaribeygi H, Butler AE, Atkin SL, Katsiki N, Sahebkar A (2018) Sodium-glucose 
cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible 
molecular pathways. J Cell Physiol 234:223-230 doi:10.1002/jcp.26851 
 
162. Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y (2017) SGLT-2 Inhibition 
with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and 
Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 
Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. 
Cardiovasc Drugs Ther 31:119-132 doi:10.1007/s10557-017-6725-2 
 
163. Zhou Y, Wu W (2017) The Sodium-Glucose Co-Transporter 2 Inhibitor, 
Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the 
Endoplasmic Reticulum Stress Pathway. Cell Physiol Biochem 41:2503-2512 
doi:10.1159/000475942 
 
164. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, 
Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators E-RO 
(2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. 
N Engl J Med 373:2117-2128 doi:10.1056/NEJMoa1504720 
  
CURRICULUM VITAE 
 
Hana Elisabeth Baker 
 
EDUCATION 
 
Indiana University                              2020 
PhD, Cellular & Integrative Physiology 
 
Indiana Institute of Technology Indianapolis     2004 
MBA, Management and Human Resources 
 
Purdue University West Lafayette      1998 
BS, Health Science  
 
 
RESEARCH EXPERIENCE 
Johnathan D. Tune, PhD Laboratory                 2017– present  
Cellular & Integrative Physiology, IU School of Medicine 
  
 
PROFESSIONAL EXPERIENCE 
Eli Lilly and Company                              2009 - present 
 Consultant Biologist 
− Drug discovery scientist with extensive experience in pharmacology, in vivo biology, 
small molecule and biomolecule discovery and development. Scientific expertise in 
dyslipidemia, cardiovascular disease, diabetes and diabetic nephropathy.  
Recruiting industry professionals to attend bi-annual networking events  
 
 
HONORS AND AWARDS 
Young Investigator Award       2018 
Society for Experimental Biology and Medicine 
 
Research Excellence Award       2019 
IU Center for Diabetes & Metabolic Diseases 2019 Annual Symposium 
 
 
PUBLICATIONS 
1. Tune JD, Baker HE, Berwick ZC, Moberly SP, Casalini ED, Noblet JN, Zhen E, Kowala 
MC, Christe ME, Goodwill AG. Cardiac and coronary effects of (Pyr)Apelin-13 are 
mediated by alterations in peripheral resistance. Am J Physiol Heart Circ Physiol. In 
review 
 
2. Tune JD, Goodwill AG, Kiel AM, Baker HE, Bender SB, Merkus D, Duncker DJ. 
Disentangling the Gordian knot of local metabolic control of coronary blood flow. Am J 
Physiol Heart Circ Physiol. In Press. PMID 31702972 
 
  
3. Baker HE, Tune JD, Goodwill AG, Mather KJ. Benefits of empagliflozin beyond 
enhancing myocardial energetics? J Am Coll Cardiol. 74:825-826, 2019. PMID 
31395139 
4. Baker HE, Kiel AM, Luebbe ST, Simon BR, Earl CC, Regmi A, Roell WC, Mather KJ, 
Tune JD, Goodwill AG. Inhibition of sodium-glucose cotransporter-2 preserves cardiac 
function during regional myocardial ischemia independent of alterations in myocardial 
substrate utilization. Basic Res Cardiol. 2019 Apr 19;114(3):25. doi: 10.1007/s00395-
019-0733-2. PubMed PMID: 31004234. 
5. Kiel AM, Goodwill AG, Baker HE, Dick GM, Tune JD. Local metabolic hypothesis is 
not sufficient to explain coronary autoregulatory behavior. Basic Res Cardiol. 2018 
Aug 2;113(5):33. doi: 10.1007/s00395-018-0691-0. PubMed PMID: 30073416. 
6. Neelamkavil SF, Stamford AW, Kowalski T, Biswas D, Boyle C, Chackalamannil S, 
Xia Y, Jayne C, Neustadt B, Hao J, Liu H, Dai X, Baker H, Hawes B, O'Neill K, Tang 
H, Greenlee WJ. Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 
Agonist for the Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2018 Apr 
10;9(5):457-461. doi: 10.1021/acsmedchemlett.8b00073. eCollection 2018 May 10. 
PubMed PMID: 29795759; PubMed Central PMCID: PMC5949837. 
7. Harlan SM, Heinz-Taheny KM, Sullivan JM, Wei T, Baker HE, Jaqua DL, Qi Z, Cramer 
MS, Shiyanova TL, Breyer MD, Heuer JG. Progressive Renal Disease Established by 
Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic 
Models. J Am Soc Nephrol. 2017  
8. Okragly AJ, Hamang MJ, Pena EA, Baker HE, Bullock HA, Lucchesi J, Martin AP, Ma 
YL, Benschop RJ. Elevated levels of Interleukin (IL)-33 induce bone pathology but 
absence of IL-33 does not negatively impact normal bone homeostasis. Cytokine 79: 
66-73, 2016. 
9. Dai X, Stamford A, Liu H, Neustadt B, Hao J, Kowalski T, Hawes B, Xu X, Baker H, 
O'Neill K, Woods M, Tang H, Greenlee W. Discovery of the oxazabicyclo[3.3.1]nonane 
derivatives as potent and orally active GPR119 agonists. Bioorg Med Chem Lett. 
25(22): 5291-5294, 2015. 
10. Xia Y, Chackalamannil S, Greenlee WJ, Jayne C, Neustadt B, Stamford A, Vaccaro 
H, Xu XL, Baker H, O'Neill K, Woods M, Hawes B, Kowalski T. Discovery of a 
nortropanol derivative as a potent and orally active GPR119 agonist for type 2 
diabetes. Bioorg Med Chem Lett. 21(11): 3290-6, 2011. 
11. Shah U, Boyle CD, Chackalamannil S, Baker H, Kowalski T, Lee J, Terracina G, Zhang 
L. Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 
20(5): 1551-4, 2010. 
12. Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, Abbondanzo SJ, Hu W, 
Yang S, Ning Y, Del Vecchio RA, Poulet F, Laverty M, Gustafson EL, Hedrick JA, 
Kowalski TJ. GPR119 is required for physiological regulation of glucagon-like peptide-
1 secretion but not for metabolic homeostasis. J Endocrinol. 201(2): 219-30, 2009.  
  
13. Terracina G, Lee J, Stamford A, Lankin C, Neelamkavil S, Shah U, Boyle C, Baker H, 
Kowalski T, Zhang X, Sorota S, Parker E and Zhang L.  Identification of three potential 
chemical lead series for 11-β-Hydroxysterol Dehydrogenase type 1 (11β-HSD1) 
inhibitors as potential treatments for metabolic syndrome.  American Society for 
Neuroscience, Abstract.  Washington D.C., November 12-16, 2005 
14. Graham JM, Baker H, Nisenbaum LK and Hemrick-Luecke SK.  Comparison of the 
effects of intracisternal administration of Orexin A and Orexin B on rat serum 
corticosterone and ACTH concentrations. American Society for Neuroscience, 
Abstract.  San Diego, CA, October 23-27, 2004 
 
POSTER/ORAL PRESENTATIONS 
 
1. Indiana Physiological Society Meeting 2017, Oral presentation.  Preclinical rodent 
models demonstrate TG lowering but no other metabolic effects following ANGPTL3 
neutralization. 
2. IU Center for Diabetes & Metabolic Diseases 2017 Annual Symposium, Hana E. 
Baker, Melissa A. Bellinger, Lan Yu, and Laura F. Michael Preclinical rodent models 
demonstrate triglyceride lowering but no other metabolic effects following ANGPTL3 
neutralization. 
3. Indiana Physiological Society Meeting 2018, Oral presentation.  Inhibition of Sodium 
Glucose Cotransporter-2 Preserves Cardiac Function during Regional Myocardial 
Ischemia via a Frank-Starling Mechanism. 
4. Experimental Biology 2018, Hana E Baker, Alexander M Kiel, Kieren J Mather, 
Johnathan D Tune, Adam G Goodwill.  Inhibition of Sodium Glucose Cotransporter-2 
Preserves Cardiac Function during Regional Myocardial Ischemia via a Frank-Starling 
Mechanism. 
5. IU Center for Diabetes & Metabolic Diseases 2019 Annual Symposium, Hana E Baker, 
Adam G Goodwill, Kieren J Mather, Mark C Kowala, Johnathan D Tune.  Inhibition of 
Sodium Glucose Cotransporter-2 Mitigates Heart Failure Progression in Obesity. 
 
INVITED LECTURES 
 
• Innovations across Lilly, Grand Rounds, Eli Lilly and Company, Indianapolis, In August 
2, 2017 
 
 
